CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  1 of 89  
  
 
 
TITLE PAGE  
Protocol  Title:  
A Randomized, Double -Blind, Placebo -controlled, Single-ascending Dose Study to Assess 
the Safety, Tolerability, and Pharmacokinetics  of JK07 in Subjects with Heart Failure with 
Reduced Ejection Fraction (HFrEF)  
Protocol Number:  JK07.1.01 Amendment 3 
Product: JK07 (recombinant fusion protein consisting of a fully human anti -human 
epidermal growth factor receptor 3 [HER3] immunoglobin G1 [IgG1] and an active 
polypeptide fragment from human neuregulin- 1 [NRG-1])  
Short  Title: Phase 1 Study of JK07 in Subjects with Heart Failure with Reduced Ejection 
Fraction (HFrEF)  
Study  Phase: Phase 1 
Sponsor  Name: Salubris Biotherapeutics, Inc. 
Legal Registered  Address: 45 West  Watkins Mill Rd, Suite E, Gaithersburg, MD 20878  
Regulatory Agency Identifying Number(s): IND 142367  
 
 
Version  Date  
Original  21 November  2019  
Amendment  1 19 February  2020  
Amendment  2 03 March  2020  
Amendment  3 09 April  2021  

CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  2 of 89  
 SPONSOR  SIGNATORY:  
 
 
I have read this  protocol  in its  entirety  and agree to conduct the  study accordingly:  
 
 
 
 
 
 
Sam Murphy, PhD 
Chief Executive Officer Salubris  Biotherapeutics   
Date  20-Apr-2021 | 13:42:27  PDT 
 
        
 
20-Apr-2021 | 13:58:05  PDT 
 
Date  
Consulting Chief  Medical  Officer and Medical  Monitor 
Salubris Biotherapeutics  
 
 
 
Neal  Salomon,  MD 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  3 of 89  
 TABLE  OF CONTENTS 
SUMMARY  OF CHANGES  ................................................................................................... 7 
LIST OF  ABBREVIATIONS  ................................................................................................ 12 
1.0 PROTOCOL  SUMMARY  ......................................................................................... 14 
1.1 Synopsis  ........................................................................................................... 14 
1.2 Schema  ............................................................................................................ 18 
1.3 Schedule  of Activities  ..................................................................................... 19 
2.0 INTRODUCTION  ...................................................................................................... 24 
2.1 Study  Rationale  .............................................................................................. 24 
2.2 Background  ..................................................................................................... 25 
2.3 Benefit/Risk  Assessment  ................................................................................ 27 
3.0 OBJECTIVES  AND ENDPOINTS  ........................................................................... 29 
4.0 STUDY DESIGN ........................................................................................................ 30 
4.1 Overall  Design  ................................................................................................ 30 
4.2 Scientific  Rationale  for Study  Design  ........................................................... 30 
4.3 Justification  for Dose  ..................................................................................... 32 
4.4 End of Study  Definition  ................................................................................. 33 
4.5 Dose  Escalation  Criteria  ................................................................................ 33 
4.6 Study  Stopping  Criteria  ................................................................................. 33 
4.6.1 Stopping Criteria  for Individual  Subjects  .......................................... 34 
4.6.2 Criteria  for Stopping Dose  Escalation  ............................................... 34 
4.6.3 Criteria  for Stopping the  Study .......................................................... 35 
5.0 STUDY POPULATION  ............................................................................................. 36 
5.1 Inclusion  Criteria  ........................................................................................... 36 
5.2 Exclusion  Criteria  .......................................................................................... 36 
5.3 Lifestyle  Considerations  ................................................................................. 38 
5.3.1 Meals  and Dietary  Restrictions  .......................................................... 38 
5.3.2 Caffeine,  Alcohol, and Tobacco  ........................................................ 38 
5.3.3 Activity  .............................................................................................. 39 
5.4 Screen  Failures  ............................................................................................... 39 
6.0 STUDY TREATMENT .............................................................................................. 40 
6.1 Study  Treatment(s)  Administered  ................................................................ 40 
6.2 Preparation/Handling/Storage/Accountability  ............................................. 41 
6.3 Randomization  and Blinding ......................................................................... 41 
6.4 Study  Treatment  Compliance  ....................................................................... 42 
6.5 Concomitant  Therapy  .................................................................................... 42 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  4 of 89  
 6.5.1 Rescue Medicine  ................................................................................42 
6.6 Dose  Modification  ...........................................................................................42 
6.7 Treatment  after the  End of the Study  ..........................................................42 
7.0 DISCONTINUATION OF STUDY TREATMENT AND SUBJECT 
DISCONTINUATION/WITHDRAWAL  .................................................................43 
7.1 Discontinuation  of Study  Treatment  ............................................................43 
7.2 Subject  Discontinuation/Withdrawal  from  the Study  ................................43 
7.3 Lost  to Follow -up ............................................................................................43 
8.0 STUDY ASSESSMENTS AND PROCEDURES  .....................................................45 
8.1 Efficacy  Assessments  ......................................................................................45 
8.2 Safety  Assessments  .........................................................................................45 
8.2.1 Physical  Examinations  .......................................................................46 
8.2.2 Injection  Site Assessment  ..................................................................46 
8.2.3 Pregnancy  Test ...................................................................................47 
8.2.4 Medical  History  .................................................................................47 
8.2.5 Electrocardiograms  ............................................................................47 
8.2.6 Vital Signs  .........................................................................................47 
8.2.7 Clinical Safety  Laboratory Assessments  ............................................48 
8.2.8 Immunogenicity  Assessments  ............................................................48 
8.2.9 Two-dimensional  Transthoracic  Echocardiography ..........................49 
8.3 Safety  Monitoring  and Reporting  .................................................................49 
8.3.1 Adverse  Events  ..................................................................................49 
8.3.2 Serious  Adverse  Events  .....................................................................49 
8.3.3 Time  Period  and Frequency  for Collecting  AE and SAE  
Information  ........................................................................................50 
8.3.4 Method of Detecting  AEs  and SAEs  .................................................51 
8.3.5 Grading and Intensity of Adverse  Events  ..........................................51 
8.3.6 Relationship  to Study  Drug  ................................................................52 
8.3.7 Recording AEs and SAEs  ..................................................................53 
8.3.8 Follow -up of AEs and  SAEs  ..............................................................55 
8.3.9 Regulatory Reporting Requirements  for SAEs  ..................................55 
8.3.10 Pregnancy ...........................................................................................55 
8.3.11 Protocol -Specified  Serious  Adverse  Events  ......................................56 
8.3.12 Disease- related Events and/or Disease- related Outcomes Not 
Qualifying as AEs or SAEs ................................................................56 
8.4 Treatment  of Overdose  ..................................................................................56 
8.5 Pharmacokinetics  ...........................................................................................56 
8.5.1 Collection  of Samples  ........................................................................56 
8.5.2 Determination  of Drug  Concentration  ...............................................57 
8.5.3 Calculation  of Derivation  of Pharmacokinetic Variables  ..................57 
8.6 Pharmacodynamics  ........................................................................................58 
8.7 Genetics  ...........................................................................................................58 
8.8 Biomarkers  ......................................................................................................58 
8.9 Health  Economics  ...........................................................................................59 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  5 of 89  
 9.0 STATISTICAL  CONSIDERATIONS  ...................................................................... 60 
9.1 Statistical  Hypotheses  .................................................................................... 60 
9.2 Sample  Size Determination  ............................................................................ 60 
9.3 Populations  for Analyses  ............................................................................... 60 
9.4 Statistical  Analyses  ......................................................................................... 60 
9.4.1 Efficacy  Analyses  .............................................................................. 61 
9.4.2 Pharmacokinetic/Pharmacodynamic  Analyses  .................................. 61 
9.4.3 Safety  Analyses  .................................................................................. 61 
9.4.4 Other  Analyses  ................................................................................... 62 
9.4.5 Missing  Data  ...................................................................................... 62 
9.5 Interim  Analyses  ............................................................................................. 62 
9.6 Data  Review  Committee  ................................................................................ 63 
10.0 REFERENCES  ........................................................................................................... 64 
11.0 APPENDICES  ............................................................................................................ 66 
Appendix  1 Cancer Screening  Guidelines  .......................................................... 66 
Appendix 2  Regulatory, Ethical,  and Study  Oversight  Considerations  .......... 69 
Appendix  3 Clinical Laboratory Tests  ................................................................ 74 
Appendix 4  Excluded  Medications/Therapy  ...................................................... 80 
Appendix 5  2-D TTE Parameters  ....................................................................... 81 
Appendix  6 Contraceptive  Guidance  .................................................................. 82 
Appendix 7  Summary  of Changes  ...................................................................... 85 
Appendix 8  Signature  of Investigator  ................................................................. 89 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  6 of 89  
 TABLE  OF TABLES 
Table 1 Schedule  of Assessments ..................................................................................19 
Table 2 Schedule  of Digital ECG  Assessments,  Specimen Collection,  and 
ECHO Assessments (Day  1 through 3)  ............................................................22 
Table 3 Study Objectives  and Endpoints  ......................................................................29 
Table 4 Dose  Escalation  Per Cohort ..............................................................................33 
Table 5 Study Treatment  Details  ...................................................................................40 
Table 6 Injection  Site Reaction  Grading Scheme  .........................................................46 
Table 7 Definitions  of Serious  Adverse  Events  ............................................................50 
Table 8 Adverse  Event  Grade  (Severity) Scale  .............................................................52 
Table 9 Relatedness  of Adverse Events  to Investigational  Product  ..............................53 
Table 10 Plasma/Serum/Whole  Blood Pharmacokinetic Parameters  ..............................58 
Table 11 Analysis  Sets ....................................................................................................60 
Table 12 Study Administrative  Structure  ........................................................................71 
Table 13 Protocol -required  Safety  Laboratory  Assessments  ..........................................75 
Table 14 Schedule  of Protocol -required  Safety  Laboratory Assessments  
Performed  by the  Local  Laboratory  .................................................................77 
Table 15 Schedule  of Protocol -required  Blood Collections  to be Obtained  by 
the Local  Laboratory  for Central  Laboratory Analysis  ....................................79 
Table 16 Highly Effective Contraceptive  Methods  .........................................................83 
 
TABLE  OF FIGURES  
Figure  1 Study Schema  ...................................................................................................18 
Figure  2 Schematic Structure  of JK07  ............................................................................24 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  7 of 89  
 SUMMARY OF CHANGES  
Summary  of changes  for prior amendments  may  be found in  Section  11.0 Appendix 7. 
Amendment  3: 09 APR  2021  
Rationale for the amendment:  
• Revision of descriptions of study procedures  for clarification  
• Update to Sponsor signatory  
• Revision and updates to eligibility  criteria  to allow  for improved documentation and 
investigator interpretation/discretion  
• Updates  to the document for consistency  including deletion  of repetitive  and unnecessary 
templated language 
• Minor editorial and grammatical  corrections  were made throughout the document. 
Where applicable added text is bolded and italicized. Deleted text has strikethrough. 
Section  Change  Reason  
Sponsor  Signatory  John  Li CEO  
Sam Murphy,  PhD,  Chief  Executive Officer  
Neal  Salomon,  MD, Chief  Consulting  Medical  Officer  and 
Medical Monitor  Administrative  
Section 1.0: 
Protocol  Summary, 
Section 3.0: 
Objectives and Endpoints and Section 11,  
Appendix  5: 2-D 
TTE Parameters  Primary:  Deletion  of thyroid  panel  from  list of laboratory 
parameters for assessment of change from baseline 
 
Exploratory:  revision  of 2D-TTE to be performed:  
• Microbubble contrast -enhanced 2 -dimensional 
transthoracic echocardiography (2D -TTE) results: 
ejection fraction , including, but not limited to: LVEF , 
multiple 2 and 4- chamber left (LV) and right  
ventricular (RV) dimensions, including end systolic left ventricular volume (LVESV), end diastolic left ventricular volume (LVEDV), left atrial area and  
volume; right ventricular size and function, right  
ventricular global longitudinal strain, tricuspid valve  
regurgitation velocity, and mitral valve regurgitation  
grade (quantitative); as well as ,  valvular insufficiency 
and/or  gradients,  (IVC) size and collapsibility  ratios; and 
multiple calculated monitoring parameters using velocity 
and flow measurements, including stroke volume (SV), 
cardiac output (CO), derived left ventricular filling  
pressure  (E /e’). ) and systemic  vascular  resistance (SVR)  
calculations . Administrative  
 
Clarification  of assessment 
parameters  
Section  1.0: Revision  of language  Clarification  of directions  
Protocol  Synopsis,   regarding  dose escalation  
Treatment  Groups   procedures  by the DRC  
and Duration,    
Section  4.1:   
Overall  Design    
Section  4.6.2:    
Criteria  for   
Stopping  Dose    
Escalation    
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  8 of 89  
  
Section  Change  Reason  
Section 1.3:  Table 
1 - Schedule of 
Activities,  Table  2 - 
Schedule of Digital 
ECG Assessments, Specimen Collection, and ECHO  Assessments 
(Day 1 through 3);  
Section 5.3.1: Meals and Dietary Restrictions; Section 8.2.5: Electrocardiograms; 
Section 8.5.1: 
(Pharmacokinetics) 
Collection of Samples;  Table  1 SoA revisions  are listed  below  and are applicable  to 
other tables and sections listed.  
Addition:  Subjects  must  be fasted  for 10 hours  before  each 
on-site visit  
Screening  Visit; extension of screening  period from  Day -35 
to Day -45 
Footnotes:  
Vital signs ; change in requirement for the need for to be 
performed  at the same  time as ECGs rather  than immediately 
following.  
Footnote  “a” In-patient stay addition : requirement  for patients 
to receive a light breakfast/ snack prior to IP administration. 
Footnote “c” Physical examination addition: requirement 
subjects  must  verify  they have  no prior  history  of malignancy 
and/or have undergone cancer screening.  
Footnote  “g” Serum  chemistry,  liver,  kidney,  and coagulation  
assessments addition : coagulation panel will not be  
performed  on Day 60, Day 90, or Day 135. Drugs of abuse  to 
be performed as per local practices at Screening only . 
Footnote “i” Lipid Panel clarification: (fasting at screening  
and on Day 90) and should  be performed  as part of clinical 
chemistry at all timepoints indicated for clinical chemistry 
(see Table 14).  
Footnote “o” ECG clarification: following IP infusion,  0.5, 1, 
2, 4, and 8 hours  from the end of the IP infusion, 24- and 48- 
hours after the start clock -time matched within ± 30 minutes 
of the IP infusion pre-dose Day 1 ECG  assessment,  prior  to a 
light breakfast/snack.  
Footnote  “q” clarification: PK Blood Samples:  at 0.5, 1, 2, 4, 
8, 12, 24 hours  (Day  2), and 48 hours  (Day  3) from  the end of 
the infusion timed to no more than 10 minutes following 
completion of ECG assessment . Addition of a +1 day 
window for sampling Day 7.  
Footnote  “r” clarification: HbA1c  to be performed  at the 
Screening visit only.  
Footnote “u” Randomization update : Randomization will 
occur approximately one to two weeks prior to scheduled 
date of IP infusion, at the time of scheduling the inpatient admission, and will trigger shipment of IP and 
administration  kit to site. See Section  6.3 for description  of 
randomization procedures.  
Footnote “v”: Study Day 11 and 20 addition:  Study visits on 
Day 11 and Day 22 may be conducted remotely at the 
discretion of the Principal Investigator based on their local risk assessment, in which case, the requirement for vital 
signs,  ECGs,  physical  examination,  and PK blood draws will 
be waived. The procedures  will be performed  as per the SoA 
if the visit take place at the clinical site.  Update  to and clarification 
of study procedures  
Section  4.6.1  Study 
Stopping Criteria  • Any emergent symptomatic or asymptomatic cardiac 
arrhythmia requiring at least urgent medical intervention.  
• Any ≥ moderate (corresponding to Common  Terminology  
Criteria for Adverse Events [CTCAE version 5 (v5)]  
Grade 2) hematologic, non- hematologic, hepato -cellular,  
renal toxicity ≥7 days . Any emergent Grade 3 or greater 
(>/=) toxicity  except  untreated  nausea,  diarrhea,  Clarification  of criteria.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  9 of 89  
  
Section  Change  Reason  
 vomiting,  constipation,  abdominal  pain.  Any of these  will 
be considered DLTs if persisting >72 hours despite 
appropriate   treatment.   Any   emergent   ≥  severe 
(corresponding to CTCAE  v5 Grade  3) hematologic,  non- 
hematologic, hepato -cellular, renal toxicity   
Section  5.1: 
Inclusion Criteria  Criterion 2 : Stable HF defined as no hospitalizations for 
cardiac- related issues within the previous 2 3 months prior to 
the screening visit or between screening and randomization, 
other than for routine percutaneous procedures such as 
device, battery, generator changes or pacemaker lead 
insertion/replacement. 
Criterion 4: Subjects must be taking clinician -directed 
appropriate pharmacological therapy for HF as per the 2017 
ACC/AHA/HFSA treatment guidelines (Yancy et al, 2017) 
and at investigator determined discretion at stable doses 
(except for diuretics) for at least 3 2 months prior to 
screening sinformed consent . 
Criterion 5 : Subjects without implantable cardioverter - 
defibrillators (ICDs) are eligible.  Subjects with implantable 
ICDs if the devices are not “pacing are allowed at the 
discretion of the investigator, but only if both the following 
criteria are met: (a)  paced beats cannot exceed  15% of beats 
as quantified by screening e -Patch, and (b) if a non -paced 
baseline ECG can be obtained on Day 1 prior to study drug administration.  
Criterion  6: Body mass  index ≥18 kg/m2 and ≤4540 kg/m2 Revision  and clarification 
of criteria to allow for improved documentation and investigator 
interpretation/discretion.  
Section  5.2: 
Exclusion Criteria  Criterion 4 : Diagnosed with medically documented acute 
coronary syndrome within 3 months of screening or a 
medically  documented  acute myocardial  infarction  within  
6 months of screening.  
Criterion 8: Sustained systolic BP <90  <100 mm Hg and/or 
diastolic BP <50 mm  Hg (confirmed by a duplicate seated 
reading) on at least 3 consecutive readings (self -monitored or  
office) …..  
Criterion 9 : Resting HR >100 beats per minute (bpm) at 
Screening (Visit 1) or prior to randomization which is 
sustained for >15 minutes in two episodes separated by one hour of observation 
except in sustained atrial fibrillation 
when HR of up to 110 bpm is acceptable.  
Criterion 10 : Cerebrovascular accident or hospitalizations for 
CV (cardiovascular) causes other than routine percutaneous 
procedures such as device, battery, generator changes or 
pacemaker lead insertion/replacement or device generator 
changes, including HF, chest pain, stroke, transient ischemic 
attack, or arrhythmias within 3 2 months prior to screening.  
Criterion 11 : Subjects at screening have an abnormal or 
clinically  significant 12-lead ECG  abnormality,  (e.g. QRS 
>120  msec, PR >210  msec, heart  rate (HR)  <45 bpm,  sustained  
HR >100 bpm)  that, in the opinion of the Investigator, would 
affect  efficacy  or safety  evaluation  or place  the subject  at risk. 
Criterion  15: For subjects  on warfarin  or other  anticoagulants, 
an INR (or PT/PTT ) considered  by the Principal Investigator  
as therapeutically  appropriate  will be allowed.  Revision  and clarification 
of criteria to allow for improved documentation and investigator interpretation/discretion.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  10 of 89  
  
Section  Change  Reason  
 Criterion 18 : Concurrent treatment with Class I a or III 
antiarrhythmic drugs ( unless  the medication was must have 
been discontinued more than 32 months before 
enrollment informed consent ). 
Criterion 20 : Known history of or active alcohol abuse (no 
more  than 14 units/week  for males  or 7 units/week  for females) 
or use of illicit drugs  within  1 year prior  to randomization  other  
than(excluding recreational use of marijuana or cannabis - 
cannabidiol [CBD] -based products).  
Criterion 22 : history of pathologically confirmed malignancy 
of any type or any pathologically confirmed pre -malignant 
condition (e.g., ductal carcinoma in situ, colonic polyp with 
premalignant diagnosis , or cervical atypia).   
Section  6.0: Study 
Treatment  New language added: This is a double -blind study. The  
investigational treatment and placebo infusions will be 
identical in physical appearance. Other than in the case of 
sentinel  subjects,  the treatment each  subject  will receive will 
not be disclosed to the Investigator, study center staff, subject, Sponsor, study vendors, or DRC. The treatment codes  will be held by a third -party clinical research services 
vendor designated by the Sponsor.  
Where possible,  and as applicable,  hospital  admission  and IP 
administration should take place on Monday or Tuesday to allow  for Day 7 follow -up visits  to take place  on the following 
Monday.  
With  the exception  of IP infusion administered  to the sentinel 
subject in each cohort, all study staff will be blinded to IP identification.  
The total infusion time,  inclusive  of saline  flush  should  be 60 
minutes and should not exceed 75 minutes.  Addition  of new language 
and revision of existing 
language to clarify study 
procedures.  
Section 6.2: 
Preparation, Handling,  and 
Storage  Revision  to allow  for pharmacy  staff to document  preparation 
of IP according to local standards of practice and to mandate that all records be available for inspection.  Simplification  of 
procedures  
Section  6.3: 
Randomization and 
Blinding  Deletion  of unnecessary  templated  language  and insertion  of 
language describing the IWRS procedures.  Clarification  of procedures  
Section 6.4.1: 
Treatment  Strategy 
and Section 6.4.2:  
Warnings  and 
Precautions  Sections  deleted.  Deletion  of unnecessary 
language.  
Section 6.5: 
Concomitant 
Medications  Substitution of ‘time of informed consent” and deletion of 
“time  of enrollment”  as the starting  timepoint for collection  of 
data Clarification  of study 
procedures.  
Section  6.6: Dose 
Modification  Deletion of language. Addition of: As this is a single -dose 
study,  dose modification within  an individual  subject  is not 
applicable.  Deletion  of unnecessary 
template language and clarification of study 
procedure.  
Section 7.2: 
Subject Discontinuation  Addition: Subjects withdrawing due to an AE should be  
followed up according to the follow -up visit  at any time  
should be followed up until resolution, stabilization, the event  is otherwise  explained,  the subject  is lost to follow -up 
(Section  8.3.8)  or until  the end of their  participation  in the Clarification  of study 
procedure  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  11 of 89  
  
Section  Change  Reason  
 study.  Subjects  should  be encouraged  to complete  the End 
of Study visit activities.   
Section  8.2: Safety 
Assessments  Addition:  Subjects  will be observed  for injection  site reactions 
until  Day 4 following  IP administration,  for DLAEs until  Day 
15 following  IP administration,  and for AEs and SAEs from 
the time of informed consent until 30 days after the IP 
administration.  Following Day  30, only SAEs deemed  at least 
possibly  related  to the study  drug  or study  procedures  will be  
collected until the End of Study visit (Day 180).  Clarification  of timelines 
for safety reporting.  
Section  8.2.5:  
Electrocardiograms  Addition:  During Screening and  beginning  no more  than  45 
days before Day 1, all subjects will be supplied with, and 
instructed how to use a e -Patch for continuous 14- day heart 
rhythm monitoring as outlined in the Table 1 SoA. A 14 - 
continuous day heart rhythm monitoring assessment will be 
collected using the e -Patch with monitoring completed no 
later  than Day -10 unless  confirmed  with the sponsor.  Where 
applicable,  the screening  ECG  and Day 1 baseline  ECG  must 
be obtained without evidence of pacing.  Addition  of description  of 
ePatch procedures  
Section 8.3.8: 
Follow -up of AEs 
and SAEs.  Revision: All SAEs will be followed until resolution, 
stabilization,  the event  is otherwise  explained,  or the subject 
is lost to follow -up (as defined in Section 7.3) or until the  
end of their participation in the study. Subjects should be 
encouraged to complete the End of Study visit activities.  Clarification  of duration  of 
follow -up for SAEs.  
Section 8.4: 
Treatment  of 
Overdose  Revision:  Obtain  blood  sample  for PK analysis  within  30 days 
from  as specified in Table 1 SoA.the date of the last dose of  
study intervention  if requested  by the medical  monitor  
(determined  on a case-by-case basis).  Revision  of study  procedure  
Section  8.8: 
Biomarkers  Addition  of lactate  dehydrogenase  Revision  of study 
procedures  
Section 9.4.3 : 
Safety  Analyses  For 12 -lead ECG parameters: If relevant, analysis excluding 
ECGs capturing paced beats will be performed.  Clarification  of procedures  
Section 9.6:  Data 
Review  Committee  Addition  of description  of procedures  outlined  in the synopsis.  Clarification  of procedures.  
Section 11: 
Regulatory,  Ethical, 
and Study Oversight, Appendix  2: Study  
and Study 
Procedures  Addition  of language  describing  procedures  for changes  to the 
protocol.  Update  of study  procedures  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  12 of 89  
 LIST OF ABBREVIATIONS  
 
Abbreviation  Definition  
2D-TTE 2-dimensional  transthoracic  echocardiography  
ACC/AHA/HFSA  American  College  of Cardiology/American  Heart  Association  Task  Force  on 
Clinical Practice Guidelines and the Heart Failure Society of America  
ACS  American  Cancer  Society  
ADA  anti-drug-antibody  
AE adverse  event  
ANC  absolute  neutrophil  count  
AUC (0-inf) area under  the plasma  concentration -time curve  from  time zero extrapolated 
to infinity  
AUC (0-last)  area under  the plasma  concentration -time curve  from  time zero to the time of 
the last quantifiable concentration  
BP blood  pressure  
bpm beats  per minute  
BUN  blood  urea nitrogen  
BNP  brain  natriuretic  peptide  
CBD  cannabidiol  
CL systemic  clearance  
Cmax maximum  concentration  
CO cardiac  output  
CPK  creatine  phosphokinase  
CPK -MB creatine  phosphokinase  – muscle/brain  
CRO  contract  research  organization  
CTCAE  Common  Terminology  Criteria  for Adverse  Events  
CTnI  cardiac  troponin  I 
CV cardiovascular  
DD2  diastolic  dysfunction  Grade  2 
DLAE  dose-limiting  adverse  events  
DRC  Data  Review  Committee  
DRE  disease -related  events  
ECG  electrocardiogram  
ECRF  case report  form 
eCRF  electronic  case report  form 
E early  diastole  
E/e’ derived  left ventricular  filling  pressure  
EGF epidermal  growth  factor  
FIH first-in-human  
GCP  Good  Clinical  Practice  
GGT  gamma -glutamyl  transferase  
GI gastrointestinal  
GLP Good  Laboratory  Practice  
GMP  Good  Manufacturing  Practice  
HCSD  highest  confirmed  safe dose 
HED  human  equivalent  dose 
HER3  human  epidermal  growth  factor  receptor  3 
HF heart  failure  
HFpEF  heart  failure  with preserved  ejection  fraction  
HFrEF  heart  failure  with reduced  ejection  fraction  
HR heart  rate 
hsCRP  high-sensitivity  C-reactive  protein  
hs-troponin  high-sensitivity  troponin  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  13 of 89  
  
Abbreviation  Definition  
ICD implantable  cardioverter -defibrillators  
ICF informed  consent  form 
ICH International  Council  for Harmonisation  
INR international  normalized  ratio 
IP investigational  product  
IRB/IEC  Institutional  Review  Board/Independent  Ethics  Committee  
IV intravenous  
IVC inferior  vena  cava 
IVRS/IWRS  Interactive  Voice/Web  Response  System  
LDH  lactate  dehydrogenase  
+LVdp/dt max maximum  rate of rise of left ventricular  pressure  
LVEDV  end diastolic  left ventricular  volume  
LVEF  left ventricular  ejection  fraction  
LVESV  end systolic  left ventricular  volume  
Max maximum  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
Min minimum  
NHP  non-human  primates  
NOAEL  no observed  adverse  effect  level 
NRG -1 neuregulin -1 
NT-proBNP  N-terminal  pro-brain  natriuretic  peptide  
NYHA  New  York  Heart  Association  
PBS phosphate  buffered  saline  
PD pharmacodynamic  
PK pharmacokinetic  
PT prothrombin  time 
PTT partial  thromboplastin  time 
QTca  heart -rate corrected  QT interval  
QTcF  QT interval  corrected  for heart  rate using  Fridericia’s  formula  
RC max ratio of Cmax 
RAUC (0-inf) ratio of AUC (0-inf)  
RAUC (0-last) ratio of AUC (0-last)  
RR respiratory  rate 
SAE serious  adverse  event  
SAP Statistical  Analysis  Plan 
SoA Schedule  of Assessments  
SUSAR  Suspected  Unexpected  Serious  Adverse  Reaction  
SVR  systemic  vascular  resistance  
t1/2 terminal  half-life 
TEAE  treatment -emergent  adverse  event  
tmax time to maximal  concentration  
ULN  upper  limit  of normal  
WOCBP  women  of child -bearing  potential  
λz terminal  rate constant  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  14 of 89  
 1.0 PROTOCOL  SUMMARY  
1.1 Synopsis  
Protocol  Title:  A Randomized,  Double -Blind,  Placebo -controlled,  Single -ascending  Dose  Study to Assess  the Safety, 
Tolerability, and Pharmacokinetics of JK07 in Subjects with Heart Failure with Reduced Ejection Fraction (HFrEF)  
Rationale: JK07 is a recombinant fusion protein consisting of a human  neuregulin-1 (NRG -1) active domain and an 
anti-human epidermal growth factor receptor 3 (HER3) monoclonal antibody, thus limiting HER3- mediated 
gastrointestinal (GI) toxicity  and oncogenic  potential while  preserving/activating  the HER4 -mediated  cardiovascular 
potential.  The main  purpose  of the study  is to evaluate the safety,  tolerability,  immunogenicity,  and pharmacokinetics 
(PK)  of JK07,  administered  intravenously  (IV) to subjects  with heart  failure  with reduced  ejection  fraction 
(HFrEF  ≤40%). Change in left ventricular ejection fraction (LVEF), potential predictive biomarkers of response to 
JK07, and changes in QT interval will be also explored.  
Objectives  and Endpoints:  
 
Objectives  Endpoints  
Primary   
• Assess the safety and tolerability profile, including 
immunogenicity,  of JK07,  administered  intravenously 
according to protocol -defined dosing regimen.  • Incidence and severity  of treatment -emergent  adverse 
events (TEAEs) and their relationship to the 
investigational product (IP).  
• 12-lead  electrocardiogram (ECG) parameters  (heart  rate, 
PR, QRS, QT, QTcF) change from baseline derived as mean from triplicate ECG  recordings as well as QT and 
QTcF outlier analyses.  
• Change from baseline in the incidence of rhythm abnormalities  (retrieved from  telemetry  readings  for 
48 hours postdose).  
• Laboratory parameters – change from baseline each 
assessment time point per Table 1  Schedule of 
Assessments (SoA)  postdose:  hematology,  chemistry, 
coagulation, and lipid panels.  
• Immunogenicity 
o Incidence of early  and delayed -type 
hypersensitivity responses.  
o Presence of serum anti -JK07 antibodies 
(confirmed  positive  antibody  response,  titer, 
neutralizing antibodies).  
• Vital signs  – change from baseline in vital signs  and the 
relationship  to JK07  compared  with placebo,  including:  
o Blood  pressure  (BP) 
o Temperature  
o Heart  rate (HR)  
o Respiratory rate (RR).  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  15 of 89  
  
Secondary   
• To determine the PK characteristics of JK07 
administered  intravenously according  to protocol - 
defined dosing regimen.  • Pharmacokinetic parameters of intact JK07 including, but not limited to, maximum concentration (C
max), time 
to Cmax (tmax), area under  the concentration- time curve  to 
the last quantifiable concentration and extrapolated to infinity [AUC
(0-last) and AUC (0-inf)], half -life (t 1/2), 
elimination rate constant (λ z), systemic clearance (CL), 
and volume  of distribution  (V z). Surrogate measurement 
of intact JK07 to be carried out through detection of  
both the JK07 antibody domain and the JK07 NRG -1 
peptide fragment in the evaluation of pharmacokinetic 
parameters.  
Exploratory   
• Explore  left ventricular  and systemic vascular  resistance 
(SVR) performance indices measured by 2 -dimensional 
transthoracic echocardiography (2D -TTE) of JK07, as 
change from baseline compared with placebo.  
• Explore  potential predictive  biomarkers  of response  to 
JK07 in this dosing regimen.  
• Explore relationship between JK07 plasma 
concentrations,  if any, and changes  in QT intervals 
during dosing.  • Microbubble contrast -enhanced 2 -dimensional 
transthoracic echocardiography (2D-TTE) results, 
including, but not limited to: LVEF, multiple 2 and 
4-chamber left (LV) and right ventricular (RV) 
dimensions, including end systolic left ventricular 
volume  (LVESV),  end diastolic  left ventricular  volume 
(LVEDV), left atrial area and volume, valvular insufficiency and/or gradients, and multiple calculated 
monitoring parameters using velocity and flow 
measurements, including stroke volume (SV), cardiac output (CO), derived left ventricular filling pressure (E/e’).
 
• Observed  biomarker  concentrations  and corresponding 
changes from baseline.  
• Concentration-QT  correlation  performed  on baseline- 
corrected QTcF time matched with PK.  
 
Overall  Design:  
This is a phase  1, randomized, double -blind,  placebo -controlled,  single -ascending  dose study to assess the safety,  
tolerability,  immunogenicity,  and PK of JK07  in subjects  18 to 80 years  of age with HFrEF  ≤40%  (Figure  1). 
Initially 5 cohorts are  planned  with the option to expand the  study to a total  of 7 cohorts. The size of the  cohorts will 
range  from  5 to 9 subjects.  Each  cohort  will include  one single  active  unblinded sentinel subject  receiving  a single  IV 
dose of JK07 prior to randomized JK07 or placebo administration in the remainder of the cohort.  
A Data  Review  Committee  (DRC)  will be established  to review  emerging  data,  to monitor  safety  aspects  of the study, 
to select the JK07 dose during dose escalation, and to adapt the randomization scheme. The DRC will evaluate the 
emerging clinical, laboratory and cardiac safety data, inclusive from the first 48 hours after dosing of the sentinel subject, and prior to randomized blinded IP administration in the remainder of the cohort.  
Number  of Investigators  and Study  Centers:  
Approximately  8 Investigators  and study centers  are expected  to participate  in this study.  
Number  of Subjects:  
A maximum of 63 subjects  will be randomized  into dose escalation  cohorts.  Five dose escalation  cohorts  are planned. 
Two additional cohorts may be added as per the DRC recommendation (total up to 7 cohorts).  
Treatment  Groups  and Duration:  
In Cohort 1, if no clinical effect is observed in the sentinel subject, the DRC  will decide whether to proceed with the 
randomization of 4 additional subjects (3:1, JK07: placebo) to receive blinded IP. Once the last subject in Cohort  1 
completes  the evaluation  period,  the DRC  will decide whether  to proceed  to Cohort  2. The evaluation  period  for dose 
escalation to the next cohort will be at a minimum, the available safety data through Day 15 following the 
administration of the IP on Day 1 for all subjects in the current dose cohort. Safety  data will continue to  be collected  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  16 of 89  
 up to 180 days following the administration of the IP and may additionally be taken into consideration for dose 
escalation when available. Cohort  2 and subsequent cohorts will proceed as Cohort  1 until either of the following 
occur: a sentinel subject exhibits, in the opinion of the DRC, a clinical effect (efficacy or safety observation), or a cohort exhibits, in the opinion of the DRC, a clinical effect.  
Once a clinical effect is observed, the DRC may, at its discretion, expand the size of that cohort in which a clinical effect is first observed, and subsequent cohorts, up to a maximum of 9 subjects (1 open -label JK07 sentinel subject, 
and 6:2 [JK07: placebo] randomized, double -blind subjects).  
Following observation of a clinical effect and a decision to expand the size of the cohort at which the clinical effect was observed, the DRC will decide whether to dose escalate after the last subject in the expansion cohort completes the evaluation period. If the DRC decides to escalate the dose, a single unblinded sentinel subject will receive JK07 at the next dose level.  If following  the completion  of the evaluation  period of that sentinel  subject  the DRC decides  to 
proceed, the remainder of the subjects in the expanded cohort size will receive JK07 or placebo according to the direction of the DRC, and this sequence will repeat until the highest planned dose level is reached or until the DRC 
determines not to dose escalate further.  
Cohort dose levels of JK07 are as follows: the starting dose has been selected at 1/30 of the human equivalent dose 
(HED)  at the no-observed adverse  effect  level  (NOAEL)  in the cynomolgus  monkey (3 mg/kg/week).  A conservative 
approach of body surface  area scaling  was employed  for this conversion (HED)  at the monkey  
NOAEL  = 0.97 mg/kg/week).  The subsequent  provisional  doses  have  been  set at a 3-fold increase from  the prior  dose 
for the first 2 dose escalations (Cohort 2 through Cohort 3). The subsequent dose escalations (Cohort 4 through Cohort  5) have been set at a 2 -fold increase from the prior dose; based on emerging safety and/or PK results of the 
previous cohorts, the DRC  can allow a 3 -fold increase. Additionally, the DRC  may also reduce the incremental dose 
escalations based on the results of the previous cohorts.  
 
Dose  Level  JK07  
Cohort  1 0.03 mg/kg  
Cohort  2 0.09 mg/kg  
Cohort  3 0.27 mg/kg  
Cohort  4 0.54 mg/kg  
Cohort  5 1.08 mg/kg  
Note:  Initially  5 cohorts  are planned.  Two additional  higher  cohorts  may be added  as per the DRC recommendation (total  up to 
7 cohorts). The highest JK07 dose administered not to exceed 2.5 mg/kg without further amending the protocol.  
Subjects  will be  observed for injection  site reactions  until Day 4 following  study  treatment and will be monitored  for 
signs of dose -limiting adverse events (DLAE) until Day 15 following study treatment.  
Beginning on Day 1 and prior  to study drug administration,  subjects  will be observed on continuous  telemetry  for the 
duration of the hospital stay. During this period blood will be collected for PK, biomarkers and safety laboratory assessments, vital sign and ECG assessments will be performed, and 2D -TTE will be performed pre- dose, and at 6- 
and 30 -hours post -dose, to observe for possible clinical activity.  
The DRC will evaluate each sentinel subject as well as active treatment subjects in each dose cohort for DLAEs. To support  dose escalation  decisions  by the DRC,  safety,  and tolerability  results  for all subjects  in each cohort  through at 
least Day 15 will be included in this review. During the review of the safety and tolerability results the DRC may make the determination  to escalate to the next dose level  or expand  the size of the current  cohort  further, if not already 
at the maximum size, following which further dose escalation could  proceed. Alternatively, the DRC  may determine 
to decrease to a lower  dose level  which  may be an additional  cohort  at an intermediary  dose or a pre-assigned  cohort. 
In the case that an intermediary  dose is selected, a single  sentinel subject  will receive  JK07  prior  to randomization  of 
the remaining  subjects  in the cohort.  Following  a dose reduction,  the DRC may subsequently decide to further  reduce 
the dose level in a subsequent cohort or increase the dose in a subsequent cohort. A sentinel subject is required only if the selected de- escalated dose is above the previously Highest Confirmed Safe Dose (HCSD).  
At the time of the DRC safety review of the entire cohort, PK results if available for that cohort, will be evaluated (along with results of prior cohorts, as available).  
Statistical  Methods:  
Sample size calculation : The sample size for this study is not based on statistical considerations but is typical for 
studies of this nature and is considered adequate to characterize the distribution of the planned endpoints. Any statistical testing will be considered exploratory and descriptive.  
Analysis  sets: 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  17 of 89  
 • Safety Evaluation Population: All subjects randomly assigned to the IP and who take 1 dose of IP. Subjects 
will be analyzed according to the treatment they received.  
• DLAE Evaluation Population: All subjects who received 1 dose of IP and completed the 15- day DLAE 
follow -up period.  
• PK Evaluation  Population:  All subjects  who received  at least 1 dose of JK07  and have  at least 1 quantifiable 
JK07 plasma concentration collected postdose without important protocol deviations/violations or events 
thought to significantly affect the PK results.  
• Exploratory  PD/biomarker  Evaluation  Population:  All subjects  who take 1 dose of IP and have  at least 
1 exploratory PD variable or biomarker endpoint collected postdose without important protocol 
deviations/violations or events thought to significantly affect the PD results.  
Safety Analyses : All data will be provided in data listings sorted by treatment group, subject number, and visit. 
Summary  data will be presented  in a tabular  format  by treatment  group,  by scheduled time point,  visit,  and overall  (as 
appropriate). Categorical data will be summarized by the number and percentage of subjects in each category. Continuous  data will be summarized  by descriptive  statistics  including  at a minimum  sample  size (n), mean,  standard 
deviation, median, minimum, and maximum. Change from baseline will be calculated as value postdose subtracted by value at baseline. The baseline measure will be defined as the last non- missing measure prior to initiation of the 
IP. Outliers for QT and QTc defined under outcome measures will be summarized using cumulative counts and 
percentages  by treatment and  sampling time, if appropriate.  Abnormal  findings on 12 -lead ECG will be summarized 
by treatment using descriptive statistics.  
PK Analyses : Intact JK07 concentrations, determined through detection of both the antibody domain and NRG -1 
peptide, and calculated parameters will be listed and descriptively summarized by active treatment for the PK Evaluation population. Dose proportionality will be explored graphically, and, if applicable, using a power model.  
Exploratory PD Analyses : Results of the exploratory endpoints (2D -TTE results and biomarkers) and their change 
from  baseline  values  (as applicable)  will be listed  and descriptively  summarized  by treatment.  Exploratory inferential 
comparisons  with placebo  may also be performed,  if appropriate.  An exploratory evaluation  of a plasma  concentration 
to QT (C -QT) relationship will be conducted using a linear mixed effects model, with the drug- free-corrected (i.e., 
predose -corrected) change from baseline in QTcF as the response variable. Independent variables will include the 
fixed effects time -matched JK07 plasma concentration obtained on Day 1, treatment indicator (treatment = 1 for 
subjects receiving JK07, and  0 otherwise), time point as a categorical variable, and random effects subject and time - 
matched JK07 plasma concentration obtained on Day 1.  
Data  Monitoring  Committee: Yes 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  18 of 89  
 
1.2 Schema  
Figure 1 Study  Schema  
 
Abbreviations:  DLAE,  dose-limiting  adverse events;  DRC,  Data Review  Committee.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  19 of 89  
 1.3 Schedule  of Activities  
Table  1 Schedule  of Assessments  
(note  that X denotes  activity  on a given  day, but may denote  a single  or multiple  instances  of the indicated  activity)  
 
 Screening  In Hospital  Follow -up  
EOS/ 
180t   Subjects  must  be fasted for  10 hours  before  each  on-site visit 
Study  Day -45 to 0 1a 2 3 4 7 11v 15 22v 30 60 90 135 
Window       +1 -1 +/-2 +/-2 +/-2 +/-5 +/-5 +/-7 +/-10 
In-patient  staya  X X X           
Hospital dischargeb    X           
Informed consent  X              
Demographics  X              
Past medical  history  X              
Height  (at screening  only)  and 
Weight  X X  
X  
X X X  
X X X X X 
Vital signs  (at same  time point  as 
ECGs)   
X  
X  
X  
X  
X  
X  
 
Xv  
X   
X  
X  
X  
X  
X 
Physical  examinationc X X X X X X Xv X Xv X X X X X 
Blood -based  pregnancy  testd X              
Urine  pregnancy  testd  X        X X X X X 
IP administration   X             
Check  for injection site  reactione  X X X X          
Adverse  eventsf  X X X X X X X X X X X X X 
Review  concomitant  medications X X X X X X X X X X X X X X 
Serum  chemistry  and liver,  kidney,  and 
coagulation panelsg X X X   
X  
X  
X  
Xg  
Xg  
Xg X 
Complete blood counth X X X X  X  X  X X X X X 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  20 of 89  
  
 Screening  In Hospital  Follow -up  
EOS/ 
180t   Subjects  must  be fasted for  10 hours  before  each  on-site visit 
Study  Day -45 to 0 1a 2 3 4 7 11v 15 22v 30 60 90 135 
Window       +1 -1 +/-2 +/-2 +/-2 +/-5 +/-5 +/-7 +/-10 
Lipid  paneli X X X   X  X  X X X X X 
Urinalysisj X X X   X  X       
Muscle and inflammatory 
biomarkersk  
X X   
X  
X  
X X X X X 
Additional biomarkers: Cardiac 
troponins,  CPK-MB,  CPK,  and hsCRP 
assessmentl  
X  
X  
X  
X   
X   
X   
X  
X  
X  
X  
X 
Immunogenicity  Assessmentm  X   X X  X  X  X  X 
Telemetryn  X X X           
Digital 12-lead ECGo X X X X X X Xv X  X X X X X 
2D-TTEp X X X   X  X  X X X X X 
PK sample collectionq  X X X X X Xv X Xv X X    
Fingerstick  glucoser  X X X X          
ECG patch recordings X              
Thyroid  panel  X              
Viral  serology X              
Randomizationu X              
Abbreviations:  2D-TTE, 2-dimensional  transthoracic echocardiography;  β-hCG,  beta-human  chorionic  gonadotrophin;  CPK-MB, creatine kinase  – muscle/brain;  CPK,  creatine 
phosphokinase; ECG, electrocardiogram; HbA1c, glycosylated hemoglobin; HDL, high density lipoprotein; hs -CRP, high -sensitivity C -reactive protein; ICD, implantable 
cardioverter -defibrillators; IP, investigational product; LDH, lactate dehydrogenase; LDL, low density lipoprotein; PK, pharmacokinetic.  
a Subjects should be admitted in the hospital study unit by 7:00 AM,  or as early as practicable, on Day 1. The subject should arrive fasted (at least 10 -hour fast). All baseline 
clinical  and laboratory assessments  should be conducted prior  to light breakfast/snack  being provided to the subject.  Subjects  will be scheduled for discharge  on the morning of 
Day 3.  
b Subjects  will be scheduled for  hospital discharge  on Day  3, after completion of  all planned in-patient  safety,  PK, and  exploratory PD/biomarker  assessments.  However, subjects 
may be asked to remain in the hospital study unit for more than 48 hours after the IP administration at the Investigator’s di scretion.  
c A full physical  examination  will be performed  at screening.  An abbreviated  physical  examination  will be conducted  at all other  visits.  See Section  8.2.1 . During screening  all 
subjects  must  verify they have  no prior  history  of malignancy  and/or  have  undergone  cancer  screening  or undergo  cancer  screening  according  to American  Cancer  Society 
Guidelines (Appendix 1  Cancer Screening Guidelines ). 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  21 of 89  
 d Women  of childbearing  potential  only.  β-hCG blood test at screening,  urine  dipstick test upon admission  on Day 1 prior  to IP administration  to confirm  absence of pregnancy,  and 
urine specimens at all time points thereafter.  
e See Section  8.2.2  for assessment  times  and parameters.  
fAll AEs,  including  SAEs will be collected  from  the time of study  enrollment  and until 30 days after the IP administration.  Following  the first 30 days,  only SAEs deemed  at least 
possibly related to the  study  drug or study procedures  should be  collected. Refer to Table  9 for additional details.  
g See Appendix 3  Clinical  Laboratory Tests  for a complete list of analytes  and schedule of collections  and analysis.  Coagulation  panel  will not be performed  on Day 60, Day 90, 
or Day 135. Drugs of abuse to be performed as per local practices at Screening only.  
h See Appendix 3  Clinical Laboratory  Tests  for parameters  included in the complete blood  count.  
i Lipid  profile  includes  total cholesterol,  HDL,  LDL, and triglycerides,  and should be performed  as part of clinical  chemistry  at all timepoints  indicated  for clinical  chemistry  (see 
Table 14 ). 
j See Table 13 for a complete list of urinalysis  parameters.  
k See Section  8.8 for a complete list of muscle and inflammatory biomarkers.  
l On Day 1 multiple  blood samples  for safety  evaluation  will be collected as  follows:  troponin I and/or  hs troponin  T, CPK,  CPK -MB,  and hsCRP  prior  to infusion  and at 4, 8, and 
12 hours from end of infusion.  
m Refer  to Section  8.2.8  for immunogenicity  assessments.  
n Continuous  telemetry  monitoring will be started  as soon  as practicable after hospital admission  on Day 1 and prior  to IP infusion,  and will be continued  until 48 hours  after the end 
of the IP infusion  on Day 3. In the case of any abnormal  finding,  the Investigator  will determine whether  the finding  constitutes  an abnormal  event  and whether  an unscheduled 
ECG should be conducted.  
o Triplicate  12-lead digital  ECGs will be performed  during screening  and starting  on Day 1 following  admission to the hospital.  ECG  assessment  will be performed  at each specified time  point 
after the subject  has been  supine  for ≥5 minutes.  At each time point at which triplicate  ECGs are  required, 3  individual  ECG  tracings should be performed as closely as  possible 
in succession but no more than 2 minutes apart.  The full set of triplicates should be completed in less than 5 minutes with no more than 2 min between them. Vital  signs  are 
scheduled  at the same  time points  and will be collected  prior to completion of the ECG  assessment,  and the ECG  assessment  will be prior to PK sample collections  at simultaneously 
scheduled time points.  
• The post-screening  times  for the ECGs  will be as follows:  prior  to the IP infusion, immediately following IP infusion,  0.5, 1, 2, 4, and 8 hours  from  the end of the IP 
infusion, 24- and 48 -hours clock-time matched within ± 30 minutes of pre-dose Day 1 ECG assessment, prior to a light breakfast/snack (see Table 2 for additional 
details).  
• These ECGs  will be read by the Investigator  to ensure  subject safety.  These ECGs  must  be taken  immediately  before  PK sampling.  
p On Day 1, 2D-TTE  measurements  will be performed  pre-dose  and at 6 ± 0.5 hours  post-dose.  On Day 2, the  assessment  is scheduled for  30 ± 0.5 hours  post-dose.  
See Section  8.2.9  for a description of  exploratory 2D-TTE  assessments.  
q The PK blood samples  will be collected  as follows:  Prior to  the IP administration, at the end of the  infusion, at  0.5, 1, 2, 4, 8, and 12 hours, at 24  hours (Day  2) and 48 hours (Day 
3) timed to  no more  than 10 minutes  following  completion  of ECG  assessment, at  72 hours  (Day  4), 144 hours  (Day  7), 240 hours  (Day 11),  336 hours  (Day 15), and  504 hours 
(Day 22) from the end of the infusion, and on Day 30 and Day 60 (see Table 2 ). Note that sample collection times may be modified based on emerging PK results and  
1 additional blood sample  may be collected if  deemed appropriate (up to  18 samples). Windows  for the first 48 hours  of PK collections  are identified  in Table 2; a ±8-hour 
window is permitted for PK collections on Day 4 and a +1 day is permitted on Day 7. Windows for subsequent PK sample collecti ons are indicated in the SoA above.  
r Blood  glucose  samples  will be collected  by fingerprick test and read using  standard  glucometer  at the same timepoint as the PK samples  through  96h (Day  4) postdose.  HbA1c  to 
be performed at the Screening visit only.  
s During the screening  period  and no more  than 45 days before  Day 1, all  subjects  will be supplied with, and instructed how to use a e-Patch for  continuous  14-day heart  rhythm 
monitoring. Subjects must then perform 14 continuous  days of heart rhythm monitoring using the e -Patch. Unless otherwise approved by the sponsor, monitoring should be 
completed no later than Day -10 to allow for processing of data by the manufacturer and evaluation of baseline ECG parameters and arrhythmia incidents by the site.  
t Subjects  who do not complete all required  visits  or withdraw  from  the study early  are required  to complete End-of Study/Early -Termination  assessments  (Day  180) as described  in 
Section 7.2. 
u Randomization will  occur  approximately one  to two weeks  prior  to scheduled  date of IP infusion, at  the time of scheduling the  inpatient admission, and will trigger  shipment  of IP 
and administration kit to site. See Section 6.3 for description of randomization procedures.  
v Study  visits  on Day 11 and Day  22 may  be conducted remotely at  the discretion  of the Principal  Investigator  based  on their local  risk assessment, in which case, the requirement 
for vital signs, ECGs, physical examination, and PK blood draws will be waived. The procedures will be performed as per the S oA if the visit takes place at the clinical site.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  22 of 89  
 NOTE: See Appendix 3  Clinical Laboratory  Tests , Table 13 for a complete list of protocol -required  laboratory  assessments  that will be performed;  see Table 14 for a list of 
safety laboratory assessments (and assessment timepoints) that will be performed by the local laboratory; see Table 15  for a list of safety and exploratory biomarker 
assessments that will be performed by a central laboratory.  
 
Table  2 Schedule  of Digital ECG  Assessments,  Specimen  Collection, and ECHO  Assessments (Day  1 through  3) 
 
Schedule  of Assessments (Day  1 – Day 3) 
(Order of activities  to be completed  left to right,  top to bottom)  
 Day 1 
Time  relative  to dosea 12-lead ECGb Specimen  Collection  (Labs)  2D-TTE  
No food consumption  for 10 hours  before  predose  ECG  assessment,  specimen  collection  and ECHO 
 
 
 
Predose  (prior  to start  of infusion)  Xc   
 Safety (local) 
Biomarkers  (central) 
PK (central)  
Glucose  (fingerstick) 
Urinalysis (local)  
Urine  β-hCG  (local)   
  X 
Light  Breakfast/  Snack  XXXX  
Drug  Infusion  XXXX  
End of infusion  (no later  than  5 minutes 
from end -of-infusion)  Xd   
 PK (central) 
Glucose  (fingerstick)   
 
0.5 hour from  end-of-infusion  X   
 PK (central) 
Glucose  (fingerstick)   
 
1 hour  from  end-of-infusion  X   
 PK (central) 
Glucose  (fingerstick)   
 
2 hours  from  end-of-infusion  X   
 PK (central) 
Glucose  (fingerstick)   
 
4 hours  from  end-of-infusion  X   
 Safety  (local) 
PK (central)  
Glucose  (fingerstick)   
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  23 of 89  
  
Schedule  of Assessments (Day  1 – Day 3) 
(Order of activities  to be completed  left to right,  top to bottom)  
 Day 1 
Time  relative  to dosea 12-lead ECGb Specimen  Collection  (Labs)  2D-TTE  
6 hours  from  end-of-infusion    X 
 
8 hours  from  end-of-infusion  X   
 Safety  (local) 
PK (central)  
Glucose  (fingerstick)   
12 hours  from  end-of-infusion   Safety  (local) 
PK (central)  
Glucose  (fingerstick)   
 Day 2 
 12-lead  ECGb Blood  Collection (Labs)  ECHO  
 
 
24 hourse from  end-of-infusion  X   
 Safety (local) 
Biomarkers  (central) 
PK (central)  
Glucose  (fingerstick) 
Urinalysis (local)   
30 hours  from  end-of-infusion    X 
 Day 3 
 12-lead  ECGb Blood  Collection (Labs)  ECHO  
 
48 hoursf from  end-of-infusion  X   
 Safety  (local) 
PK (central)  
Glucose  (fingerstick)   
Abbreviations:  2D-TTE, 2-dimensional  transthoracic echocardiography;  β-hCG,  beta human  chorionic  gonadotrophin;  ECHO,  ECG,  electrocardiogram;  PK, pharmacokinetics  
a ±5-minute  window  will be allowed for  PK samples  taken up to 1-hour  postdose;  a ±15-minute  window  will be allowed for  samples  taken at  2 to 12 hours  postdose, samples  taken 
at 24 - and 48- hours postdose must be taken within 10 minutes after the 24- and 48- hour ECG assessments.  
b At the time of ECGs, subject  should have  rested  in a supine  position  for at least 5 minutes.  
c 12-lead digital ECG must be performed prior to the PK sample collection and should be collected as close to the scheduled times as possible. For 12-lead digital ECG 
assessments  scheduled for  up to and including 4 hours,  the ECG  assessments  should be within  10 minutes  prior  to the  PK sample collection;  for subsequent  ECG  assessment, a 
window of 30 minutes prior to PK collection (or less) is desired.  
d All required ECG  leads  will be secured  to the  patient  and attached  to an  ECG  machine prior  to administration  of the IP to facilitate immediate post-infusion recording.  
e For the 24-hour time point  on Day 2,  the ECG  assessment  should be clock time-matched within  ±30 minutes  of the pre-dose  Day 1 ECG  assessment, prior  to light 
breakfast/snack, and the PK sample should be clock time-matched to no more than 10 minutes following completion of the ECG assessment.  
f For the 48-hour time point  on Day 3,  the ECG  assessment  should be clock time matched within ±30  minutes  of the pre-dose  Day 1  ECG  assessment, prior  to light breakfast/ 
snack, and the PK sample should be clock time matched to no more than 10 minutes following completion of the ECG assessment.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  24 of 89  
 
2.0 INTRODUCTION  
2.1 Study  Rationale  
Salubris Biotherapeutics, Inc. (hereafter referred to as SalubrisBio, or “the Sponsor”) is developing a 
therapeutic protein, JK07, for the treatment of chronic heart failure (HF) with reduced ejection fraction 
(HFrEF) (New York Heart Association [NYHA] Class II -III). JK07 is a recombinant fusion protein 
consisting of a fully human monoclonal antibody that antagonizes human epidermal growth factor (EGF) 
receptor  3 (HER3)  and an active  polypeptide  fragment  of human growth factor  neuregulin -1 (NRG- 1). The 
EGF -like domain of NRG -1β2α is fused to the C -terminus of the antibody heavy chain via a linker in a 
homodimeric configuration ( Figure 2).  
Figure  2 Schematic Structure  of JK07  
 
 
Neuregulin- 1 is a member of the EGF family. All isoforms of NRG -1 share a common EGF -like domain 
essential for its biological activity (Parodi and Kuhn, 2014). Neureglin- 1 is known to be the ligand for 
HER3 and HER4 (Parodi and Kuhn, 2014). Binding of NRG -1 to either HER3 or HER4 enables 
heterodimerization of the bound receptor with HER2 and subsequent tyrosine protein kinase activation, 
which transduces intracellular signaling cascades. Human HER4, but not HER3, is expressed in adult 
myocardium  (Sundaresan et al., 1998;  Zhao  et al., 1998;  Rohrback et al., 1999). Upon engagement  of HER4 
receptor, NRG -1 can induce cardiomyocyte differentiation, promote cardiac function, and protect 
cardiomyocytes from apoptosis (Sundaresan et al., 1998).  
Numerous animal studies have demonstrated that NRG -1 has an ameliorative effect in HF (Odiete et al., 
2012), including ischemic HF, dilated cardiomyopathy, chemotherapy- induced HF, and viral myocarditis. 
Several  clinical studies  in patients  with HF have  also shown  that both full length  NRG -1 (cimaglermin)  and 
a recombinant NRG -1 protein fragment containing the EGF -like domain (recombinant human NRG -1 
[Neucardin®]) can have  acute and sustained  positive  hemodynamic  effects (Lenihan  et al., 2016;  Gao et al., 
2010; Jabbour et al., 2011).  
Three  key factors,  however,  limit  the clinical  applications and utility  of recombinant  human  NRG- 1. Firstly, 
signaling of NRG -1 through HER3 may promote cancer development and/or progression, raising serious 
concerns for any application requiring chronic administration or without grave cardiovascular (CV) risk factors. Secondly, HER3 is normally expressed on the gastrointestinal (GI) tract and over -activation of 
HER3 by NRG -1 may disrupt GI epithelial integrity and homeostasis, leading to severe GI toxicity and 
thus, loss of a therapeutic window for NRG -1. In fact, several clinical studies testing recombinant NRG -1 
have reported that the most commonly observed treatment -related adverse events were GI in nature 
(Lenihan et al., 2016; Gao et al., 2010; Jabbour et al., 2011). Thirdly, both clinically tested recombinant human NRG -1 molecules (Neucardin and cimaglermin) have shown a short half -life, indicating that 
burdensome  dosing  and administration  schedules  may be required  to achieve  the desired  therapeutic  levels 
of exposure. Hence, there exists a need to provide an NRG -1-based therapeutic that retains clinically 
significant  therapeutic  potential  across a variety  of CV indications  including  HF but with a lower  risk of 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  25 of 89  
 oncogenesis or promotion of cancer progression, better GI tolerability, and a more favorable 
pharmacokinetic  (PK)  profile.  To that end, SalubrisBio  has developed  JK07, a recombinant  protein  in which 
a sequence corresponding to the EGF -like domain of NRG -1 is fused to the C -terminus of the HER3 - 
specific antagonistic  antibody  heavy chain, to  limit  the HER3  activation  in response  to NRG- 1 stimulation 
without compromising the activity of NRG -1 in inducing HER4 activation, and at the same time the 
antibody backbone format confers a molecular half -life of a typical monoclonal antibody, enabling more 
convenient  dosing and administration,  and a potentially  favorable  PK profile  from  the standpoint  of efficacy 
and safety.  
This first -in-human (FIH), randomized, double -blind, placebo- controlled, single -ascending dose study for 
JK07 is intended to support development to reduce the risk of CV death and hospitalization for HF in 
patients with chronic HF (NYHA Class II -III) and reduced ejection fraction when administered in 
conjunction with other HF therapies. The nonclinical pharmacology program for JK07 exhibits its pharmacodynamic (PD) actions and efficacy in vitro and in non- human primate models of HFrEF and 
HFpEF, and a rodent model of HFrEF. The safety and toxicokinetic profile of JK07 for investigation in 
human clinical trials has been further established in single- dose and repeated- dose toxicology studies 
conducted in cynomolgus macaques and Sprague -Dawley rats.  
2.2 Background  
Heart failure is a potentially fatal disease that affects more than 6.5 million people in the United States. 
Within  5 years  of diagnosis,  the mortality  rate of diseased  individuals  is 50 % (Shah  et al, 2017). Due to an 
aging population, the condition has continued to increase over the past several decades, and among Americans aged 40  and older, there is a 20  % lifetime  risk of developing the disease (Chavey et al, 2017).  
JK07 consists of a fully human monoclonal antagonistic antibody specific for HER3 and an active 
polypeptide fragment of the cardioprotective growth factor NRG -1 (Figure 2). It is designed to stimulate 
cardioprotective signaling mediated by NRG -1 through HER4 while at the same time mitigating NRG -1 
stimulation of HER3 signaling, a pathway that is thought to cause side effects and toxicity without contributing to the therapeutic potential.  
In vitro  studies  have demonstrated that JK07  induced HER2:HER4  dimerization  with  potency similar  to NRG -1; 
whereas its ability  to induce  HER2:HER3  dimerization  was significantly  reduced  in comparison to NRG- 1. In 
vivo, JK07 has demonstrated pharmacodynamic activity in rodent and non- human primate (NHP) models 
of heart failure.  
Briefly, in rodents, histopathological analysis of myocardial tissues performed at 4 weeks post -treatment 
showed that JK07  partially  alleviated  the pathological  changes  in the myocardial  infarction  zone,  including 
significant  reduction of necrotic cells, narrowed interstitial spaces between  myocardial cells,  and recovery 
of myocardial fiber arrangement towards normal structure. JK07 significantly improved cardiac 
contractility, increased ejection fraction and +LVdp/dt
max, partially reversed left ventricular enlargement, 
reduced left ventricular preload, reduced pulmonary edema and paw edema, lowered the plasma levels of 
N-terminal pro -brain natriuretic peptide (NT -proBNP) and brain natriuretic peptic (BNP), and alleviated 
myocardial pathological damage.  
Compared to other animal models, NHPs have a relatively longer life span and are more susceptible to diseases that are the high -risk factors for heart failure, such as hypertension, abnormal lipid metabolism, 
type 2 diabetes mellitus and other metabolic diseases (Gong et al., 2013), making them more prone to the development of spontaneous heart failure. NHPs with spontaneous heart failure are highly similar to 
humans in terms of etiology, pathogenesis, and progression of the disease. Therefore, NHP with spontaneous heart failure is a uniquely clinically relevant model for studying the pathogenesis of heart failure in humans, as well as for the pre- clinical evaluation of drugs treating heart failure.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  26 of 89  
 Based  on the systolic/diastolic  functions  of the left ventricle,  heart  failure  is categorized  into two 
types: heart failure with reduced ejection fraction  (HFrEF) and  heart failure with preserved ejection 
fraction  (HFpEF).  JK07  was examined  in a study of 26 middle/old -aged  rhesus  monkeys  with  spontaneous 
chronic heart failure with either HFpEF with diastolic dysfunctional characteristics of e’<8, E/e’>8 and 
grade  II diastolic  dysfunction (DD2)  (13 monkeys), or HFrEF with systolic  dysfunctional  characteristics of 
left ventricular ejection fraction (LVEF) at 30 -51 % and cardiac remodeling (13 monkeys). Enrolled 
animals were assigned into 3 groups and received weekly IV injection of JK07 1 mg/kg for a total of two injections (5 animals each with HFrEF and HFpEF), Entresto
® (sacubitril/valsartan) at the human - 
equivalent dose (HED) (6.6 mg/kg/day) for a total of 49 days (7 weeks) (5 animals each with HFrEF and 
HFpEF),  and placebo  IV injection  of phosphate  buffered  saline  (PBS)  (3 for each with HFrEF  and HFpEF) 
for a total of two injections.  
JK07  significantly  improved the systolic  function in rhesus monkeys  with HFrEF.  Specifically,  3/5 animals 
in the JK07  group showed a statistically  significant increase in  LVEF  from  their corresponding baseline  at 
3 weeks post -treatment,  accompanied  by significant  improvement  in cardiac remodeling. At  7 weeks  post - 
treatment (6 weeks after the last dosing of JK07) LVEF remained significantly increased over baseline in 2/5 animals. In contrast, none of the animals in the placebo group showed significant changes in LVEF 
throughout  the study. In the sacubitril/valsartan  group, 1/5 animal  at 3 weeks  post-treatment  and 3/5 animals 
at 7 weeks post -treatment demonstrated statistically significant increases in LVEF from baseline.  
JK07  resulted  in significant  increases in peak  velocity  of mitral annulus  at early  diastole  (e’) and significant 
decreases in ratio of peak velocity of mitral blood flow  at early diastole  to peak velocity of mitral annulus 
at early diastole (E/e’) from baselines in 3/5 animals with HFpEF at both 3 - and 7 - weeks post -treatment. 
The grade  of diastolic  dysfunction was improved by at least one grade  in these  3/5 animals  receiving JK07, 
according to the clinical criteria used for the diagnosis of diastolic dysfunction. In the sacubitril/valsartan 
group, only 1/5 animal demonstrated mild improvement in diastolic function after 7 weeks of continuous 
dosing. Animals receiving placebo showed no improvement from their baselines in diastolic function 
throughout the study.  
No incidences of AEs were observed during the study, except that mild elevations of some of the liver 
function indexes were detected in animals receiving JK07. Specifically, mild elevations in alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), and/or gamma glutamyl transferase (GGT) 
were  detected  from  Day 10 to Day 11 in 2/10 animals  receiving  JK07  (1 mg/kg). Animals  were  each given  
0.3 g/day of glutathione through intramuscular injection for 3 days, and most liver function indexes were 
returned to baseline on Day 15. 
Overall, JK07 not only improved LVEF and alleviated cardiac remodeling in rhesus monkeys with 
spontaneous HFrEF, but also significantly improved the diastolic function in monkeys with HFpEF. 
Moreover, these improvements in systolic/diastolic function were sustained even after the treatment had 
been stopped for 6 weeks. No severe AEs were observed during the study, except for the abnormality in 
liver function which may arise in animals receiving repeat -dose of JK07.  
JK07 has also been tested in a comprehensive toxicology program. Single dose IV studies have been 
performed  in monkey with a 2-week  follow -up. Weekly  Good Laboratory Practice  (GLP)  compliant repeat - 
dose IV studies  for durations  of up to 2 weeks in the rat, with  a 2-week  recovery  period, and up to 4 weeks 
in the monkey with a 4-  week recovery period, have also been completed. Tissue cross -reactivity of JK07 
with human tissues in vitro has been conducted.  
From  the repeat -dose GLP  toxicology study  in the more  relevant  monkey species,  the no-observed adverse 
effect  level  (NOAEL) was  defined as 3 mg/kg  which  is equivalent  to a dose  of 0.96 mg/kg  in humans. The 
lowest effective dose was 1 mg/kg in the monkey PD study, in which two doses were administered, and 
this dose level is equivalent to 0.32 mg/kg in humans (FDA 2005). Overall, single IV administration of 
JK07 support the proposed IV clinical route of administration. These studies demonstrate that an IV 
infusion  of JK07  at an HED  of 0.32 mg/kg has potential  cardiac benefit  in the absence of toxicity  in 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  27 of 89  
 monkeys. The FIH starting dose is 0.03 mg/kg as a single 60- minute IV administration and is 32 x lower 
than the estimated  NOAEL  in humans  derived  from  a repeat -dose toxicity  study  in monkeys  and 10 x lower 
than the effective HED derived from the PD studies in monkeys with HFrEF.  
A detailed description of the chemistry, nonclinical pharmacology, pharmacological, and safety results of 
JK07 is provided in the Investigator’s Brochure.  
2.3 Benefit/Risk  Assessment  
JK07 is a FIH study and has, therefore, not been previously evaluated in human subjects with HFrEF; 
however, clinical safety reported with recombinant human NRG -1 therapies include most commonly GI 
disorders (e.g., nausea, diarrhea, vomiting, poor appetite) and reports of headache, dizziness, and fatigue 
(Lenihan et al., 2016;  Gao et al., 2010;  Jabbour  et al., 2011). Gastrointestinal AEs were  most  often  observed 
at the higher doses. Serious treatment -emergent AEs (TEAEs) were uncommon with both agents.  
While these initial studies showed that recombinant human NRG -1-based therapies were generally well 
tolerated in patients, the observance of long- term cardiac effects makes clinical evaluation in healthy 
volunteers unethical. It is the sponsor’s opinion that given the potential for an extended duration of CV effects, the FIH study should be conducted in subjects with HFrEF (LVEF ≤40 %). 
Additionally, consistent with findings in studies conducted and published with NRG -1 in humans 
(Lenihan et al., 2016;  Jabbour  et al. 2011), JK07  showed sustained  ameliorative  effects  following  an acute 
dosing period in rat and rhesus monkey models of HF, further reinforcing the rationale for a FIH study in 
patients.  
JK07 has been  tested  in a comprehensive toxicology program.  A single dose IV  study has been performed 
in monkeys  with a 2-week  follow -up. Repeat -dose IV studies  for durations  of up to 2 weeks in the rat, with 
twice -weekly  administrations  and a 2-week  recovery  period,  and up to 4 weeks  in the monkey, with weekly 
administrations and a 4- week recovery period, have also been completed. Tissue cross- reactivity of JK07 
with human tissues in vitro has been conducted.  
In the more relevant monkey species, two toxicology studies were conducted. In a single -dose non- GLP 
toxicology study, reflective  of the single -dose study design  proposed for the FIH clinical  study,  the NOAEL 
was 30 mg/kg, or 320 x the proposed starting HED of 0.03 mg/kg. Target organ effects were observed in 
heart  and/or  kidney in males  and female  animals given  ≥10 mg/kg  in this study, which  is 107 x higher  than 
the proposed starting HED. In a repeat -dose pivotal GLP toxicology study in monkeys, the NOAEL was  
3 mg/kg, or 32 x the proposed starting HED. 
Overall, IV administration in non- clinical studies of JK07 supports the proposed IV clinical route of 
administration.  These studies demonstrate  that an IV bolus  infusion  of JK07  at HEDs  of 0.16 to 
0.32 mg/kg/dose  has potential  cardiac  benefit  in the absence of toxicity  in rats and NHP,  respectively.  
In the GLP -compliant  4-week  repeated -dose toxicity  study in cynomolgus  monkeys,  minimal  and transient 
JK07 -related prolongation in heart rate corrected QT (QTca) intervals were observed. The maximum 
increase recorded was approximately 23 msec; a QTca dose response was not evident. The minimal and transient QTca prolongation observed in this study did not result in any cardiac electrical instability. No 
JK07 -related abnormalities in rhythm or waveform morphology were found at any dose level based on 
comparison  of predose  and postdose  electrocardiographic recordings.  There  were  no JK07 -related  changes 
in ECG parameters and all ECGs evaluated in this study were qualitatively considered normal for 
cynomolgus  monkeys. Nevertheless,  an inpatient  stay will be required  in this FIH study in order  to monitor 
subjects by ECG  and telemetry during the first 48 hours after IP administration, with additional  follow -up 
monitoring at later time points as detailed in Table 1  (SoA).  
The Sponsor will immediately notify the Principal Investigator if any additional safety or toxicology 
information  becomes  available  during the study.  This study will be performed  in compliance  with the 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  28 of 89  
 protocol, International Council for Harmonisation (ICH) Good Clinical Practice (GCP), and applicable 
regulatory  requirements.  Aspects of the study concerned  with the investigational  product(s)  (IPs)  will meet 
the requirements of Good Manufacturing Practice (GMP).  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  29 of 89  
 3.0 OBJECTIVES  AND ENDPOINTS  
The study objectives and endpoints are described  in Table  3. 
Table  3 Study  Objectives and Endpoints  
 
Objectives  Endpoints  
Primary   
• Assess the safety and tolerability 
profile, including immunogenicity,  of 
JK07, administered IV according to 
protocol -defined dosing regimen.  • Incidence and severity  of TEAEs  and their  relationship to the  IP. 
• 12-lead  ECG parameters  (heart  rate, PR, QRS,  QT, QTcF)  change  from  baseline 
derived as  mean from  triplicate  ECG  recordings  as well as QT and QTcF outlier 
analyses.  
• Change  from baseline in the incidence of rhythm  abnormalities  (retrieved  from 
telemetry readings for 48 hours postdose).  
• Laboratory parameters  – change  from  baseline each assessment  time point  per 
Table 1  SoA postdose: hematology, chemistry, coagulation, and lipid panels.  
• Immunogenicity 
o Incidence of early  and delayed -type  hypersensitivity responses.  
o Presence of serum  anti-JK07  antibodies  (confirmed  positive  antibody 
response, titer, neutralizing antibodies).  
• Vital signs  – change  from  baseline in vital signs  and the relationship  to JK07 
compared with placebo, including:  
o Blood  pressure  (BP) 
o Temperature  
o Heart  rate (HR)  
o Respiratory rate (HR)  
Secondary   
• To determine the PK characteristics  of 
JK07 administered IV according to protocol -defined dosing regimen.  • PK parameters of intact JK07 including, but not limited to, maximum 
concentration (C
max), time to C max (tmax), area under the  concentration -time  curve 
to the last quantifiable concentration and extrapolated to infinity [AUC (0-last) and 
AUC (0-inf)], half-life (t1/2), elimination  rate constant  (λz), systemic clearance (CL), 
and volume of distribution (V z). Surrogate measurement of intact JK07 to be 
carried out through detection of both the JK07 antibody domain and the JK07 NRG -1 peptide fragment in the evaluation of PK parameters.  
Exploratory   
• Explore left ventricular and systemic 
vascular  resistance (SVR) performance 
indices measured by 2 -dimensional 
transthoracic echocardiography  
(2D-TTE)  of JK07,  as change  from 
baseline compared with placebo.  
• Explore potential predictive 
biomarkers  of response  to JK07  in this 
dosing regimen.  
• Explore relationship between JK07 
plasma concentrations, if any, and changes  in QT intervals  during  dosing.  • Microbubble  contrast -enhanced (2D -TTE) results
, including,  but not limited 
to: LVEF, multiple 2 and 4 -chamber left (LV) and right ventricular (RV) 
dimensions, including end systolic left ventricular volume (LVESV), end diastolic  left ventricular  volume  (LVEDV),  left atrial  area and volume,  valvular 
insufficiency and/or gradients, and multiple calculated monitoring parameters 
using velocity and flow measurements, including stroke volume (SV), cardiac 
output (CO), derived left ventricular filling pressure (E/e’).  
• Observed  biomarker  concentrations  and corresponding  changes  from baseline.  
• Concentration-QT  correlation  performed  on the QTcF  time matched  with PK. 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  30 of 89  
 4.0 STUDY DESIGN  
4.1 Overall Design  
This is a phase 1,  randomized, double -blind, placebo -controlled, single -ascending  dose study to assess the 
safety,  tolerability,  immunogenicity, and PK of JK07  in HF subjects  18 to 80 years of age with 
LVEF ≤40 %.  
To be eligible for this trial, subjects must have been maintained on an optimal HF medical regimen for at 
least 2 months  prior  to informed  consent  and remain  on the same  treatment  regimen  throughout  the course 
of the study, per the 2017 American College of Cardiology/American Heart Association Task Force on 
Clinical Practice Guidelines/Heart Failure Society of America (ACC/AHA/HFSA) treatment guidelines 
(Yancy et al, 2017).  
Subjects will give informed consent prior to initiation of screening procedures. During screening, all 
subjects  will undergo 2D-TTE to measure the following  parameters:  left ventricular  chamber  dimensions, 
including LVESV and left ventricular end diastolic volume (LVEDV), LVEF, and multiple calculated 
monitoring parameters using velocity and flow measurements (i.e., stroke volume [SV], cardiac output 
[CO], derived left ventricular filling pressure (E/e’) according to the American Society of 
Echocardiography guidelines (full set of measurements provided in Section 11.0, Appendix 5). Subjects 
will also undergo a physical examination, 12- lead ECG assessment, blood sampling for laboratory 
parameters, and urine testing. Safety assessments at screening will include hematology, biochemistry, 
coagulation,  liver,  and thyroid  function. There  will be additional  blood sample  collection  prior  to 
IP administration for baseline myocardial biomarkers, PK, and immunogenicity assessment ( Table 1 ). 
A Data Review Committee (DRC) will be established to review emerging data, to monitor safety aspects of the study, to select the JK07 dose during dose escalation, and to adapt the randomization scheme. The 
DRC will evaluate the emerging clinical, laboratory and cardiac safety data, from the first three days 
postdose for the sentinel subject, prior to randomized blinded IP administration in the remainder of the 
cohort.  
Initially 5 dose escalation cohorts are planned with the option at the discretion of the DRC to expand the 
study to a total of 7 dose escalation cohorts. The size of the cohorts will range from 5 to 9 subjects. A 
maximum of 63 subjects will be enrolled into dose escalation cohorts. Each dose escalation cohort will 
include  one single  active  unblinded  sentinel  subject  receiving  a single  IV dose of JK07  prior  to randomized 
JK07 or placebo administration in the remainder of the cohort.  
Subjects will be observed in the hospital on continuous telemetry from as soon as practicable following admission and prior to IP administration, and until shortly before discharge on Day 3. During this time, 
they will additionally have safety labs, vital signs, PK, and biomarker samples collected, and ECGs and 
2D-TTEs performed. Hospital evaluation is performed for safety reasons. 12- lead ECG values will be 
extracted  within  10 minutes  prior  to the time-matched  PK sample collections. Subjects  will be observed for 
injection site reactions until  Day 4 following IP administration, for dose -limiting adverse events  (DLAEs) 
until Day 15 following  IP administration, and  for SAEs  from  the time  of enrollment  until 30 days  after  the 
IP administration. Following the Day 30, only SAEs deemed at least possibly related to the study drug or study procedures should be collected.  
4.2 Scientific Rationale for Study  Design  
Compared with an open- label design, double -blind trials are an especially stringent way of conducting a 
trial that attempts  to eliminate  subjective,  unrecognized biases carried  out by experimental  subjects (usually 
human bias)  and conductors. In most  cases,  double -blind studies  are regarded to  achieve a higher  standard 
of scientific rigor than single -blind or unblinded studies. 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  31 of 89  
 Evaluating JK07  using a rigorous  double -blind trial in  a patient  population with HF provides  more  reliable 
data to assess the safety and exploratory efficacy of the product in patients affected by HF. Furthermore, 
since subjects enrolled in this trial must have been maintained on an optimal HF medical regimen (Yancy 
et al, 2017) for at least 2 months prior to informed consent and remain on the same treatment regimen 
throughout the course of the study, there is no detriment to the blinding, either to placebo group or the active treatment group. Specifically, subjects will remain on their standard clinician -directed appropriate 
pharmacological  therapy, meaning  there  is no added  risk related  to medication  changes for subjects enrolled 
in the trial. Moreover, initial  confinement  of subjects at the clinic  and overall  extensive  safety  assessments 
will permit careful monitoring of study effects under blinded conditions, and analysis by categorical and continuous descriptive statistics.  
Key inclusion criteria  of this proposed phase  1 study  are “subjects between  ≥18 and ≤80 years of age with 
stable NYHA Class II or III HF diagnosis, LVEF ≤40  %, and on stable doses of HF therapy (except for 
diuretics)  as per the 2017 ACC/AHA/HFSA treatment  guidelines  (Yancy  et al, 2017)  for at least 2 months 
prior to informed consent” (Section 5.1). This population is appropriate for the primary safety evaluation 
of JK07 in this FIH study and includes patients who may benefit from this treatment. In order not to 
confound the initial safety  results with tenuous  subjects,  subjects with NYHA Class IV will not be included. 
Analogous recombinant human NRG -1 therapies were generally well -tolerated in NYHA Class II and III 
subjects (Lenihan et al., 2016; Gao et al., 2010; Jabbour et al., 2011). The cimaglermin phase 1 study enrolled adult patients with NYHA Class II and III HF with reduced ejection fraction (LVEF ≤40 %) 
(Lenihan et al., 2016). Similarly,  patients  with NYHA Class II and III HF with LVEF <40 %  were  enrolled 
in both published Neucardin phase 2 studies  (Gao  et al., 2010; Jabbour  et al., 2011). All  3 studies  enrolled 
patients on stable standard therapy.  
Generation of initial phase 1 data in this moderately affected HF population will provide support for the 
evaluation  of safety  and efficacy  in future  studies  that may include  more  severe  patients,  including NYHA 
Class IV  HF. While  the sponsor  expects  more  severe HF patients could  benefit  from treatment with JK07, 
inclusion of NYHA Class II patients showing mild symptoms and impairment due to HF is important, as 
these  patients  may have  more  of an opportunity  to benefit  from  cardiac  regeneration  due to JK07  treatment 
earlier during disease, to slow, stabilize, or reverse disease progression. Moreover, although the primary 
objective  of the study  is to assess the safety  of JK07,  the recruitment  of HFrEF patients  rather  than healthy 
volunteers may increase the ability of this study to detect signals of efficacy.  
The study will  also include  a sentinel subject (1 active treated subject)  in each  dosing cohort  to protect  the 
population involved in the study by potentially identifying any serious AE in a single subject prior to 
exposing an entire  cohort to the  treatment, thereby increasing  the level of safety in this JK07 phase 1 trial. 
The low(er) dose cohorts  are sized  at 5 subjects  (1 active  lead-in followed  by a randomized  active:  placebo 
[3:1] main cohort) to effectively escalate through dose levels not anticipated to exert any effects. Dose escalation  will not occur until at least 14  days of safety  data (i.e., through Day 15) have  been  evaluated by 
the DRC and the dose has been established as safe and well tolerated. Following observation of a clinical effect, the DRC has the option to expand the size of the cohort at which the clinical effect was observed 
and subsequent cohorts to a total of 9 subjects (1 active lead -in followed by a randomized active:placebo 
[6:2] main cohort). The expanded cohort size will allow a more robust evaluation of JK07 doses with 
clinical activity. All cohorts shall proceed per the treatment algorithm, with continuous monitoring of 
emerging safety data, including clinical signs, laboratory values, and cardiac safety monitoring. Although 
it is appreciated that some adverse effects could take longer to manifest, it is believed that the time frame 
between the dosing of the sentinel subject and the subsequent cohort of approximately 5x the anticipated 
half-life (t
1/2) of the JK07 is enough to minimize this risk.  
A GLP -compliant 4- week repeated -dose toxicity study in cynomolgus monkeys showed minimal and 
transient  JK07 -related  prolongation  in QTca  intervals (the maximum increase  recorded  was approximately 
23 msec;  a QTca  dose response  was not evident).  The current  phase  1 study  requires  subjects  to be confined 
in the hospital  on continuous  12-lead Holter/telemetry  combination  prior  to dose administration  and for 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  32 of 89  
 48 hours following dose administration. Baseline -corrected (clock -time matched) QT and QT interval 
corrected  for heart  rate using  Fridericia’s correction  formula  (QTcF)  intervals  will be evaluated  for potential 
effects by JK07. If effects are evident, a concentration -response relationship between time -matched JK07 
concentrations and change in QTcF interval will be explored.  
In the same study dose -independent minimal to moderate myocardial degeneration was observed during 
autopsy. The current phase  1 study requires 2D -TTE monitoring at screening, during the hospital stay and 
at multiple  follow -up visits  to check  for improvement  or worsening of indexes  of myocardium  contractility.  
In the same study, there  were  also a dose-independent  minimal JK07 -related  increases in cardiac troponin I 
(cTnI) at 10 and 30 mg/kg on Day 8 and at 30 mg/kg on Day 28, with recovery by Day 56. Although the 
highest  cTnI  values  occurred in a control  animal  at multiple  time points  (Animal  No. 1504, Days  -7 through 
28), the increased frequency of values at 10 and 30 mg/kg suggested a possible JK07- related effect. Since 
the increases in cTnI  could potentially  be correlated  with microscopic  findings  of myocardial  degeneration, 
this phase  1 study  will monitor  a wide  panel  of safety  and efficacy  biomarkers  which  are useful  to carefully 
detect any effect of JK07 on myocardium (NT -proBNP, total BNP, high- sensitivity C -reactive protein 
[hsCRP (], troponin- I, high- sensitivity [hs] -troponin T, creatine phosphokinase [CPK], creatine kinase - 
muscle/brain [CPK -MB]). It should be noted that NRG -1 directly activates NT -proBNP expression which 
complicates the normal relationship between the levels of that biomarker and cardiomyocyte damage. Changes in this biomarker, therefore, need to be interpreted with caution and in the context of the totality 
of the data.  
Systemic  exposure  of JK07  will be measured  by utilizing  an immunoassay  targeting  two different  domains 
of JK07. The capture antibody will be specific for the NRG- 1 sequence of JK07, and the detection  antibody 
will be specific  for the antibody domain, using  a biotinylated  anti-idiotype  antibody  binding  to the variable 
sequence of JK07 antibody domain. Use of the two antibodies together will provide exposure data 
specifically for the intact JK07 molecule over time across JK07 dose levels. NRG -1 peptide cleaved from 
JK07, with or without the linker, is expected to have a very short half -life in circulation and to be below 
detectable levels in circulation.  
As JK07 is a monoclonal antibody, anti -drug antibody (ADA) response for JK07 will be evaluated 
periodically  throughout  the study with blood samples collected  as early  as 3 days after dose administration.  
4.3 Justification  for Dose 
Cohort  dose  levels  of JK07  are as follows:  the clinical  starting  dose of a single  0.03  mg/kg  IV infusion  has 
been  selected  at 1/32 of the HED at the NOAEL  in the cynomolgus  monkey (3 mg/kg/week).  A conservative 
approach of body surface area scaling was employed for this conversion of HED at the monkey NOAEL 
(0.97 mg/kg/week).  The subsequent  provisional  doses have  been  set at a 3-fold increase  from  the prior  dose 
for the first 2 dose escalations (Cohort 2 through Cohort 3). The subsequent dose escalations (Cohort 4 
through Cohort 5) have been set at a 2- fold increase from the prior dose; based on emerging safety and/or 
PK results of the previous cohorts; the DRC can allow a 3 -fold increase. Additionally, the DRC may also 
reduce the incremental dose escalations based on the results of the previous cohorts ( Table 4 ). 
The sponsor  and the FDA  agreed  that, as a conservative approach,  a starting dose should be chosen which 
is unlikely to exhibit any clinical effect. On a molar equivalent basis, the starting dose is equivalent to the 
cimaglermin dose of 0.015 mg/kg, which is at the low end of the three pooled dose levels which did not 
show clinical efficacy with cimaglermin (0.007 mg/kg, 0.021 mg/kg, and 0.063 mg/kg), and 100 x below 
the dose level at which a DLAE was observed for cimaglermin.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  33 of 89  
 Table  4 Dose  Escalation  Per Cohort  
 
Dose  Level  JK07 
Cohort  1 0.03 mg/kg  
Cohort  2 0.09 mg/kg  
Cohort  3 0.27 mg/kg  
Cohort  4 0.54 mg/kg  
Cohort  5 1.08 mg/kg  
Note:  Initially  5 cohorts  are planned.  Two additional  higher  cohorts  may be added  as per the DRC recommendation  (total  up to 7 cohorts). 
The highest JK07 dose administered not to exceed 2.5 mg/kg without further amending the protocol.  
 
4.4 End of Study  Definition  
A subject  is considered  to have  completed  the study  if he/she  has completed  all phases of the study  including 
the last scheduled procedure shown in Table 1  SoA.  
4.5 Dose Escalation Criteria  
The DRC  will evaluate each sentinel,  as well as active  and placebo  subjects in each dose cohort  for DLAEs. 
To support dose escalation, safety, and tolerability results for all subjects within a cohort through at least 
Day 15 will be included in this review.  At the time of the DRC  safety  review  of the entire  cohort, PK results, 
if available for that cohort, will be evaluated (along with results of prior cohorts, as applicable).  
At any time during the trial, the Sponsor has the right to discontinue the trial. Any consented subject who 
is withdrawn due to an AE or screen failure prior to the IP administration will be replaced.  
If recommended by the DRC, up to 2 additional higher dose cohorts, at incremental dose levels to be 
determined  by the DRC,  may be enrolled  to further  evaluate  the safety  and tolerability,  PK parameters,  and 
exploratory PD/biomarker endpoints of JK07 at doses greater than 1.08 mg/kg without a protocol 
amendment. The highest JK07 dose administered will  not exceed 2.5 mg/kg without further amending the 
protocol. After due consideration, the DRC may recommend a modification to the Table 1  SoA based on 
emerging safety  or PK results.  Scheduled  times of  assessments may  be modified  without  an amendment if 
the length of the study duration  (end- of-study visit) is  not extended, and  the changes do not result in  more 
than 1 additional  visit.  Furthermore,  collection  of blood  for 1 additional  set of laboratory evaluations,  1 PK 
sample, and/or 1 biomarker sample may also be added without a protocol amendment. Should the DRC 
make recommendations for more extensive changes to the study, the Sponsor may choose to amend the 
protocol to allow for these changes.  
Also  see Section  4.1, Overall  Design  
Note: Should a safety concern arise other than the DLAE, the DRC might recommend that the trial stop after discussion with the Sponsor. The dataset may be unblinded for each cohort but no less than 30 days 
after the DRC has made the decision to proceed to the next cohort.  
4.6 Study  Stopping  Criteria  
Intravenous administration for any individual subject will be stopped if the subject experiences a serious 
adverse event (SAE) or a clinically significant, drug- related AE during the infusion, which in the opinion 
of the study physician, Principal  Investigator,  or Sponsor’s  medical  representative,  warrants  discontinuation 
of the study for that subject’s well-being.  The definitions  of an AE and an SAE  can be found in Section  8.3. 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  34 of 89  
 The final determination of whether any AE observed following JK07 administration is considered dose - 
limiting will be at the discretion of the DRC. Guidance provided to the DRC will be to view as a possible 
DLAE any AE at least possibly related to IP that results in any new finding of the following if observed 
within the first 15 days of treatment (DLAE assessment period):  
• Any febrile neutropenia [absolute neutrophil count (ANC)] <1000/mm3, temperature >38.3 °C 
(101 °F)] for >1 hour.  
• Any signs and/or symptoms of myocardial ischemia/myocardial infarction (diagnosis to be based 
on Thygesen et al. 2018), and any asymptomatic/symptomatic  significant  (> 2 mm for > 2 minutes) 
new ST segment deviation (elevation or depression), as defined in Hicks et al. 2018. 
• Any emergent symptomatic or asymptomatic cardiac arrhythmia requiring at least urgent medical 
intervention.  
• Any ≥ QTc(F)  prolongation  of >500 msec  or >60 msec  above  baseline  (based  on an average QTcF 
value of triplicate ECGs).  
• Any emergent ≥ severe (corresponding to CTCAE v5 Grade 3) hematologic, non- hematologic, 
hepato- cellular, or renal toxicity except for untreated nausea, diarrhea, vomiting, constipation, 
abdominal pain. Any of these will  be considered  DLTs  if persisting  >72 hours  despite appropriate 
treatment.  
• Any at least moderate  CD4  lymphocyte  count  ≤400 mm3. 
• Any at least moderate  infusion- related  reaction  or inability  to deliver  a complete  dose due 
to possible treatment- related toxicity.  
• An AE or SAE  that, in the opinion of the DRC,  is of potential clinical significance  such that further 
dose escalation would expose subjects to unacceptable risk. In addition, the DRC may identify as 
a DLAE,  any AE that impairs  daily  function, or abnormality  occurring in subjects treated  with JK07 
at any time during the trial.  
Each  DLAE  must  be recorded  in the eCRF.  
4.6.1 Stopping  Criteria  for Individual  Subjects  
The infusion for any individual subject will be stopped if the subject experiences a SAE or a clinically 
significant  possibly drug-related  related  AE during the infusion,  which  in the opinion  of the study  physician, 
Principal  Investigator, or Sponsor’s  medical  representative,  warrants  discontinuation  of the infusion for that 
subject’s well -being.  
4.6.2 Criteria  for Stopping  Dose  Escalation  
The decision to stop dose escalation will be  at the discretion of the DRC and  all the criteria leading  to this 
decision will be documented in the meeting minutes.  
If the DRC  decides not to dose escalate,  the current  cohort  may be expanded, if not already  at the maximum 
size, following which further dose escalation could proceed. If the decision is to de- escalate to the prior 
cohort, up to 8 subjects randomized (6:2, JK07:placebo), without an additional unblinded sentinel subject 
may be added to the cohort, after which, safety and tolerability will be reassessed. If the decision is to de-  
escalate to an intermediate  dose between  the prior  cohort  and the cohort  at which  dose escalation  was halted, 
the cohort  will comprise  a single  sentinel  subject  receiving  JK07  followed by randomization of a minimum 
of 4 subjects (3:1, JK07:placebo)  in the cohort. See Section  9.6 for details  regarding  the number  of subjects 
to be enrolled in de -escalated or intermediate de- escalated cohorts.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  35 of 89  
 4.6.3 Criteria  for Stopping  the Study  
Criteria for stopping the study will be at the discretion of the DRC and all decisions taken will be clearly 
documented in  the meeting  minutes.  This decision  will be  based  on the  cumulative  evaluation  of the study 
results and include not only DLAE but also safety concerns other than DLAEs which may arise.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  36 of 89  
 5.0 STUDY POPULATION  
Prospective  approval of protocol deviations  to recruitment  and enrollment  criteria,  also known as protocol 
waivers or exemptions, is not permitted.  
5.1 Inclusion Criteria  
Subjects  are eligible  to be included in the study only if all of the following  criteria  apply:  
1. 18 to 80 years of age, with stable NYHA Class II or III HF diagnosis, evident at least 6 months 
prior to enrollment as confirmed by medical history.  
2. Stable HF defined as no hospitalizations for cardiac- related issues within the previous 2  months 
prior to the screening visit or between screening and randomization, other than for routine 
percutaneous procedures such as device, battery, generator changes or pacemaker lead 
insertion/replacement.  
3. Subjects  with  clearly  interpretable  ECHO images and  with a screening  LVEF ≤40 %  in the 
absence of ≥Grade 3 valvular disease on 2D -TTE.  
4. Subjects must be taking clinician -directed appropriate pharmacological therapy for HF as per the 
2017 ACC/AHA/HFSA treatment guidelines (Yancy et al, 2017) and at investigator determined 
discretion at stable doses (except for diuretics) for at least 2 months prior to informed consent.  
5. Subjects without implantable cardioverter -defibrillators (ICDs) are eligible.  Subjects with ICDs 
are allowed at the discretion of the investigator, but only if both of the following criteria are met:  
(a) paced beats cannot exceed 15% of beats as quantified by screening e- Patch, and (b) if a non-  
paced baseline ECG can be obtained on Day 1 prior to study drug administration.  
6. Body mass  index ≥18 kg/m2 and ≤45 kg/m2 
7. Screening hemoglobin  ≥9.0 g/dL, platelets  ≥100x109 /mL,  ANC  ≥1500/mL.  
8. Sexually mature male subjects must agree to use a medically accepted method of contraception 
throughout the study and be willing and able to continue contraception until the end of the study 
(6-month time point).  
9. Females of childbearing potential must present with a negative blood pregnancy test, must not be 
lactating, and must agree to employ adequate birth control measures for the duration of the study and be willing and able to continue contraception until the end of the study (6- month time point).  
10. Subject is capable of giving signed informed consent as described in Section 11.0 Appendix 2, 
which includes compliance with the requirements and restrictions listed in the informed consent 
form (ICF) and in this protocol.  
11. Subject  is willing  and able  to comply  with  the requirements  of the protocol.  
5.2 Exclusion  Criteria  
Subjects  are excluded from  the study if any of the following  criteria  apply:  
1. Participating in any other study and have received any other investigational drug within 30 days 
prior  to screening  or 5-half-lives,  whichever  is longer,  or any other  investigational  implanted  device 
within  30 days prior  to screening,  or are taking  part in a nonmedication study which,  in the opinion 
of the Investigator, would interfere with study compliance or outcome assessments.  
2. Any past participation in a study that has investigated the NRG -1 pathway (e.g., Neucardin, 
cimaglermin).  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  37 of 89  
 3. Heart failure due to hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic 
right  ventricular  dysplasia (ARVD),  stress -induced ("Takotsubo")  cardiomyopathy,  chemotherapy - 
induced cardiomyopathy, peripartum cardiomyopathy, infiltrative or inflammatory 
cardiomyopathies, and primary valvular disease.  
4. Diagnosed with medically documented acute coronary syndrome within 3 months of screening or 
a medically documented acute myocardial infarction within 6 months of screening. 
5. Cardiac surgery, coronary artery revascularization, percutaneous coronary intervention, or 
valvuloplasty within 3 months prior to screening.  
6. Any subject who has received an indication for coronary revascularization within 3 months prior 
to screening.  
7. Any major surgical procedure within 1 month prior to screening or planned surgical procedure 
during the study period.  
8. Sustained  systolic  BP <90 mm Hg and/or  diastolic  BP <50 mm Hg (confirmed  by a duplicate  seated 
reading) on at least 3 consecutive readings (office) following informed consent and prior to 
randomization, or overt symptomatic hypotension defined as a decrease in systolic BP of 20 mm 
Hg or a decrease in diastolic BP of 10 mm Hg within three minutes of standing when compared 
with BP from the sitting or supine position or accompanied by dizziness, syncope, blurry vision.  
9. Resting  HR >100 beats per  minute  (bpm)  at Screening  (Visit 1) or prior  to randomization  which  is 
sustained  for >15 minutes  in two episodes  separated  by one hour of observation except  in sustained 
atrial fibrillation when HR of up to 110 bpm is acceptable.  
10. Cerebrovascular accident or hospitalizations for CV (cardiovascular) causes other than routine 
percutaneous procedures such as device, battery, generator changes or pacemaker lead 
insertion/replacement, including HF, chest pain, stroke, transient ischemic attack, or arrhythmias 
within 2 months prior to screening.  
11. Subjects  at screening  have  an abnormal or  clinically  significant  12-lead ECG  abnormality, that, in 
the opinion of the Investigator, would affect efficacy or safety evaluation or place the subject at risk. 
12. History  or evidence  of clinically  significant  arrhythmias  uncontrolled by drug therapy or  use of an 
implantable  defibrillator,  long QT syndrome, or  evidence  of QT prolongation with  QTcF  >450  ms 
for males or QTcF >470 ms for females during screening and/or prior to randomization.  
13. Clinically  significant renal  dysfunction as measured  by the estimated  glomerular  filtration  rate of 
<45 mL/min/1.73m
2 as calculated by local laboratory standards (Cockcroft -Gault equation for 
estimation  of creatinine  clearance [CrCl]  [Cockcroft  and Gault.  1976])  at screening, or  a clinically 
significant change in renal function between screening and baseline.  
14. Clinically significant liver dysfunction as measured by: ALT >2.0 × the upper limit of normal 
(ULN), alkaline phosphatase > 2.0 × ULN, AST >2.0 × ULN, or GGT >2.0 × ULN or serum bilirubin ≥ 1.2 × ULN at screening, or a clinically significant change in liver function between 
screening and baseline.  
15. Subjects with alteration of the coagulation panel (international normalized ratio [INR]) and/or 
prothrombin time (PT) ≥1.5 × the ULN;  activated  partial  thromboplastin  time (aPTT)  ≥1.5 × ULN, 
or serum albumin ≤3 gm/dL. For subjects on warfarin or other anticoagulants, an INR (or PT) 
considered by the Principal Investigator as therapeutically appropriate will be allowed. 
16. Subjects with values of total CPK and/or CK -MB >2.5x ULN per institutional standards at 
screening.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  38 of 89  
 17. Any subject who by Investigator’s judgement, has a significant hematuria or proteinuria at 
screening.  
18. Concurrent treatment with Class Ia or III antiarrhythmic drugs (the medication must have been 
discontinued more than 2 months before informed consent).  
19. Positive screening for human immunodeficiency virus antibodies, hepatitis B surface antigen, or 
hepatitis C virus antibodies. 
20. Known history of or active alcohol abuse (no more than 14 units/week for males or 7 units/week 
for females)  or use of illicit drugs  within  1 year  prior  to randomization  (excluding  recreational  use 
of marijuana or cannabidiol [CBD] -based products).  
21. Other medical or psychiatric condition that, in the opinion of the Investigator, would preclude 
obtaining voluntary consent/assent or would confound the secondary objectives of study.  
22. A history  of pathologically  confirmed  malignancy  of any type or any pathologically  confirmed  pre- 
malignant condition  (e.g., ductal carcinoma in  situ, colonic polyp with premalignant diagnosis, or 
cervical atypia). All subjects are to undergo cancer screening following study enrollment in 
accordance with American Cancer Society Guidelines (See Section 11.0 Appendix 1).  
23. Pregnant  or lactating  at screening. 
24. Subjects with clinically significant or poorly controlled disease including, but not limited to, 
endocrine (including diabetes and thyroid) disease, neurological or psychiatric (even mild), GI, 
hematological, urological, immunological, or ophthalmic diseases as determined by the 
Investigator.  
25. Subjects who are not non- smokers or light smokers (no more than 5 cigarettes per day) and who 
cannot  abstain  from  smoking  from  2 weeks  prior  to the administration  of IP through  the end of the 
study. 
5.3 Lifestyle  Considerations  
5.3.1 Meals and Dietary  Restrictions  
Subjects  are required  to fast for at least 10 hours  prior  to each visit,  including  the Day 1 hospital  admission.  
On Day 1, pre -dose assessments will be performed after a minimum 10 hour fast. A light breakfast/snack 
will be provided after completion of all scheduled pre -dose assessments. Subjects will receive a typical 
institutional  lunch  and dinner  for a HF patient.  A snack  may be allowed  in the evening of Day 1. The snack 
must be consumed to allow for a minimum 10- hour fast so that the 24- hour Day 2 procedures are clock-  
time matched to the extent possible to predose of Day 1 (See Table 2 ). Subjects should receive the same 
lunch, the same dinner, and the same evening snack, at as close to the same times as possible, on Day 2. 
Subjects must again be fasted for at least 10 hours prior to the 48- hour Day 3 study procedures.  
5.3.2 Caffeine,  Alcohol,  and Tobacco  
Subjects with a known history of alcohol abuse will be excluded from this study. From Day 1 until completion  of the 12-lead ECG  and related  study procedures  on Day 3, subjects will abstain  from  ingesting 
caffeine-  or xanthine -containing products (e.g., coffee, tea, cola drinks, and chocolate). Subject will have 
to abstain from ingesting caffeine - or xanthine -containing products (e.g., coffee, tea, cola drinks, and 
chocolate) starting 24 hours before any subsequent visit. 
From Day - 3 until completion of the 12- lead ECG and related study procedures on Day 3 subjects will 
abstain from alcohol intake and will have to abstain from alcohol intake starting 24 hours before all 
subsequent visits.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  39 of 89  
 Subjects who use tobacco or e -cigarette products, or CBD products, will be instructed that use of  
nicotine -containing  products  (including  nicotine  patches)  or CBD  products  will not be permitted  from  two 
weeks prior to IP administration until after the final follow -up visit.  
5.3.3 Activity  
Subjects will remain in the hospital for Day 1 and the initial 48 hours of the postdose period for safety 
evaluations: vital sign assessments, physical exams, blood, and urine collections for PK (blood only), 
biomarkers,  and safety  laboratory assessments,  and telemetry/ECG  evaluation.  During the full course  of the 
study any contact or vigorous competitive sporting activity must be avoided.  
5.4 Screen  Failures  
Screen failures are defined as subjects who consent to participate in the clinical study but are not 
subsequently  assigned  to study treatment.  A minimal  set of screen  failure  information is required  to ensure 
transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting Trials 
publishing requirements and to respond to queries from regulatory authorities. Minimal information 
includes demography, screen failure details, eligibility criteria, and any SAE.  
Individuals  who do not meet  the criteria  for participation  in this study  (screen  failure)  may not be rescreened 
without consent of medical monitor.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  40 of 89  
 6.0 STUDY TREATMENT 
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo, or medical 
device(s) intended to be administered to a subject according to the study protocol ( Table 5 ). 
This is a double -blind study. The investigational treatment and placebo infusions will be identical in 
physical appearance. Other than in the case of sentinel subjects, the treatment each subject will receive will not be disclosed  to the Investigator, study  center  staff,  subject,  Sponsor,  study vendors, or DRC.  The 
treatment  codes  will be held by a third -party  clinical  research  services  vendor  designated  by the Sponsor.  
Where possible,  and as applicable,  hospital  admission  and IP  administration  should take place on  Monday 
or Tuesday to allow for Day 7 follow -up visits to take place on the following Monday.  
6.1 Study  Treatment(s) Administered  
Table  5 Study  Treatment  Details  
 
 
 
Study  Treatmenta Name:  JK07 (recombinant fusion protein 
consisting of a fully human 
immunoglobulin G1 monoclonal 
antibody and an active polypeptide 
fragment  of the human  growth factor 
NRG -1)  
 
JK07  matching  placebo  
Dosage Formulation:  Sterile  solution  Sterile  solution  
 
Unit  Dose  Strength(s)/Dosage 
Level(s):  20 mg/mL JK07 in 2 mL of formulation 
buffer containing 25 mM 
histidine/histidine -HCl,  205 mM sucrose,  
0.04 % (w/v)  polysorbate  80, pH 6.0. Formulation  buffer 
(25 mM histidine/histidine -HCl,  
205 mM sucrose,  0.04 % 
polysorbate -80, pH 6.0). 
 
Route  of Administration:  Intravenous  (IV) infusion  over 
60 minutes  using a syringe  pump or 
infusion pump  IV infusion  over 60 minutes  using  a 
syringe pump or infusion pump  
Dosing Instructions:  Single  dose per protocol  treatment 
regimen  Single  dose per protocol  treatment 
regimen  
 
 
Packaging and Labeling:  Study treatment will be provided in a 
single -use vial or vials. Each vial will be 
labeled as required per country 
requirement. JK07 will be provided with 
the appropriate  infusion kits as part of the 
Clinical Trial Supplies.   
JK07 -matching placebo will be 
provided in the appropriate  infusion 
kits as part of the Clinical Trial 
Supplies.  
Manufacturer:  Emergent  Camden  Emergent  Camden  
 
Prepared  Solution  Expiration:  JK07 infusions will be prepared at the study  center  for administration  within  4 
hours following the dose preparation.  Placebo infusions will be prepared at 
the study center for administration within  4 hours  after dose preparation.  
a With  the exception  of IP infusion  administered  to the sentinel  subject  in each cohort,  all study staff will be blinded  to IP 
identification  
The infusion  will be managed  through a syringe  pump  or infusion  pump.  A needle  or catheter  between  16G 
and 21G is required by this protocol (choice as per Site procedures); needles narrower than 21G are NOT 
allowed. The total infusion time, inclusive of saline flush should be 60 minutes and should not exceed 75 
minutes,  and reasons  to exceed  this time must  be reported.  The infusion  time should  not be less than 
60 minutes under any circumstance. The date/time of start and time of stop of the infusion, infusion rate, 
volume infused, any interruption, and stop/restart will be documented in the eCRF. 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  41 of 89  
 A detailed  description of the shipment,  storage, and preparation  of IP is provided in the Pharmacy  Manual.  
In the event of a presumed acute infusion reaction, institutional standard of care treatment should be 
undertaken. If the infusion must be stopped in the opinion of the investigator due to an AE, the infusion 
may NOT be restarted ( Section 4.6.1 ). The AE must be documented in the eCRF. 
6.2 Preparation/Handling/Storage/Accountability 
1. All investigational drug supplies in the study will be stored at 2- 8 °C in a secure place under the 
responsibility of the Investigator or other authorized individual.  
2. The Investigator  or designee  must  confirm  appropriate  temperature  conditions  have  been  maintained 
during transit  for all study  treatment  received  and any discrepancies  are reported  and resolved  before 
use of the study treatment.  
3. Only  subjects enrolled  in the study  may receive study treatment  and only authorized study  center  staff 
may supply or administer study treatment. Designated pharmacy staff will prepare the study drug. 
All study treatments must be stored in a secure, environmentally controlled, and  monitored (manual 
or automated) area in accordance with the labeled storage conditions with access limited to the 
Investigator and authorized study center staff. Preparation of study drug will be documented in 
accordance with local site standard of practice.  
4. The Investigator, institution, or the head of the medical institution (where applicable) is responsible 
for study treatment accountability, reconciliation, and record maintenance (i.e., receipt, 
reconciliation, and final disposition records). All records must be available for inspection.  
5. Further  guidance and  information  for the final disposition of unused study  treatment are  provided in 
the Pharmacy Manual and Clinical Monitoring Plan.  
6.3 Randomization  and Blinding  
All subjects  other  than sentinel  subjects will be centrally  assigned  to randomized  study treatment  using an 
Interactive Voice/Web Response System (IVRS/IWRS). Before the study is initiated, the telephone 
number and call -in directions for the IVRS and/or the log in information & directions for the IWRS will 
be provided to each study center.  
Subjects  will be randomized to study  treatment  via stratified  randomization.  Separate  randomization 
schedules will be used within each cohort (randomly permuted blocks within strata).  
 
Blind  Break (IVRS/IWRS) The IVRS/IWRS will be programmed with blind -breaking instructions. In case of an 
emergency, the Investigator has the sole responsibility for determining if unblinding of a 
subject’s treatment assignment is warranted. Subject safety must always be the first 
consideration in making such a determination. If the Investigator decides that unblinding is 
warranted, the Investigator should make every effort to contact the Trial Management 
Associate and Sponsor prior to unblinding a subject’s treatment assignment unless this could delay  emergency  treatment  of the subject.  Under  no circumstances  should there  be any delay  in 
emergency  treatment  of a subject.  If a subject’s  treatment  assignment  is unblinded,  the Sponsor 
must be notified within 24 hours after breaking the blind. The date and reason that the blind 
was broken must be recorded in the source documentation and case report form (eCRF), as 
applicable.  
Blinded  FIH which  may 
require unblinding subject/cohort  After  each dose group, the  DRC  will determine the dosing regimen(s)  for the next cohort. This 
decision will generally be made without breaking the randomization code. If judged necessary 
by the DRC, an individual or the complete cohort may be unblinded during evaluation of the 
study  data.  Before  unblinding,  a decision  should  be made about  the action  to be taken  based  on 
the revealed treatment allocation. The rationale for unblinding, etc., will be documented in 
meeting minutes.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  42 of 89  
  
Sentinel  Subject  Each  cohort  at a new dose level  higher  than those  previously tested  shall  have  a single 
unblinded sentinel subject who will receive active treatment.  
Unblinding by cohort  Thirty  days following  the decision  by the DRC  to dose escalate to a new dose level,  unblinding 
of the previous cohort is permitted.  
6.4 Study  Treatment Compliance  
The prescribed dosage, timing, and mode of administration may not be changed. Any departures from the 
intended regimen must be recorded in the eCRFs. All dose administrations will be performed in the study 
center, in resting conditions under the supervision of appropriately trained staff.  
6.5 Concomitant Therapy  
Any medication  or vaccine  (including  over the counter  or prescription  medicines,  vitamins,  and/or  [herbal] 
supplements)  that the subject  is receiving at  the time  of informed  consent  (within  30 days  before  informed 
consent) or receives during the study must be recorded in the eCRF along with:  
• Reason  for use. 
• Dates of administration  including start and end dates.  
• Dosage  information  including dose and frequency.  
All medications  and concomitant  treatment  administered  from  screening  through the final study  visit (Early 
Termination or End of Treatment) will be recorded. Documentation will include the name of treatment, 
indication, dose (including units), and date(s) of administration.  
The Medical  Monitor  should be contacted  if there  are any questions  regarding  concomitant  or prior  therapy. 
A list of excluded medications/therapy is provided in Section 11.0, Appendix 4. Initiation of any new 
medications after enrollment must be discussed with the CRO and Sponsor Medical Monitor prior to initiation.  
Other than in the event of an infusion reaction, acetaminophen use is prohibited for the period beginning  
7 days pre-dose and ending 15 days postdose, and outside  of this time should be used only occasionally  and 
at doses  approved  for the age of the subject. Occasional  use of ibuprofen or naproxen  sodium  for pain relief, 
at doses  approved  for the age of the subject,  is permitted.  Other  concomitant  medication  may be considered 
on a case- by-case basis by the Investigator in consultation with the Medical Monitor, if required.  
6.5.1 Rescue Medicine  
Not applicable.  
6.6 Dose Modification  
As this is a single- dose study, dose modification within an individual subject is not applicable. Dose 
escalation and de- escalation criteria within a cohort may be found in Section 4.5 . 
6.7 Treatment after  the End  of the Study  
The Sponsor will not provide any additional care to subjects after they leave the study because such care 
should not differ from what is normally expected for subjects with HFrEF, so these subjects will continue 
with the optimal therapy for HFrEF as established by the 2017 ACC/AHA/HFSA treatment guidelines 
(Yancy et al, 2017).  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  43 of 89  
 7.0 DISCONTINUATION OF STUDY TREATMENT AND SUBJECT 
DISCONTINUATION/WITHDRAWAL  
7.1 Discontinuation  of Study  Treatment  
Subjects are free to withdraw consent and discontinue participation in the study at any time, without 
prejudice. A subject’s participation in the study may be discontinued at any time at the discretion of the 
Investigator, as further described in the protocol.  
The process  for dose escalation  and the stopping criteria  for the study  are described  in Section  4.0. 
If a subject, who does not meet enrollment criteria, is inadvertently enrolled, and the failure to meet enrollment criteria is discovered prior to IP administration, the subject should be discontinued from the 
study and Sponsor or Sponsor designee must be contacted. If a subject, who does not meet enrollment 
criteria,  is inadvertently  enrolled in the study, and has already  received  IP administration,  the subject  should 
be allowed to continue with the study given that following the single IP administration there are no 
additional treatments or invasive tests other than standard blood draws.  
Any consented  subject  who is withdrawn  prior  to the IP administration  will be replaced.  
7.2 Subject  Discontinuation/Withdrawal from  the Study  
A subject  may withdraw  from  the study at any time at his/her  own request  or may be withdrawn  at any time 
at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons.  
The following actions  must  be taken  if a subject  discontinues  or withdraws  from  the study:  
• If the subject withdraws consent for disclosure of future information, the Sponsor may retain and 
continue to use any data collected before such a withdrawal of consent.  
• If a subject  withdraws  from  the study,  he/she  may request  destruction  of any samples taken  and not 
tested, and the Investigator must document this in the study center study records.  
• See Table 1  SoA, End of Study visit (Day 180) for data to be collected at the time of study 
discontinuation. Should a subject  request or  decide to  withdraw  from  the study  prior  to the End of 
Study visit, all efforts must be made to complete and report the observations as thoroughly as possible up to the date of withdrawal. Subjects withdrawing due to an AE at any time should be 
followed up until resolution, stabilization, the event is otherwise explained, the subject is lost to 
follow -up (Section  8.3.8) or until the end of their participation in the study. Subjects should be 
encouraged to complete the End of Study visit activities. 
• Subjects  who voluntarily withdraw  will be termed  dropouts. Dropouts  and subjects  withdrawn  due 
to protocol violations may be replaced following discussion with the Principal Investigator and 
Sponsor. 
7.3 Lost to Follow-up  
A subject  will be considered  lost to follow -up if he or she repeatedly  fails to return  for scheduled  visits  and 
is unable to be contacted by the study center.  
The following  actions  must  be taken  if a subject  fails to return  to the study center  for a required  study visit:  
• The study center must attempt to contact the subject and reschedule the missed visit as soon as 
possible and counsel the subject on the importance of  maintaining the assigned visit schedule and 
ascertain whether the subject wishes to and/or should continue in the study.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  44 of 89  
 • Before a subject is deemed lost to follow -up, the Investigator or designee must make every effort 
to regain contact with the subject (where possible, 3 telephone calls and, if necessary, a certified 
letter to the subject’s last known mailing address or local equivalent methods). These contact 
attempts should be documented in the subject’s medical record.  
• Should the subject continue to be unreachable, he/she will be considered to have withdrawn from 
the study.  
Discontinuation  of specific  study  centers or of the study  are handled as part of Section  11.0 Appendix  2. 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  45 of 89  
 8.0 STUDY ASSESSMENTS AND PROCEDURES  
Study procedures and their timing are summarized in the Table 1 , Table 2, and Appendix 3, Table 13  and 
Table 14.  
• Protocol  waivers  or exemptions  are not allowed. 
• Immediate safety concerns should be discussed with the Sponsor as soon as practicable upon 
occurrence or awareness to determine  if the subject  should  continue  or discontinue  study treatment.  
• Adherence to the study design requirements, including those specified in the Table 1 SoA, is 
essential and required for study conduct.  
• All screening  evaluations  must be completed  and reviewed  to confirm that potential  subjects meet 
all eligibility  criteria.  The Investigator  will maintain  a screening  log to record  details  of all subjects 
screened and to confirm eligibility or record reasons for screening failure, as applicable.  
• Procedures conducted as part of the subject’s routine clinical management (e.g., blood count) and 
obtained before  signing of the ICF may be utilized  for screening  or baseline  purposes  provided  the 
procedures met the protocol -specified criteria and were performed within the time frame defined 
in the Table 1  SoA.  
• The maximum amount of blood collected from each subject over the duration of the study, 
including any extra assessments that may be required, is expected not to exceed 420 mL. The planned blood collections over the first month of the study are not expected to exceed 270 mL. 
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples.  
• Demographic  information,  including date of birth,  gender, ethnicity,  race,  height,  and weight,  will 
be recorded at the Screening Visit.  
8.1 Efficacy  Assessments  
Not applicable.  
8.2 Safety Assessments  
Planned time points  for all safety  assessments  are provided  in Table  1, and Table  2, and Appendix 3, Table  
13 and Table 14.  
Subjects will be observed for injection site reactions until Day 4 following IP administration, for DLAEs 
until Day 15 following IP administration, and for AEs and SAEs from the time of informed consent until 
30 days after the IP administration. Following Day 30, only SAEs deemed at least possibly related to the 
study drug or study procedures will be collected until the End of Study visit (Day 180).  
The safety of JK07 in patients with heart failure with reduced ejection fraction will be evaluated based on 
criteria described by the CTCAE Version 5.0.  
The investigator will  monitor the occurrence of  all AEs during the first 30 days after  administration of  the 
study drug. All AEs must be recorded in the source documents and on the appropriate page(s) of the case 
report form. All SAEs including any deaths, which occur up to and including 30 days after administration 
of the study drug, must be reported to the Medical Monitor within one working day, whether or not 
considered causally related to the study drug. Following the first 30 days, only SAEs deemed at least 
possibly related to the study drug or study procedures should be collected and reported as such. All AEs 
and SAEs will be followed until resolution, stabilization, until the event is otherwise explained, until the 
end of their participation in the study, or until the subject is lost to follow -up. 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  46 of 89  
 8.2.1 Physical  Examinations  
A complete physical examination will be performed at screening and include, at a minimum, assessments 
of the CV, respiratory, GI, and neurological systems. Height (i.e., at screening only) and weight will also 
be measured and recorded.  
A brief physical examination will be conducted at all other visits and include, at a minimum, assessments 
of the skin, lungs, CV system, and abdomen (liver and spleen).  
Investigators  should pay special  attention  to clinical signs  related  to previous  serious  illnesses.  
8.2.2 Injection  Site Assessment  
The site of infusion of the study drug will be assessed for local reactions at the times shown in the SoA 
(Table  1). Any findings  (or lack thereof) will be  documented in the subject’s  eCRF.  During Day 1 (1 early 
assessment  and 1 late assessment/end  of the day),  the Investigator  may choose  to evaluate the  infusion site 
as deemed appropriate.  
Infusion site evaluations will be made by clinical staff as described below; if an injection site reaction greater  than that typically  expected  for the insertion  of an IV line is observed, a physician will characterize 
and document the reaction as an AE. The infusion site will continue to be reviewed at the time points 
indicated in the SoA ( Table 1 ), or until the AE is resolved.  
Infusion sites will be monitored for pain, tenderness, erythema and swelling. Each infusion site reaction will be categorized  using  the intensity  grading scheme presented  in Table  6; the intensity  of each resulting 
AE will be categorized as described in (e.g., at least moderate intensity injection site reaction may be 
recorded as a mild AE if considered appropriate according to the Investigator’s judgement).  
Table  6 Injection  Site Reaction  Grading  Scheme  
 
Intensity  Grading  
Reaction  Absent 
(0) Mild  a 
(1) Moderate a 
(2) Severe a 
(3) Potentially  Life- 
threatening  
(4) 
Pain Absent  Does not 
interfere  with 
activity  Repeated  use of 
non-narcotic 
pain reliever or 
prevents  daily 
activity  Any use of narcotic pain 
reliver or 
prevents  daily 
activity  Hospital  visit (A 
and E) or 
hospitalization  
Tenderness  Absent  Mild  discomfort 
to touch  Discomfort  with 
movement  Significant 
discomfort  at 
rest A and E visit or 
hospitalization  
Erythema/redness  Absent  2.5 to 5.0 cm 5.1 to 10.0 cm >10.0 cm Necrosis  or 
exfoliative dermatitis  
Induration/swelling  Absent  2.5 to 5.0 cm 
and does not interfere  with 
activity  5.1 to 10.0 cm or 
interferes with activity  >10.0 cm or prevents  daily 
activity  Necrosis  
Otherb Absent   Present   
Abbreviation:  A and E; adverse event.  
a Measurements  refer  to the  reaction at  the greatest  single  diameter.  
b Any other  reactions  such as bruising,  itching,  or ulceration will be recorded as absent  or graded  as to severity.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  47 of 89  
 8.2.3 Pregnancy  Test 
Subjects  of childbearing  potential will have  a blood- based  β-hCG  pregnancy test performed  at screening,  a 
hospital -based qualitative immuno- assay for hCG in urine  performed on Day 1 and confirmed negative 
prior to IP administration , and urine pregnancy tests performed at Days 30, 60, 90, 135, and 180. The 
screening and Day 1 results must be available and must be negative before the subject is administered the 
dose of the IP. A positive pregnancy test at screening or on Day 1 will disqualify the subject from the 
participation in the study.  
8.2.4 Medical  History  
A complete evaluation of past medical history will be performed at screening and will include details of 
subjects with a stable NYHA Class II or III HF diagnosis at least 6 months prior to screening and at the 
time of enrolment.  
8.2.5 Electrocardiograms  
During Screening  and beginning no more  than 45 days before  Day 1, all subjects  will be supplied with, 
and instructed how to use a e -Patch for continuous 14- day heart rhythm monitoring as outlined in the 
Table 1  SoA. A 14- continuous day heart rhythm monitoring assessment will be collected using the e - 
Patch with monitoring completed no later than Day - 10 unless confirmed with the sponsor.  
Triplicate 12 -lead ECGs will be performed  prior  to PK sample  collection  as outlined in  Table  1 and Table  
2. Local site will calculate heart rate and measure HR, PR, QRS, QT, and QTcF intervals for the first 48 
hours. Where applicable, the screening ECG and Day 1 baseline ECG must be obtained without evidence 
of pacing.  
All required ECG leads will be secured to the patient and attached to an ECG machine prior to 
administration of the IP to facilitate immediate post- infusion recording.  
Subject  should  be supine  for ≥5 minutes  prior  to each ECG  performed.  
At each time point at which triplicate ECGs are required, 3 individual ECG tracings should be performed 
as closely as possible in succession but no more than 2  minutes apart. The full set of triplicates should be 
completed in <5 minutes with no more than 2 min between them.  
All ECGs must be collected prior to simultaneously scheduled blood sample collections (PK, biomarker, 
and/or laboratory assessments).  
In the first 48- hours hours post -infusion, ECGs and PK samples must be performed in close proximity 
(within 10 minutes up to 4 hours postdose and after the 24-  and 48- hour ECGs clock- time matched to the 
baseline ECG; within 30 minutes prior at other times greater than 4 hours postdose).  
For safety  reasons  triplicate  12-lead ECGs  will be printed  and evaluated  onsite.  
8.2.6 Vital Signs  
• Temperature,  RR, HR, and BP measurements  will be assessed.  
• BP and HR measurements  will be assessed  in resting  position,  with a completely  automated  device. 
Manual techniques will be used only if an automated device is not available.  
• BP should be measured  using the arm not  used for the IP administration. 
• BP and HR measurements  should  be preceded  by at least 5 minutes  of resting  position for the 
subject in a quiet setting without distractions (e.g., television, cell phones).  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  48 of 89  
 • Vital signs (to be taken before blood collection for laboratory tests) will consist of 3 BP 
measurements (3 consecutive BP readings will be recorded at intervals of at least 1  minute). The 
average of the 3 BP readings will be recorded in the eCRF.  
• Vital signs will be collected at the same timepoint as scheduled ECG collections and prior to 
collection of blood for PK, biomarker and/or safety laboratory assessments.  
8.2.7 Clinical  Safety  Laboratory Assessments  
• See Appendix 3 Table  13 for the list of clinical  laboratory tests to be performed  and to the Table  1 
SoA for the timing and frequency. See Appendix 3 Table 13 and Table 14, respectively for local 
and central laboratory assessments.  
• The Investigator  must  review  the laboratory report,  document  this review,  and record  any clinically 
relevant  changes occurring  during the  study  in the AE section  of the eCRF.  The laboratory  reports 
must be filed with the source documents. Clinically significant abnormal laboratory findings are 
those that are not related to HFrEF or any other pre -existing condition at the time of enrollment, 
unless judged by the Investigator to be more severe than expected for the subject’s condition.  
• All laboratory tests with values considered clinically significantly abnormal, relative to baseline 
values, within 30 days after the dose of study treatment should be repeated until the values return 
to normal or baseline or are no longer considered clinically significant by the Investigator or 
Medical Monitor.  
− If such values do not return to normal/baseline within a period judged reasonable by the Investigator, the etiology should be identified, and the Sponsor notified.  
− All protocol -required  laboratory  assessments,  as defined  in Appendix  3, must  be conducted 
in accordance with the laboratory manual and the Table 1  SoA.  
− If laboratory values from non- protocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in subject management or are considered clinically significant by the Investigator (e.g., SAE or AE or dose modification), then the 
results must be recorded in the eCRF.  
8.2.8 Immunogenicity  Assessments 
Antibodies  to JK07  will be evaluated  in serum  samples  collected  from  all subjects according  to the Table  1 
SoA.  Additionally, serum  samples  should  also be collected  at the final visit from  subjects  who discontinued 
study treatment  or were  withdrawn  from  the study. These  samples will be tested  by the Sponsor  or Sponsor's 
designee.  
Serum samples will be screened for antibodies binding to JK07. Samples which show a positive response 
in the screening assay will be evaluated using a confirmatory ADA assay, and the confirmed positive 
samples will be reported and their potential for neutralizing activity will be explored. Other analyses will 
be performed to verify the stability of JK07 and to further characterize the immunogenicity of JK07.  
The detection and characterization  of antibodies  to JK07  will be performed  using a validated  assay  method 
by or under the supervision of the Sponsor. Antibodies may be further characterized and/or evaluated for 
their ability to neutralize the activity of the study treatment(s).  Samples may be stored for a maximum of 
10 years (or according to local regulations) following the last subject’s last visit for the study at a facility 
selected by the Sponsor to enable further analysis of immune responses to JK07.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  49 of 89  
 8.2.9 Two -dimensional  Transthoracic  Echocardiography  
Left ventricular and hemodynamic performance indices measured by 2D -TTE will be explored. Potential 
effects of JK07  will be evaluated  as change  from  baseline  and will be compared  with changes from  baseline 
in subjects receiving placebo.  
On Day 1, 2D-TTE will be performed  locally  following  American  Society  of Echocardiography  guidelines 
and recommendations, pre -dose and at 6  hours ± 30 minutes, and on Day 2 at 30 hours ± 30 minutes 
following completion of the dosing infusion, and at subsequent times described in the Table 1 SoA.  
The full examination will be evaluated locally for safety and will be digitally transferred to the Central 
Laboratory for centralized  evaluation  and centralized  calculation  of the measurements.  Measurements  taken 
by the Central Laboratory will include but are not limited to: ejection fraction, multiple LV chamber 
dimensions, including LVESV, LVEDV, as well as multiple calculated monitoring parameters using 
velocity and flow measurements including SV, CO, and E/e’ calculations (Please see Appendix 5 for 
detailed listing).  
8.3 Safety Monitoring and Reporting  
8.3.1 Adverse  Events  
In accordance with the ICH E2A guideline, and 21 Code of Federal Regulations (CFR) §312.32, an AE is 
defined as any untoward medical occurrence in a clinical study subject administered a pharmaceutical 
product, which  does  not necessarily  have  a causal  relationship  with  this treatment.  An AE can therefore be 
any unfavorable  and unintended sign (including  an abnormal  laboratory finding),  symptom,  or disease  (new 
or exacerbated) temporally associated with the use of study treatment.  
This includes  the following:  
• Any abnormal  laboratory test results relative  to baseline values  (hematology, clinical  chemistry,  or 
urinalysis) or other safety assessments (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical and 
scientific judgment of the Investigator (i.e., not related to progression of underlying disease).  
• Exacerbation  of a chronic  or intermittent pre-existing  condition including either  an increase  in 
frequency and/or intensity of the condition.  
• New conditions  detected  or diagnosed after study treatment  administration  even  though it may have 
been present before the start of the study.  
• Signs,  symptoms,  or the clinical  sequelae of a suspected  drug- drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a 
concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self -harming intent. Such overdoses should be 
reported regardless of sequelae.  
8.3.2 Serious Adverse Events  
An SAE  is defined  as an event  that, at any dose, meets  any of  the criteria  in Table  7. 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  50 of 89  
 Table  7 Definitions  of Serious  Adverse Events  
 
Criteria  Description  
Fatal:  The AE resulted  in death  
Life-threatening:  The AE placed  the subject  at immediate risk of death.  (This  classification  does not apply 
to an AE that hypothetically might have caused death if it had been more severe)  
Hospitalization/prolongation  of 
hospitalization: The AE resulted  in hospitalization or  prolongation of hospitalization  
Disability/incapacity: The AE resulted  in a disability,  significant  incapacity,  or substantial disruption of the 
subjects’ ability to conduct normal life functions  
Congenital  anomaly/birth defect:  The AE was an adverse outcome in a child  or fetus  of a subject  exposed  to the study 
treatment regimen before conception or during pregnancy  
 
 
Medically  important  The AE was a medically important event that did not meet any of the above criteria, but 
may have jeopardized the subject  and may have required medical or  surgical intervention 
to prevent  one of the outcomes  listed  above  (examples  include  allergic  bronchospasm  that 
required  treatment in an emergency room,  seizures that  do not result in  hospitalization,  or 
blood dyscrasias)  
This SAE  classification  does not apply  for the following  hospitalizations:  
• Admissions for social or situational reasons (e.g., no place to stay, live too far away to come for 
hospital visits) in the absence of any clinical AE  
• Admissions  at the discretion  of the Investigator  
• Admissions for elective or pre -planned treatment or procedure for a pre -existing condition that is 
unrelated to the condition under study and has not worsened since providing informed consent  
• Admissions  for routine  treatment  (e.g., platelet  transfusion, IV diuresis)  or monitoring  of the 
condition under study not associated with any deterioration in condition  
• Admissions  for routine  procedures  (e.g., bone  marrow  aspiration,  thoracentesis)  associated  with the 
disease under study  
• Emergency outpatient treatment or observation that does not result in admission, unless fulfilling 
other seriousness criteria above  
Note:  Complications  and/or  prolonged admissions  for routine  treatment  or procedure  do require  SAE 
reporting.  
8.3.3 Time  Period  and Frequency  for Collecting  AE and SAE  Information  
All AEs, including SAEs will be collected from the time of enrollment and until 30  days after the IP 
administration.  Following  the first 30 days, only SAEs  deemed  at least possibly  related  to the study  drug or 
study procedures should be collected.  
Medical  occurrences that begin before  the start of study  treatment  but after obtaining informed  consent  will 
be recorded on the Medical History/Current Medical Conditions section of the eCRF, not the AE section.  
Investigators  are not obligated to actively  seek AEs or SAEs  for subjects after their study participation  ends. 
However, if the Investigator learns of any SAE, including a death, at any time after a subject has been discharged  from  the study, and he/she  considers the event  to be reasonably  related  to the study treatment  or 
study participation, the Investigator must promptly notify the Sponsor.  
All SAEs  will be  recorded on an  SAE  report  form  and reported  to the Sponsor  designee  within  24 hours  of 
the investigator’s  awareness of  the event.  The Investigator  will submit any updated SAE data to  the Sponsor  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  51 of 89  
 designee within  24 hours  of the investigator’s awareness of  any follow -up information associated  with the 
event.  
SAE  reports  will be submitted  to IQVIA  Biotech  Safety  Management  Department  via one of the following 
methods:  
Safety email in -box: Safety -Inbox.Biotech@IQVIA.com  
Safety  Fax:  +1 919.313.1412 (US Toll-free:  1-866-761-1274)  
For initial  SAE  reports, the following minimum  criteria  must  be reported  on the SAE form:  
• Subject  Number  
• Date  of event  onset  
• Description  of event  
• Study treatment  
• Relationship  to study  treatment  
8.3.4 Method  of Detecting  AEs and SAEs  
Adverse events will be reported by the patient (or, when appropriate, by a caregiver, surrogate, or the 
patient's legally authorized representative).  
The Investigator and any designees are responsible for detecting, documenting, and recording events that 
meet the definition of an AE or SAE and remain responsible for following up AEs that are serious, 
considered  related  to JK07  or study  procedures, or  that caused  the patient  to discontinue  JK07  or the study 
(see Section 7.0).  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open- ended and nonleading 
verbal questioning of the subject is the preferred method to inquire about AE occurrences.  
8.3.5 Grading  and Intensity  of Adverse  Events  
Adverse events will be graded using CTCAE v5 as shown in Table 8 . The reported verbatim term should 
be the most descriptive medical diagnosis and does not have to be found in CTCAE v5. Regardless of 
severity, some events may also meet regulatory serious criteria (See Section 8.3.2 ). 
The terms “severe” and “serious” are not synonymous. Note the distinction between the severity and the 
seriousness of an AE. Severity refers to the intensity of an AE. A severe event is not necessarily an SAE. 
For example,  headache  may  be severe  (interferes  significantly  with  the patient’s usual  function)  but would 
not be classified as serious unless it met one of the criteria for SAEs listed in Section 8.3.2. “Serious” is  a 
regulatory definition and is based on subject or event outcome or action criteria usually associated with 
events  that pose  a threat to  a subject’s life or vital functions. Seriousness  (not severity) serves as the guide 
for defining regulatory reporting obligations. Severity and seriousness should be independently assessed 
when recording AEs and SAEs on the eCRF.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  52 of 89  
 Table  8 Adverse Event  Grade  (Severity)  Scale  
 
Grade  Severity  Alternate Description  a 
 
1 Mild  (apply event -specific NCI 
CTCAE v5 grading criteria) Transient  or mild discomfort  (<48 hours);  no interference with the subject’s 
daily activities; no medical intervention/therapy required  
 
2 Moderate (apply  event -specific NCI 
CTCAE v5 grading criteria) Mild  to moderate interference with the subject’s  daily  activities; no or minimal 
medical intervention/therapy required  
 
3 Severe (apply event -specific NCI 
CTCAE v5 grading criteria) Considerable  interference with the subject’s  daily  activities; medical 
intervention/therapy required; hospitalization possible  
 
 
4  
Very  severe,  life threatening,  
or disabling  (apply event -specific NCI 
CTCAE v5 grading criteria)  
Extreme limitation  in activity; significant medical  intervention/therapy required, 
hospitalization probable  
5 Death  related  to adverse  event   
Source:  National  Cancer  Institute  Common  Terminology  Criteria  for Adverse  Events  (NCI CTCAE),  Version  5.0 
a. Use  the alternative  descriptions  for Grade  1, 2, 3, and 4 events  when the  observed or reported AE  does not appear  in the NCI 
CTCAE v5 listing.  
8.3.6 Relationship  to Study  Drug  
The investigators should use their knowledge of the subject, the circumstances surrounding the event, and 
an evaluation of any potential alternative causes to determine whether or not an AE is considered to be 
related to the study drug. Some considerations are presented in Table 9 . 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  53 of 89  
 Table  9 Relatedness of Adverse  Events  to Investigational  Product  
 
 
 
NOT  RELATED:  This category is applicable to those AEs that are clearly due to extraneous causes (concurrent drugs, 
environment, etc.) and/or the clinically plausible temporal sequence is inconsistent with the onset of the 
event  and the administration  of the study  drug and do not meet  the criteria  for drug relationship  listed  under 
UNLIKELY, POSSIBLY, or DEFINITELY RELATED.  
UNLIKELY 
RELATED:  This category  is applicable  to those  AEs that could easily  be explained  by the patient’s  clinical  status  or 
other factors and/or there is a poor temporal relationship with the administration of the study drug.  
 
 
POSSIBLY RELATED:  This category  applies  to those  AEs that, are judged to be perhaps  related  to the study  drug administration. 
An AE may be considered POSSIBLY RELATED when it meets at least one of the following criteria:  
1. It follows  a reasonable temporal  sequence from  administration  of the study drug.  
2. It could not readily  have  been  produced by the patient’s  clinical  state,  environmental  or toxic 
factors, or other modes of therapy administered to the patient.  
3. It follows  a known or expected response  pattern to  the study  drug.  
 
 
 
 
 
DEFINITELY 
RELATED:  This category  applies  to those  AEs that are incontrovertibly related  to study  drug administration.  An AE 
may be assigned to this category if it meets at least the first three of the following criteria:  
1. It follows  a reasonable temporal  sequence from  administration  of the study drug.  
2. It could  not be reasonably  explained  by the known characteristics  of the patient’s  clinical  state, 
environmental or toxic factors, or other modes of therapy administered to the patient.  
3. It disappears  or decreases  on cessation  or reduction  in study  drug dose.  There are exceptions  when 
an AE does not disappear upon discontinuation of the drug, yet drug relatedness clearly exists 
(e.g., depression, fixed drug eruptions, tardive dyskinesia, etc.).  
4. It follows  a known or expected response  pattern to  the study  drug.  
5. It reappears  or worsens  when  the study  drug is re-administered.  
• The Investigator  will use clinical  judgment  to determine  the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as 
well as the temporal relationship of the event  to study treatment administration will be  considered 
and investigated.  
• The Investigator  will also consult  the IB in his/her  assessment.  
• For each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed 
the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred, and the Investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important that the 
Investigator  always assess causality  for every  event  before  the initial  transmission  of the SAE  data 
to the Sponsor.  
• The Investigator may change his/her opinion of causality considering follow -up information and 
send a SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
8.3.7 Recording  AEs and SAEs  
When  an AE/SAE  occurs,  it is the responsibility  of the Investigator  to review  all documentation (e.g., 
hospital progress notes, laboratory reports, and diagnostics reports) related to the event.  
The Investigator  will then record  all relevant  AE/SAE  information  in the eCRF.  Each  event  must be 
recorded separately.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  54 of 89  
 It is not acceptable for the Investigator to send photocopies of the subject’s medical records in lieu of 
completion  of the AE/SAE  eCRF  page. There  may be instances  when  copies of medical  records  for certain 
cases are requested. In this case, all subject identifiers, except for the subject number, will be redacted on the copies of the medical records before provided.  
Each  AE is to be evaluated  for: 
• AE diagnosis  or syndrome  (if not known, signs  or symptoms)  
• Dates of onset and resolution 
• Severity  (including grade  changes  as per the CRF  completion  guidelines  
• Causal  relationship  with study  drug or protocol -mandated  procedures  
• Seriousness  
• Action  taken  
• Outcome  
Whenever  possible, a unifying diagnosis  should be reported  as opposed to a listing  of individual  symptoms. 
However, symptoms should be grouped into a diagnosis only if each sign or symptom is a medically 
confirmed component of that diagnosis as evidenced by current standard medical textbooks. If any aspect 
of a sign or symptom does  not fit into a classic pattern  of the diagnosis,  the individual  symptom  should be 
reported as a separate AE.  
A preexisting medical condition is one that is present during the screening period for this study. Such 
conditions  should be recorded  as General  Medical  History  and Baseline Conditions. A preexisting  medical 
condition should be recorded  as an AE only if the frequency, severity,  or character  of the condition worsens 
during the study.  
For hospitalizations or surgical or diagnostic procedures, the illness leading to the surgical or diagnostic 
procedure  should be recorded  as the SAE,  not the procedure  itself.  The procedure  should be captured  in the 
narrative as part of the action taken in response to the illness.  
When reporting an SAE of progression of the disease under investigation, specific manifestations of the progression (e.g., acute coronary syndrome, acute pulmonary edema) should be reported, rather than the 
general term “disease progression.”  
Any emergent laboratory abnormality (e.g., clinical chemistry or hematology) or other abnormal assessment 
findings (e.g., ECG or vital signs) that meets any of the following criteria should be recorded as an AE or 
SAE:  
• Associated  with clinical signs  and/or  symptoms  
• Requires  medical  or surgical  intervention  
• May require a change in current therapy, and leads to study treatment discontinuation, delay, or 
interruption  
• Otherwise clinically  significant  as determined  by the Investigator  
Whenever  possible, the clinical  diagnosis,  rather  than the laboratory  result,  should be reported  by the 
Investigator (e.g., anemia versus low hematocrit).  
Emergent  and clinically  significant abnormal  laboratory  values occurring during the study  will be followed 
until repeat tests return to normal, stabilize, or are no longer clinically significant.  
Laboratory abnormalities  that are not deemed  clinically  significant  by the Investigator  should not be 
reported as AEs.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  55 of 89  
 All deaths that occur during the protocol -specified AE reporting period, regardless of attribution, will be 
recorded  on an eCRF  and SAE report  form,  and expeditiously reported  to the Sponsor.  This includes  death 
attributed to progression of disease.  
• When recording a death on an eCRF or SAE Report Form, the event or condition that caused or 
contributed to the fatal outcome should be recorded as the single medical concept.  
• Death is an outcome of an event. The event that resulted in death (e.g., sepsis, stroke, myocardial infarction, etc.) should be recorded in the eCRF and reported on the SAE report form.  
• If the death is attributed to progression of disease, record “disease progression” as the SAE term on the SAE Report Form.  
• The term “unexplained death” should be captured if the cause of death is not known. However, 
every  effort  should be made  to capture the established  cause of death, which  may become  available 
later on (e.g., after autopsy). 
8.3.8 Follow -up of AEs  and SAEs  
After  the initial AE/SAE  report, the Investigator  is required  to proactively  follow  each subject  at subsequent 
visits/contacts. All SAEs will be followed until resolution, stabilization, the event is otherwise explained, 
or the subject is lost to follow -up (as defined in Section 7.3) or until the end of their participation in the 
study. Subjects should be encouraged to complete the End of Study visit activities. 
8.3.9 Regulatory Reporting  Requirements  for SAEs  
• Prompt notification by the Investigator to the Sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of subjects and the safety of a study 
treatment under clinical investigation are met.  
• The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation. 
• Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
(SUSAR) according to local regulatory requirements and Sponsor policy and forwarded to 
Investigators as necessary.  
• An Investigator who receives an Investigator safety report describing an SAE or other specific 
safety information (e.g., summary or listing of SAEs) from the Sponsor will review and maintain 
it in the site’s regulatory binder along with the IB and will notify the IRB/IEC, if appropriate 
according to local requirements.  
8.3.10  Pregnancy  
Notify the sponsor or its designee regarding a pregnancy that occurs in either a study patient or occurs in 
the female partner of a male patient during his participation in this study within 24 hours.  
If a female subject becomes pregnant after consent and during the screening process but prior to IP administration,  the subject  should be withdrawn  immediately,  and should not receive IP. If a female  subject 
becomes pregnant after treatment, the subject should be allowed to continue with the study given that 
following the single  IP administration  there  are no additional  treatments  and no invasive  tests or procedures. 
Counseling should be provided to the subject in order to inform their decisions on study continuation and on the pregnancy.  
While pregnancy itself is not considered an AE, any pregnancy complication should be reported to the 
sponsor  or its designee.  Abnormal  pregnancy outcomes  (e.g., spontaneous  abortion,  fetal death,  stillbirth,  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  56 of 89  
 congenital  anomalies,  ectopic  pregnancy)  are considered  SAEs  and should be reported  to the sponsor  or its 
designee as soon as the Investigator or his/her staff learns of the event. The outcome of all pregnancies 
(spontaneous  miscarriage,  elective  termination,  normal  birth, or  congenital  abnormality)  must  be followed 
up and documented even if the patient was discontinued from the study.  
The Investigator will attempt to collect pregnancy information on any male subject’s female partner who becomes pregnant while the male subject is in this study. This applies only to male subjects who receive 
JK07. Details  of all pregnancies  in female  partners  of male  patients  will be collected  after the start of JK07 
and until 28 days after IP administration.  
If a male  subject  has a female  partner  who becomes pregnant  during  the study, the subject  must  be unblinded 
in order  to inform  whether  appropriate counseling of  the female partner  is necessary.  In this  circumstance, 
the unblinded male subject can remain on study and continue with follow -up visits as scheduled.  
After obtaining the necessary signed ICF from the pregnant partner directly, the Investigator will record pregnancy information on the appropriate form and submit it to the Sponsor designee within 24 hours of 
learning of the partner’s pregnancy, in the same fashion as an SAE, as noted in Section 8.3.3.  
The pregnant  partner  will also be followed  to determine the  outcome  of the pregnancy. Information on the 
status  of the mother  and child  will be forwarded to the Sponsor. Generally,  the follow -up will be  no longer 
than 6 to 8 weeks  following  the estimated  delivery  date.  Any termination  of the pregnancy will be reported 
regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
8.3.11  Protocol -Specified Serious  Adverse Events  
There  are no protocol -specified  SAEs  in this study.  
8.3.12  Disease- related  Events  and/or  Disease- related  Outcomes  Not Qualifying  as AEs or SAEs  
The DRC  will carefully  evaluate  all AEs as to whether  they are considered  a TEAE or DLAE.  
 
8.4 Treatment of Overdose 
The JK07 dose administered in this study should not exceed 2.5 mg/kg without further amending the protocol  (See dose escalation  in Table  4). An overdose  is any dose above  the assigned  dose level  for a given 
cohort that is administered over the pre -specified 60- minute period.  
In the event  of an overdose,  the Investigator/treating physician should:  
1. Contact  the Medical  Monitor  immediately.  
2. Closely  monitor  the subject  for any AEs/SAEs  and laboratory  abnormalities  until study treatment  can 
no longer be detected systemically or through the EOS visit (180 days; whichever is longer).  
3. Obtain  blood samples for PK analysis as specified  in the Table  1 SoA.  
4. Document  the quantity of the excess dose as well as the duration of  the infusion in the eCRF.  
5. Overdose  is reportable  to Safety  only when  associated  with an SAE.  
Decisions regarding dose interruptions or modifications will be made by the investigator in consultation 
with the medical monitor based on the clinical evaluation of the participant.  
8.5 Pharmacokinetics  
8.5.1 Collection  of Samples  
Venous blood samples of approximately 5 mL will be collected for measurement of serum concentrations 
of JK07  at times  as specified  in the Table  1 SoA and Table  2. Instructions  for the collection  and handling  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  57 of 89  
 of biological samples will be provided by the Sponsor  in a separate Laboratory Manual. Blood samples will 
be taken  either  by direct venipuncture  or an indwelling  cannula  inserted  in a forearm  vein. The  actual  date 
and time (24- hour clock time) of each sample will be recorded. The start date/time and stop date/time of 
the infusion and other pertinent information (See Section 6.1) will also be recorded. Samples will be 
collected, labelled, stored, and shipped as detailed in the Laboratory Manual.  
Predose  samples may be collected  within  30 minutes  prior  to start  of infusion. The  end- of-infusion sample 
must  be taken  no later than 5 minutes  from  end-of-infusion. A 5-minute  window  will be allowed  for samples 
taken up to 1 -hour postdose; a 15 -minute window will be allowed for samples taken at 2 to 12 hours 
postdose, a  10-minute  window  from  the completion  of ECG  assessments at 24- and 48-hours  postdose;  a 
±8-hour window is permitted for PK collections on Day 4, and a +1 day window for Day 7. For all 
subsequent days, the PK sample should be collected within the Table 1  SoA specified windows.  
8.5.2 Determination  of Drug  Concentration  
Samples  for the determination  of JK07  serum  concentration  will be analyzed  on behalf  of the Sponsor  using 
appropriate validated bioanalytical methods. JK07 concentrations are to be determined from an 
immunoassay targeting both the antibody domain and the NRG -1 peptide fragment. Full details of the 
bioanalytical methods will be described in the separate Bioanalytical Report(s).  
All samples still within the known stability of the analyte of interest at the time of receipt by the bioanalytical laboratory will be analyzed.  
Remaining serum samples may be subjected to further analysis by the Sponsor or designee for the 
development of additional bioanalytical assays and/or for further investigation of JK07 
stability/degradation. Samples collected for analyses of JK07 concentration may also be used to evaluate 
safety or efficacy aspects related to concerns arising during or after the study.  
8.5.3 Calculation  of Derivation  of Pharmacokinetic  Variables  
Pharmacokinetic parameters  will be derived  using noncompartmental  methods  with Phoenix
® WinNonlin® 
Version  8.0 or higher  (Certara,  L.P. Princeton, New Jersey,  United  States  of America  [USA])  and/or  SAS® 
EG 7.23 or higher (SAS Institute, Inc., Cary, North Carolina, USA). Actual elapsed time  from dosing will 
be used for the final serum PK parameter calculations. Nominal time from dosing will be used for any 
interim PK parameter calculations.  
The PK parameters in Table 10  will be determined for serum JK07 concentrations obtained from both 
assays, when possible. A minimum of 4  quantifiable postdose concentrations will be required for all 
calculations.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  58 of 89  
 Table  10 Plasma/Serum/Whole  Blood  Pharmacokinetic  Parameters  
 
Pharmacokinetic Parameter Definition  
Cmax Maximum  concentration  obtained  directly  from  the observed  concentration  versus  time 
data. 
tmax Time to Cmax. 
AUC (0-inf) Area under  the serum  concentration -time  curve  from  time zero extrapolated  to infinity, 
calculated by linear up/log down trapezoidal summation. If the percentage of AUC 
obtained by extrapolation is greater than 30%, AUC (0-inf) and related parameters (CL 
and V z) will be listed but not included in any summaries or inferential analyses.  
AUC (0-last) Area under  the serum  concentration -time  curve  from  time zero to the time of the last 
quantifiable  concentration,  calculated  by linear  up/log  down trapezoidal  summation.  
CL Systemic clearance.  
Vz Volume  of distribution.  
t½ Terminal  half-life: a  minimum  of 3 points  will be used for  estimation.  
λz Terminal  rate constant:  if Rsq(adj) is <0.800,  then λz, t½, and related  parameters  will be 
listed but not included in any summaries or inferential analyses  
Dose  normalized  exposure  parameters  will also be calculated.  
Additional serum parameters may be calculated if deemed appropriate. Further details with respect to the 
PK analysis will be provided in the Statistical Analysis Plan (SAP).  
Drug concentration information that may unblind a given cohort will not be reported to study centers or 
blinded personnel until that cohort has been unblinded.  
Any changes in the timing  or addition of time points  for any planned  study assessments must  be documented 
and approved by the relevant study team  member and  then archived in the Sponsor and study center study 
files but will not constitute a protocol amendment.  
8.6 Pharmacodynamics  
Pharmacodynamics  will not be evaluated  in this study. The exploratory 2D-TTE assessments  are described 
in Section 8.2.9. Exploratory biomarker assessment details are outlined in Section 8.8. 
8.7 Genetics  
Genetics  will not be evaluated  in this study.  
8.8 Biomarkers  
• Collection  of samples for biomarker  research  is a component  of the safety  monitoring for this study 
and also an exploratory part of this study. Samples will be tested for predictive muscle and 
inflammatory  biomarkers  to evaluate  their association  with the observed clinical  responses  to JK07. 
The following  samples for the safety  and exploratory muscle  and inflammatory  biomarkers  will be 
collected from all subjects in this study as specified in the SoA:  
− Additional biomarkers: hsCRP, troponin- I and/or hs -troponin T, CPK, CPK -MB, and 
lactate dehydrogenase.  
− Exploratory biomarkers:  NT-proBNP, total BNP 
• Venous blood samples of approximately 10 mL will be collected at several time points as per the 
SoA (Table  1) and Appendix  3, Table  15, for measurement  of exploratory biomarkers.  Instructions  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  59 of 89  
 for the collection  and handling of biological samples will be provided  by the Sponsor  in a separate 
Laboratory Manual.  
• Serum  biomarker  samples will be analyzed  by the Sponsor  designated  clinical  laboratory 
(Q2 Solutions).  
8.9 Health Economics  
Health Economics/Medical Resource Utilization and Health Economics parameters are not evaluated in 
this study.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  60 of 89  
 9.0 STATISTICAL  CONSIDERATIONS  
9.1 Statistical Hypotheses  
Formal statistical hypothesis testing is not planned for this study. All analyses will be considered 
exploratory and descriptive. 
9.2 Sample  Size Determination  
The study  will enroll  up to a maximum of 63 subjects  who will be randomized  into dose escalation  cohorts. 
The sample size is not based on statistical considerations but is typical for studies of this nature and is 
considered  adequate  to characterize the distribution  of the planned endpoints. Any statistical  testing  will be 
considered exploratory and descriptive.  
9.3 Populations for Analyses  
For purposes  of analysis,  the analysis  sets are defined in Table  11. 
Table  11 Analysis  Sets 
 
Analysis  Set Description  
Safety  Evaluation  Population  All subjects  randomly  assigned  to the IP and who take at least 1 dose of IP. Subjects 
will be analyzed according to the treatment they received.  
Dose -limiting  Adverse  Event  (DLAE) 
Evaluation Population  All subjects  who received  at least 1 dose of IP and completed  the 15-day  DLAE 
follow -up period.  
Pharmacokinetic (PK)  Evaluation 
Population  All subjects  who received  at least 1 dose of IP and have  at least 1 quantifiable  IP 
plasma concentration collected postdose without important protocol 
deviations/violations or events thought to significantly affect the PK results.  
Exploratory Pharmacodynamic 
(PD)/Biomarker Evaluation Population  All subjects  who take at least 1 dose of IP and have  at least 1 exploratory PD variable 
or biomarker endpoint collected postdose without important protocol 
deviations/violations or events thought to significantly affect the PD results.  
9.4 Statistical Analyses  
The SAP  will be  developed  and finalized  before  database lock and will describe  the subject  analysis  sets to 
be included in the analyses, and procedures for accounting for missing, unused, and spurious data. This 
section  focusses on the summary  of the planned  statistical  analyses  of the primary  and secondary endpoints.  
All analyses,  summaries,  and listings  will be performed  using SAS® software (EG 7.23 or  higher). Results 
will be summarized by treatment and overall, where appropriate. Subjects who received placebo will be 
combined into 1 treatment  group for purposes  of analysis.  Change  from  baseline  will be calculated  as value 
postdose subtracted by value at baseline. The baseline measure will be defined as the last non -missing 
measure prior to initiation of IP.  
The following  descriptive  statistics  will be used as applicable to summarize the study  data unless  otherwise 
specified:  
• Continuous variables: sample size (n), mean, standard deviation (SD), median, minimum (min), 
and maximum (max).  
• Summaries for JK07 concentrations will include the coefficient of variation and PK parameter 
summaries will also include the geometric mean (except for t max which will only be presented as 
min, median, max).  
• Categorical  variables:  frequencies and percentages.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  61 of 89  
 Individual  subject  data will be presented  in listings.  
9.4.1 Efficacy  Analyses  
See Section  9.4.4 for assessment  of exploratory efficacy  analyses.  
9.4.2 Pharmacokinetic/Pharmacodynamic  Analyses  
PK Analysis:  
JK07  concentrations  derived  from  the validated  assay,  concentration  ratios,  and calculated  parameters will 
be listed and descriptively summarized by active treatment for the PK population (subjects who have 
received JK07 and do not have any protocol deviations/events which may affect the PK results). JK07 
serum  concentration- time profiles  will be graphically  displayed  by treatment  on linear  and semilogarithmic 
scale for each assay, as appropriate. Scatter plots of individual values and geometric means of PK 
parameters, area under the plasma concentration -time curve from time zero extrapolated to infinity 
(AUC (0-inf) [or area under the plasma concentration -time curve from time zero to the time of the last 
quantifiable  concentration  (AUC (0-last)) if AUC (0-inf) is not calculable in most  subjects]),  Cmax as well as dose- 
normalized exposure parameters versus dose will be presented.  
Dose proportionality of PK parameters such as C max and AUC (0-inf) [or AUC (0-last) if AUC (0-inf) is not 
calculable in most subjects] over the administered dose range may also be explored using a power model.  
Further  details  will be presented  in the SAP.  
Exploratory  Exposure -Response  Analysis : 
An exploratory evaluation of a plasma concentration to QT (C -QT) relationship  will be conducted using a 
linear  mixed  effects model,  with the drug -free-corrected  (Day  -1-corrected)  change  from  baseline  in QTcF 
as the response variable, denoted as ∆ QTcF. Independent variables will include the fixed effects time - 
matched JK07 plasma concentration obtained on Day 1, treatment indicator (treatment = 1 for subjects 
receiving  JK07, and 0 otherwise),  time point  as a categorical  variable,  and random  effects subject  and time- 
matched  JK07  plasma  concentration obtained on Day 1. The analysis  will be performed  for the exploratory 
PD/biomarker  population. Figures  for mean  time -matched  change  from  baseline QTcF  values  versus  JK07 
mean concentrations (time -matched with QTcF) on Days 1 will also be generated.  Hysteresis will be 
examined via by- subject hysteresis plots. Departures from a linear relationship will be examined 
graphically, and additional C -QT relationships other than the linear relationship may be explored if 
supported by data.  A detailed  plan of this analysis will be presented  as part of the statistical  analysis 
plan. The results for the C -QT analysis will be included in the CSR for this study. Further details will be 
presented in the SAP.  
Exposure -response relationships may also be explored for safety and/or biomarker endpoint. Details 
regarding these analyses will be provided in the SAP.  
Pharmacokinetic data from this study may be pooled with data from other future study(ies) and analyzed 
using population modeling approaches or used to explore exposure -response relationships. If performed, 
separate analysis plan(s) will be prepared; results from these analyses will not be part of the clinical study 
report.  
9.4.3 Safety  Analyses  
All safety  analyses  will be performed  on the Safety  Population.  
All safety  data will be listed  according to treatment  group, subject  number,  and visit. 
The AEs are defined in Section 8.3.1. The DLAE are defined in Section 4.6.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  62 of 89  
 AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22. The 
number of AEs and incidence rates will be tabulated by preferred term and system organ class.  
The AEs  will be  coded by maximum severity,  relationship  to study treatment,  as SAEs  or DLTs  as needed, 
and will be categorized and tabulated for each treatment group (cohort).  
DLAEs  will be presented  in the same  manner  as the AEs. 
Incidence of injection site reactions will be summarized by treatment group, and if appropriate by 
assessment time.  
All laboratory test results, vital signs measurements, ECG results, weight, and body mass index will be 
summarized  for each treatment group using descriptive statistics at each  visit for  raw numbers  and change 
from baseline. The incidence of treatment -emergent abnormal laboratory, vital sign, and ECG values will 
also be summarized using descriptive statistics.  
For 12- lead ECG parameters (HR, PR, QRS, QT, QTcF), the 90 % confidence interval will also be 
presented for each parameter mean and change from baseline values. Outliers for QT and QTcF defined under  outcome  measures will be summarized  using counts  and percentages by treatment  and sampling time, 
if appropriate and using subject -level maximum over time by treatment. The following categories will be 
presented by treatment and overall, for JK07:  
• outlier  QT and QTcF  intervals  (450- 480 ms, 480-500 ms and >500 ms) 
• change  from  baseline in QT and QTcF  intervals  (30-60 ms and >60 ms) 
Additional corrections to QT may also be similarly analyzed. If relevant, analysis excluding ECGs 
capturing paced beats will be performed.  
Abnormal  findings  on 12-lead ECG  will be summarized  by treatment  using  descriptive  statistics.  
All recorded ECGs will be interpreted on site and subsequently collected, digitized, and sent for central 
laboratory standardized measurements. The incidence (number of subjects and percent) of a confirmed 
positive  ADA response  will be summarized  by treatment.  The incidence  of neutralizing  anti-drug antibody 
response will also be summarized, if appropriate.  
All data will be  provided in data listings  sorted  by treatment  group, subject  number, and visit.  
9.4.4 Other  Analyses  
Results of the exploratory endpoints (2D -TTE and biomarkers) and the change from baseline values (as 
applicable)  will be listed  and descriptively  summarized  by treatment  and scheduled  time point. Exploratory 
inferential comparisons to placebo may also be performed, if appropriate.  
9.4.5 Missing  Data  
Data  from  subjects  who withdraw  from  the study, including AEs and any follow -up, will be included  in the 
analyses of all outcomes.  
Missing  data will be excluded from  the analyses.  No imputation  will be performed,  unless  specified.  
9.5 Interim  Analyses  
No formal interim analyses are planned. Pharmacokinetic parameters will be calculated using available 
JK07  concentrations  and scheduled sampling  times  to support  JK07  dose escalation  decisions,  as applicable. 
Handling of the safety results obtained up to Day 15 after dose administrations will be described in the 
DRC Charter which will be prepared separately from the protocol.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  63 of 89  
 9.6 Data Review Committee  
A DRC consisting of members who are independent from the Sponsor will be established. The DRC will 
be composed of a minimum of 3 qualified cardiologists (independent voting members), and 3 non-voting 
members (including a biostatistician and Sponsor’s medical monitor). When needed, ad hoc members or 
subject matter  experts can be invited  to participate  as nonvoting participants.  The DRC  will have a separate 
charter from the protocol. 
The DRC is responsible for reviewing and evaluating unblinded safety data for sentinel subjects, and 
blinded safety  data (and safety  data unblinded only on an as-needed  basis)  collected  for at least 14 days and 
subsequently  cumulatively  at regularly  scheduled  meetings as defined in a separate  DRC  charter (minimum 
prior to each planned dose escalation). The DRC may also meet in ad hoc meetings at its discretion as needed in response to events occurring in the study. The DRC will be responsible for making recommendations as to whether it is scientifically and ethically appropriate to continue enrollment, 
discontinue treatment groups, or stop the study. Additional responsibilities for the DRC include initiation 
of enrollment at the next dose level. The DRC meetings will be documented in written meeting minutes.  
In the first cohort, if no clinical effect is observed in the sentinel subject, the DRC will decide whether to proceed with the randomization of four additional subjects (3:1, JK07:  placebo) to receive blinded IP. Once 
the last subject  in the first cohort completes  the evaluation period, which  includes  assessments through Day 
15, the DRC  will decide whether  to proceed to the second  cohort. The second  cohort and subsequent  cohorts 
will proceed  as the first cohort until either  of the following occur: a sentinel  subject  exhibits in the opinion 
of the DRC, a clinical effect (efficacy or safety observation), or a cohort exhibits, in the opinion of the 
DRC, a clinical effect.  
Once  a clinical  effect  is observed, the  DRC  may, at  its discretion,  expand the  size of that cohort in which  a 
clinical effect is first observed, and subsequent cohorts, up to a maximum of nine subjects (1 open -label 
JK07 sentinel subject, and 6:2 [JK07:placebo] randomized, double-blind subjects). 
Following observation of a  clinical effect and a decision to expand the size of the  first cohort at which the 
clinical effect was observed, the DRC will decide whether to dose escalate after the last subject in the 
expansion cohort completes the evaluation period. If the DRC establishes to escalate the dose, a single 
unblinded sentinel subject will receive JK07 at the next dose level. If following the completion of the 
evaluation period of that sentinel subject the DRC decides to proceed, the remainder of the subjects in the 
expanded cohort size will receive JK07  or placebo  according to the direction of the DRC,  and this sequence 
will repeat  until the highest planned dose level  is reached  or until the  DRC  determines not to  dose  escalate 
further.  
During the review  of the safety/tolerability  results  the DRC  may make the determination  to expand the size 
of the current cohort further, if not already at the maximum size, following which further dose escalation could proceed. Alternatively, the DRC  may determine  to decrease  to a lower dose  level with an additional 
cohort, which may be an intermediary dose or a pre -assigned cohort, which would include up to eight 
subjects randomized 6:2 [JK07: placebo], with or  without an additional unblinded active sentinel subject. 
If the decision is to de -escalate to an intermediate dose between the prior cohort and the cohort at which 
dose escalation was halted, the cohort will comprise a single sentinel subject receiving JK07 followed by randomization of a minimum of 4 subjects (3:1, JK07: placebo) in the cohort. For any dose reduction to a 
dose below the highest established safe dose (i.e., below a dose for which the DRC approved expansion 
from  a sentinel  subject  to enrollment of a full cohort), no sentinel subject will be required. Following a dose 
reduction, the DRC may subsequently decide to further reduce the dose level in a subsequent cohort of 
similar size or increase the dose in a subsequent cohort with or without the inclusion of a sentinel subject 
at the discretion of the DRC.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  64 of 89  
 10.0 REFERENCES  
 
Chavey WE, Hogikyan RV, Van Harrison  R, et al. Heart  Failure  Due to Reduced Ejection  Fraction:  Medical 
Management. Amer Fam Phys. 2017;95(1):13- 20. 
Cockcroft  DW,  Gault  MH. Prediction of creatinine  clearance form  serum  creatinine.  Nephron. 
1976;1691):31- 41. 
Common Terminology  Criteria  for Adverse  Events  (CTCAE)  Version  5.0 Published:  November  27, 2017. 
Available at: 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_ 
5x7.pdf  Accessed October 28, 2020.  
FDA: US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Estimating the Maximum Safe Starting Dose in 
Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. July 2005. Available at: 
https://www.fda.gov/media/72309/download. Accessed October 23, 2020.  
Gao R, Zhang J, Cheng L, et al. A phase 2, randomized, double -blind, multicenter, based on standard 
therapy, placebo -controlled  study  of the efficacy  and safety  of recombinant  human  neuregulin- 1 in patients 
with chronic heart failure. J Am Coll Cardiol . 2010; 55:1907- 1914.  
Gong L, Zeng W, Yang Z, et al., Comparison of the Clinical Manifestations of Type 2 Diabetes Mellitus 
Between Rhesus Monkey (Macaca mulatta lasiotis) and Human Being. Pancreas . 2013; 42:537- 542. 
Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and Stroke Endpoint Definitions for 
Clinical Trials. J Am Coll Cardiol. 2018;71(9):102134 
Jabbour A, Hayward CS, Keogh AM, et al. Parenteral administration of recombinant human  neuregulin- 1 
to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic 
responses. Eur J Heart Fail. 2011; 13:83- 92. 
Lenihan DJ,  Anderson SA,  Lenneman CG.  A phase  1, Single  Ascending  Dose  Study  of Cimaglermin  Alfa 
(Neuregulin 1β3) in Patients  with Systolic  Dysfunction  and Heart  Failure.  JACC  Basic  Transl  Sci. 
2016; 1:576- 586. 
Odiete  O, Hill MF, Sawyer  DB. Neuregulin in cardiovascular  development  and disease.  Circulation  Res. 
2012;111(10):1376- 1385.  
Parodi  EM, Kuhn B. Signaling between  microvascular  endothelium  and cardiomyocytes  through 
neuregulin. Cardiovascular Research. 2014;102(2):194- 204. 
Rohrbach S, Yan X, Weinberg  EO, Hasan  F, Bartunek  J, Marchionni  MA, Lorell  BH. Neuregulin in cardiac 
hypertrophy in rats with aortic  stenosis.  Differential  expression  of erbB2  and erbB4  receptors.  Circulation . 
1999;100(4):407- 12. 
Shah A, Gandhi D, Srivastava S, et al. Heart Failure: A Class Review of Pharmacotherapy. P&T: A Peer - 
reviewed Journal for Formulary Management. 2017;42(7):464-  472.  
Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology. 1998; 
139(12):4756- 4764., Volume 139, Issue 12, 1 December 1998, Pages 4756–4764.  
The Joint European Society of Cardiology/ American College of Cardiology Committee JACC Vol. 36, 
No. 3, 2000; September 2000:959 –69 
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. Circulation . 
2018;138: e618- e651 [Universal Definition of Myocardial Infarction (UDMI]  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  65 of 89  
 Yancy  CW, Jessup  M, Bozkurt  B, et al. 2017 ACC/AHA/HFSA Focused Update  of the 2013 ACCF/AHA 
Guideline for the Management of Heart Failure: A Report of the American College of 
Cardiology/American  Heart Association  Task  Force  on Clinical Practice  Guidelines  and the Heart Failure 
Society of America. Circulation . 2017;136(6):e137- e161. 
Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA. Neuregulins promote 
survival  and growth of cardiac myocytes.  Persistence  of ErbB2  and ErbB4  expression  in neonatal  and adult 
ventricular myocytes. J Biol Chem . 1998;273(17):10261- 10269.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  66 of 89  
 11.0 APPENDICES  
Appendix  1 Cancer  Screening  Guidelines  
AMERICAN CANCER  SOCIETY  GUIDELINES  FOR  THE 
EARLY DETECTION OF CANCER  
Screening  tests are used to find cancer  before  a person has any symptoms. Here  are the American  Cancer 
Society's recommendations to help guide you when you talk to your doctor about screening for certain 
cancers.  
Breast  cancer  
• Women  ages 40 to 44 should have  the choice to start annual  breast  cancer  screening  with 
mammograms (x -rays of the breast) if they wish to do so.  
• Women  age 45 to 54 should get mammograms  every  year.  
• Women  55 and older  should switch  to mammograms  every  2 years  or can continue  yearly 
screening.  
• Screening should continue  as long as a woman  is in good health  and is expected  to live 10 more 
years or longer.  
• All women  should  be familiar  with  the known benefits,  limitations,  and potential  harms  linked  to 
breast cancer screening.  
Women  should also know  how their breasts  normally  look and  feel and report  any breast  changes  to a 
health care provider right away. 
Some women – because of their family history, a genetic tendency, or certain other factors – should be 
screened with  magnetic resonance  imaging (MRIs)  along with  mammograms  (the number of women who 
fall into this category  is very small.)  Talk  with a health  care provider  about  your risk for breast  cancer  and 
the best screening plan for you.  
Colon  and rectal  cancer and  polyps  
For people at average risk for colorectal cancer, the American Cancer Society recommends starting 
regular  screening  at age  45. This can be done  either with  a sensitive test that  looks  for signs  of cancer  in a 
person’s stool (a stool -based test), or with an exam that looks at the colon and rectum (a visual exam).  
Talk to your health care provider about which  tests might be  good  options  for you, and to your insurance 
provider about your coverage. No matter which test you choose, the most important thing is to get 
screened.  
If you’re  in good health, you should continue  regular  screening  through  age 75. 
For people ages 76 through 85, talk with your health care provider about whether continuing to get 
screened  is right  for you. When  deciding,  take into account your own preferences,  overall health,  and past 
screening history.  
People  over  85 should no longer  get colorectal  cancer  screening.  
If you choose  to be screened  with  a test other  than colonoscopy, any  abnormal  test result  needs  to be 
followed up with a colonoscopy.  
Cervical  cancer  
• Cervical  cancer  testing  should  start  at age 21. Women  under  age 21 should  not be tested.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  67 of 89  
 • Women  between  the ages  of 21  and 29 should have  a Pap test done  every  3 years.  HPV testing 
should not be used in this age group unless it’s needed after an abnormal Pap test result.  
• Women between the ages of 30 and 65 should have a Pap test plus an HPV test (called “co - 
testing”)  done  every  5 years.  This  is the preferred  approach,  but it’s OK to have  a Pap test alone 
every 3 years.  
• Women over age 65 who have had regular cervical cancer testing in the past 10 years with 
normal results should not be tested for cervical cancer. Once testing is stopped, it should not be 
started  again. Women  with a history of a serious  cervical  pre-cancer  should continue  to be tested 
for at least 20 years after that diagnosis, even if testing goes past age 65.  
• A woman  who has had her uterus and cervix  removed  (a total  hysterectomy)  for reasons  not 
related to cervical cancer and who has no history of cervical cancer or serious pre -cancer should 
not be tested.  
• All women  who have  been  vaccinated  against  HPV should still follow  the screening 
recommendations for their age groups.  
Some  women  – because of their health  history  (HIV  infection,  organ  transplant,  DES exposure,  etc.) – 
may need  a different screening schedule for cervical cancer. Talk  to a health care provider about your 
history.  
Endometrial  cancer  
The American  Cancer  Society  recommends that at the time of menopause, all women  should be told 
about the risks and symptoms of endometrial cancer. Women should report any unexpected vaginal 
bleeding or spotting to their doctors.  
Some  women  – because  of their history  – may need  to consider  having  a yearly  endometrial biopsy. 
Please talk with a health care provider about your history.  
Lung cancer  
The American  Cancer  Society  recommends  yearly  lung cancer  screening  with a low-dose CT scan 
(LDCT) for certain people at higher risk for lung cancer who meet the following conditions:  
 Are aged  55 to 74 years  and in fairly  good health  
and 
 Currently  smoke  or have  quit smoking in the past 15 years  
and 
 Have at least a 30 pack -year smoking history. (A pack- year is 1 pack of cigarettes per day per 
year.  One pack  per day for 30 years or 2 packs  per day for 15 years  would  both be 30 pack -years.)  
Before  getting screened,  you should talk to your health  care provider  about:  
• Your risk for lung cancer  
• How you can quit smoking,  if you still smoke  
• The possible  benefits,  limits,  and harms  of lung cancer  screening  
• Where you can get screened  
You should  also talk with your insurance  provider  about  your coverage.  
Prostate  cancer  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  68 of 89  
 The American Cancer Society recommends that men make an informed decision with a health care 
provider about whether to be tested for prostate cancer. Research has not yet proven that the potential 
benefits of testing outweigh  the harms of testing  and treatment. We  believe that men should not be  tested 
without  first learning  about  what  we know  and don’t  know  about  the risks  and possible  benefits  of testing 
and treatment.  
Starting  at age  50, men should talk to a health  care provider about  the pros  and cons of testing  so they can 
decide if testing is the right choice for them.  
If you are African  American  or have  a father  or brother  who  had prostate  cancer  before  age 65, you 
should have this talk with a health care provider starting at age 45.  
If you decide  to be tested,  you should get a PSA blood test with  or without  a rectal  exam.  How often 
you’re tested will depend on your PSA level.  
Source:  https://www.cancer.org/healthy/find- cancer -early/american -cancer -society -guidelines -for-the- 
early -detection -of-cancer.html  Accessed March 30, 2021  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  69 of 89  
 Appendix  2    Regulatory, Ethical,  and Study  Oversight  Considerations  
Regulatory and Ethical Considerations  
• This study  will be conducted in accordance with the protocol  and with the following:  
− Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki of World Medical Association and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical Guidelines.  
− Applicable  ICH Good Clinical  Practice (GCP)  Guidelines.  
− Applicable  laws and regulations. 
• The protocol, protocol  amendments,  ICF, Investigator  Brochure, Administrative  Letters,  and other 
relevant  documents  (e.g., advertisements)  must  be submitted  to an IRB/IEC  by the Investigator  and 
reviewed and approved by the IRB/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC and regulatory authority approval, when 
applicable, before implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to subjects.  
• The Investigator  will be responsible  for the following:  
− Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently  in accordance  with the requirements,  policies,  and procedures  established  by the 
IRB/IEC.  
− Notifying  the IRB/IEC  of SAEs  or other  significant  safety  findings  as required  by IRB/IEC 
procedures.  
− Providing oversight of the conduct of the study at the study center and adherence to requirements  of 21 Code  of Federal Regulations (CFR),  ICH guidelines,  the IRB/IEC and 
all other applicable local regulations.  
• After  reading  the protocol,  each Investigator  will sign the protocol  signature  page  and send a copy 
of the signed page to the Sponsor or representative ( Appendix 8 Signature of Investigator ). The 
study will not start at any study center at which the Investigator has not signed the protocol.  
Adequate  Resources  
The Investigator is responsible for supervising any individual or party to whom the Investigator delegates 
study- related duties and functions conducted at the study center.  
If the Investigator/institution retains the services of any individual or party  to perform  study related duties 
and functions, the Investigator/institution should ensure this individual, or party is qualified to perform 
those study- related duties and functions and should implement procedures to ensure the integrity of the 
study- related duties and functions performed and any data generated.  
Financial  Disclosure  
Investigators  and sub-Investigators  will provide  the Sponsor  with sufficient,  accurate  financial  information 
as requested to allow the Sponsor to submit complete and accurate financial certification or disclosure 
statements  to the appropriate  regulatory  authorities.  Investigators  are responsible  for providing information 
on financial interests during the study and for 1 year after completion of the study. 
Insurance 
Sponsor  will provide  insurance  in accordance with local  guidelines  and requirements  as a minimum  for the 
subjects in this study. The terms of the insurance will be kept in the study files.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  70 of 89  
 Informed  Consent  Process  
• The Investigator or his/her representative will explain the nature of the study to the subject and 
answer all questions regarding the study.  
• Subjects must be informed that their participation is voluntary. Subjects will be required to sign a 
statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH 
guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where 
applicable, and the IRB/IEC or study center.  
• The medical  record  must  include  a statement that written  informed  consent  was obtained  before  the 
subject was entered in the study and the date the written consent was obtained. The authorized 
person obtaining the informed consent must also sign the ICF. 
• Subjects must be re -consented to the most current version of the ICF(s) during their participation 
in the study.  
• A copy of the ICF(s) must be provided  to the subject.  
The ICF will contain a separate section  that addresses the use of remaining  mandatory samples for optional 
exploratory research.  The Investigator  or authorized designee will  explain  to each subject  the objectives  of 
the exploratory research. Subjects will be told that they are free to refuse to participate and may withdraw 
their consent  at any time and for any reason  during  the storage  period. A separate signature  will be required 
to document a subject’s agreement to allow any remaining specimens to be used for exploratory research. 
Subjects who decline to participate in this optional research will not provide this separate signature.  
Data  Protection  
• Subjects will be assigned a unique identifier by the Sponsor. Any subject records or datasets that 
are transferred to the Sponsor will contain the identifier only; subject names or any information 
which would make the subject identifiable will not be transferred.  
• The subject  must be informed that his/her personal study -related data will be used by the Sponsor 
in accordance with local data  protection  law. The level of disclosure  must also  be explained to  the 
subject.  
• The subject must be informed that his/her medical records may be examined by Clinical Quality 
Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate 
IRB/IEC members, and by inspectors from regulatory authorities.  
Administrative  Structure  
In addition to safety monitoring by  the investigators, safety will be monitored by the DRC as described in 
Section 9.6. The Principal Investigator and the Sponsor, when appropriate, will invite other specialist 
individuals to participate in the review, e.g., PK scientists, statisticians, clinical specialists etc. The administrative structure of the study is described in Table 12.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  71 of 89  
 Table  12 Study  Administrative  Structure  
 
Function  Responsible  Organization  
Study  Operations  Management 
Medical Monitoring  CRO  (IQVIA  Biotech)  
Neal  Salomon,  MD - Consulting  Chief  Medical  Officer  and Medical 
Monitor  
Study  Master  File CRO  (IQVIA  Biotech)  
Randomization  Code  CRO  (IQVIA  Biotech)  
Data Management  CRO  (IQVIA  Biotech)  
Clinical Supply  Management  3rd Party  
Biostatistics  Medical  Writing  CRO  (IQVIA  Biotech)/  IQVIA 
Laboratory Assessments  3rd Party  
Electrocardiogram  Collection,  Review,  and Analysis  3rd Party  
Pharmacokinetic Sample Testing  3rd Party  
Management  of Event  Adjudication  CRO  (IQVIA  Biotech)  
Adjudication  Committee  CRO  (IQVIA  Biotech)  
Steering Committee  N/A 
Safety  Monitoring  Committee (see Section  9.6) CRO  (IQVIA  Biotech)  
Medical  Monitor  
Neal  Salomon, MD 
Consulting Chief  Medical  Officer  and Medical  Monitor, SalubrisBio 
Phone: 410- 419-8501 (cell)  
Fax: 410-560-1562  
Email: neal.salomon@salubrisbio.com  
Dissemination  of Clinical Study  Data  
The results  of the study  should be reported within  1 year from  the end of the clinical  study. It shall  be 
accompanied by a summary written in a manner that is understandable to laypersons.  
Data  Quality  Assurance  
• All subject data relating to  the study will be recorded either as printed source documents from the 
subject’s medical record, or will be recorded on printed eCRF’s, it will then be entered into the 
study’s electronic data capture system (EDC), unless it is data that is being transmitted to the Sponsor or designee electronically (e.g., laboratory data). The Investigator is responsible for 
verifying that data entries  are accurate and correct  by physically or electronically  signing  the eCRF.  
• The Investigator  must  maintain  accurate documentation (source  data)  that supports  the information 
entered in the eCRF. 
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
• The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  72 of 89  
 • Study monitor will perform ongoing source data verification to confirm that data entered into the 
eCRF by authorized study center personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of subjects are being protected; and that the study is being 
conducted in accordance with the currently  approved protocol  and any other  study agreements,  ICH 
GCP, and all applicable regulatory requirements.  
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the Investigator for 2 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the 
retention period without the written approval of the Sponsor. No records may be transferred to 
another location or party without written notification to the Sponsor.  
Source  Documents  
The Investigator/institution should maintain adequate and accurate source documents and study records 
that include all pertinent observations on each of the study center’s subjects. Source data should be 
attributable,  legible,  contemporaneous, original,  accurate,  and complete.  Changes  to source  data should  be 
traceable, should not obscure the original entry, and should be explained if necessary (e.g., via an audit 
trail).  
• Source documents provide evidence for the existence of the subject and substantiate the integrity 
of the data collected. Source documents are filed at the Investigator’s study center.  
• Data  reported  on the eCRF  or entered  in the eCRF  that are transcribed  from  source  documents  must 
be consistent with the source documents or the discrepancies must be explained. The Investigator 
may need to request previous medical records or transfer records, depending on the study. Also, 
current medical records must be available.  
• Definition  of what  constitutes  source  data can be found in the Clinical Monitoring Plan. 
Changes  to the Protocol  
This protocol is to be followed exactly. Amendments must receive IRB/IEC approval prior to 
implementation. As appropriate, protocol amendments will be submitted to regulatory authorities on a 
timely basis.  
Administrative changes (not affecting the subject benefit/risk ratio) may be made without the need for a 
formal  amendment.  All amendments  and administrative  change  directives  will be distributed  to all protocol 
recipients with appropriate instructions.  
The IRB/IEC  will be informed of any safety issues that require alteration of the safety monitoring scheme 
or amendment of the ICF. 
Study  and Study  Center Closure 
The Sponsor  designee  reserves  the right  to close  the study  center  or terminate  the study at any time for any 
reason at the sole discretion of the Sponsor. Study centers will be closed upon study completion. A study 
center  is considered  closed  when  all required  documents  and study  supplies  have  been  collected  and a study 
center closure visit has been performed.  
The Investigator may initiate study center closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study center by the Sponsor or Investigator may include but are not 
limited to:  
• Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the Sponsor’s procedures, or GCP guidelines.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  73 of 89  
 • Inadequate  recruitment  of subjects  by the Investigator.  
• Discontinuation of further study treatment development. 
Publication Policy  
The data generated by this study are confidential information of the Sponsor. The Sponsor may make the 
results of the study publicly available. The publication policy with respect to the Investigator and study 
center will be set forth in the Clinical Trial Agreement.  
• The results of this study may be published or presented at scientific meetings. If this is foreseen, 
the Investigator  agrees to submit  all manuscripts  or abstracts to the Sponsor  at least 30 days before 
submission. This allows the Sponsor to protect proprietary information and to provide comments.  
• The Sponsor  will comply with the requirements  for publication of study  results.  In accordance with 
standard  editorial  and ethical  practice,  the Sponsor  will generally  support  publication of multicenter 
studies only in their entirety and not as individual study center data. In this case, a Coordinating Investigator will be designated by mutual agreement.  
• Authorship will be determined by mutual agreement and in line with International Committee of 
Medical Journal Editors authorship requirements.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  74 of 89  
 Appendix  3 Clinical Laboratory  Tests  
• Blood will be collected  for local  laboratory  assessments  at times  when  the central  laboratory results 
are not expected to be available in time for either study treatment administration and/or response 
evaluation. The local laboratory results must be entered into the eCRF. Table 14  identifies local 
laboratory assessments scheduled for this study (and the specific timepoints for assessment) but 
may not be fully  comprehensive  in cases where additional  safety  follow -up deemed  appropriate  by 
the Investigator. Table 15 identifies blood draw requirements for central lab assessment.  
• Protocol -specific requirements for inclusion  or exclusion of subjects are detailed  in Section  5.0 of 
the protocol.  
• Additional tests may be performed at any time during the study as determined necessary by the  
Investigator or required by local regulations.  
• All results must  be recorded  in the eCRF.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  75 of 89  
 Table  13 Protocol -required  Safety  Laboratory Assessments  
 
Laboratory 
Assessments  Parameters  
Hematology  Platelet  Count  WBC  Count  with Differential : 
 RBC  Count  Neutrophils  
 Hb Lymphocytes  
 Hct Monocytes  
 RBC  Indices : Eosinophils  
 MCV  Basophils  
 MCH   
 MCHC   
 %Reticulocytes   
Clinical  Chemistry  ALT/  SGPT   
 Albumin  Phosphate  
 ALP Potassium  
 AST/  SGOT  Total  bilirubin  (conjugated  and unconjugated 
if clinically indicated)  
 BUN  Direct  bilirubin  
 Calcium  Total  Cholesterol  
 Carbon  dioxide  (bicarbonate)  Total Protein  
 Chloride  Triglycerides  
 Creatinine  Uric acid 
 Fasting  Glucose   
 GGT   
 HDL  Cholesterol   
 LDL  Cholesterol   
Coagulation  INR aPTT  
 Prothrombin  time (PT) Fibrinogen  
Additional  biomarkers  CPKa hs CRP 
 CPK -MBa Troponin  I b 
 hs Troponin  T b LDH  
Urinalysis  Leucocytes  RBCs  
 Protein  pH 
 Bilirubin  Nitrite  
 Urobilinogen  Specific  gravity  
 Ketones  Glucose  
 Microscopy  (if clinically  indicated)  Myoglobin  
Viral  serology  HIV I and II HCV  
 HBsAg  HBV  PCR 
Drugs  of abuse  and 
alcoholc   
 
Thyroid  profile  TSH 
Total  T4 
T3 T4 
Total T3 
Glycosylated 
hemoglobin  HbA1c  
 
Other  screening tests Urine  β-hCG  pregnancy test  (as needed  for subjects  of childbearing  potential)  
Study -required  laboratory assessments  will be performed  by local  and central  laboratories.  Table  
14 shows the Safety  Laboratory Assessments Performed  by Local  Laboratories.  Table  15 lists the 
protocol required local laboratory collections for Central Laboratory Analysis.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  76 of 89  
  
Laboratory 
Assessments  Parameters  
 The results  of each test must  be entered in the  eCRF.  
Abbreviations: ALP, alkaline  phosphatase; aPTT, activated partial  thromboplastin time; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; β -hCG, beta human chorionic gonadotrophin; BUN, blood urea nitrogen; CPK, creatine 
phosphokinase; CPK -MB, creatinine phosphokinase –  muscle brain fraction; GGT, gamma glutamyl transferase; Hb, 
hemoglobin; HBV, Hepatitis B Virus; HCT, hematocrit; HCV, Hepatitis C Virus; HDL, high -density lipoprotein; HIV, Human 
Immunodeficiency Virus; hs -CRP, high sensitivity C -reactive protein; INR, International Normalized Ratio; LDH, lactate 
dehydrogenase; LDL, low -density lipoprotein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin 
concentration; MCV, mean corpuscular volume; PCR, polymerase chain reaction; PT, prothrombin time; RBC, red blood cell; 
SGOT,  serum  glutamic -oxaloacetic transferase;  SGPT,  serum  glutamic -pyruvic  transaminase;  T3, free triiodothyronine;  T4, free 
thyroxine; TSH, thyroid stimulating hormone; WBC, white blood cell  
a For safety laboratory assessments performed by the local laboratory, if CPK and CPK -MB are  not included together on a single 
panel,  then CPK -MB  alone  can be measured.  If CPK  and CPK -MB  are not included  together  on a single  panel  and there is no 
local test available for CPK -MB, then CPK alone may be measured.  
b For local  laboratory  safety  assessments,  only one of either  Troponin  I or hs Troponin  T must  be included,  and the second 
biomarker may be optionally included.  
c Performed  as per local  standard  of practice/guidelines  at Screening  visit only 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  77 of 89  
 Table 14  Schedule  of Protocol -required  Safety  Laboratory  Assessments Performed  by the 
Local Laboratory  
 
Day Time (hours)  Panel  Comment  
 
 
 
 
 
Screening   
 
 
 
No more than 
45 days prior to 
IP administration  Chemistrya  
Hematology   
Coagulation   
Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I and/or  hs Troponin  T, 
hsCRP, LDH  
HIV/HBV/HCV   
β-hCG  (blood sample)   
Urinalysis   
Thyroid  profile   
 
 
 
Day 1 prior  to 
IP 
administration   
 
 
 
Upon admission  Chemistrya  
Hematology   
Coagulation   
Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I and/or  hs Troponin  T, 
hsCRPc, LDH  
Glucose  Fingerstick  
Urinalysis  Including  urine -based  pregnancy  dipstick  for pre- 
menopausal women  
 
 
 
 
 
Day 1 postdose  End of infusion  Glucose  Fingerstick  
 
4 Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I and/or  hs Troponin  T, 
hsCRPc, LDH  
Glucose  Fingerstick  
 
8 hours  postdose  Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I and/or  hs Troponin  T, 
hsCRPc, LDH  
Glucose  Fingerstick  
 
12 hours postdose  Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I and/or  hs Troponin  T, 
hsCRPc, LDH  
Glucose  Fingerstick  
 
 
 
 
2  
 
 
 
24 hours postdose  Chemistrya  
Hematology   
Coagulation   
Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I and/or  hs Troponin  T, 
hsCRPc, LDH  
Glucose  Fingerstick  
Urinalysis   
 
 
3  
 
48 hours postdose  Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I and/or  hs Troponin  T, 
hsCRPc, LDH  
Hematology   
Glucose  Fingerstick  
4 72 hours postdose  Glucose  Fingerstick  
 
7  Chemistrya  
Hematology   
Coagulation   
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  78 of 89  
  
Day Time (hours)  Panel  Comment  
  Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I and/or  hs Troponin  T, 
hsCRPc, LDH  
Urinalysis   
 
 
 
15  Chemistrya  
Hematology   
Coagulation   
Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I and/or  hs Troponin  T, 
hsCRPc, LDH  
Urinalysis   
 
 
30  Chemistrya  
Hematology   
Coagulation   
Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I c and/or  hs Troponin  T c, 
hsCRPc, LDH  
 
 
60  Chemistrya  
Hematology   
Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I c and/or  hs Troponin  T c, 
hsCRPc, LDH  
 
 
90  Chemistrya  
Hematology   
Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I c and/or  hs Troponin  T c, 
hsCRP, LDH  
 
 
135  Chemistrya  
Hematology   
Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I c and/or  hs Troponin  T c, 
hsCRPc, LDH  
 
 
180  Chemistrya  
Hematology   
Additional  biomarkers  CPK  b, CPK -MB b, Troponin  I c and/or  hs Troponin  T c, 
hsCRPc, LDH  
End-of-study 
(prior to Day 
180 due to 
patient or 
investigator - 
initiated  
withdrawal)   Chemistrya  
Hematology   
Coagulation   
Additional  biomarkers  CPK  b, CPK -MB b, Troponin I c and/or  hs Troponin T c, 
hsCRP  
Abbreviations:  β-hCG,  beta human  chorionic  gonadotrophin;  CPK,  creatine phosphokinase;  CPK -MB,  creatinine phosphokinase 
– muscle brain fraction; hs -CRP, high sensitivity C -reactive protein; LDH, lactate dehydrogenase 
a All clinical  chemistries  are to be drawn FASTING  >10hours.  
b For safety laboratory assessments performed by the local laboratory, if CPK and CPK -MB are  not included together  on a single 
panel,  then CPK -MB  alone  can be measured.  If CPK  and CPK -MB  are not included  together  on a single  panel  and there is no 
local test available for CPK -MB, then the test may be omitted.  
c For local  laboratory  safety assessments, only  one of either  Troponin I  or hs Troponin T must  be included,  and the second 
biomarker may be optionally included.  
Investigators  must  document  their review  of each laboratory  safety  report. 
Laboratory results that could  unblind  any blinded  cohort  will not be reported  to study centers or other 
blinded personnel until the cohort has been unblinded.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  79 of 89  
 Table 15  Schedule  of Protocol -required  Blood  Collections  to be Obtained  by the Local 
Laboratory for Central Laboratory Analysis  
 
Day Sample  to be Collected  for Central  Lab Analysis  by the Local 
Laboratory  
Day 1 (Pre-infusion)  Exploratory biomarkersa / PK / Immunogenicity 
Day 1 (End of infusion  [EoI]) PK 
Day 1 (0.5 hour from  EoI) PK 
Day 1 (1 hour  from  EoI) PK 
Day 1 (2 hours  from  EoI) PK 
Day 1 (4 hours  from  EoI) PK 
Day 1 (8 hours  from  EoI) PK 
Day 1 (12 hours  from  EoI) PK 
Day 2 (24 hours  from  EoI) Exploratory biomarkersa / PK 
Day 3 (48 hours  from  EoI) PK 
Day 4 (72 hours  from  EoI) PK / Immunogenicity  
Day 7 Exploratory biomarkersa / PK / Immunogenicity 
Day 11 PK 
Day 15 Exploratory biomarkersa / PK / Immunogenicity 
Day 22 PK 
Day 30 Exploratory biomarkersa / PK / Immunogenicity 
Day 60 Exploratory biomarkersa / PK 
Day 90 Exploratory biomarkersa / Immunogenicity 
Day 135 Exploratory biomarkersa 
Day 180 /  End of  Study Visit Exploratory biomarkersa / Immunogenicity 
Abbreviations:  EOI, end of  infusion;  PK, pharmacokinetics  
a BNP,  hsCRP,  NT-proBNP,  Troponin  I, hs Troponin T 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  80 of 89  
 Appendix  4 Excluded  Medications/Therapy  
Excluded medications/therapy is listed below. The use of an excluded medication/therapy is a protocol  
violation and must be recorded in the eCRF.  
• Any recombinant  neuregulin  apart  from  JK07  
− Neucardin  and cimaglermin  
• Class  1a (including  procainamide, quinidine,  disopyramide)  and Class  3 (including  amiodarone, 
sotalol, dofetilide, ibutilide) antiarrhythmics  
• Acetaminophen for the period  beginning 7 days pre-dose and ending  15 days postdose  
• Drugs  that are known to prolong QT: 
− Fluoroquinolones:  ciprofloxacin,  levofloxacin, gatifloxacin,  and moxifloxacin  
− Macrolides:  erythromycin,  azithromycin,  clarithromycin 
− Antifungal  agents:  ketoconazole,  itraconazole,  pentamidine  
− Antipsychotics:  thioridazine, haloperidol, droperidol, atypical  antipsychotic, 
(e.g., ziprasidone)  
− Antidepressants:  citalopram,  escitalopram  
− Antiemetics: dolasetron, droperidol, ondansetron, granisetron  
− Others:  propofol,  chloroquine  
For a complete  listing  of all prohibited  medications,  please consider  the listed  drugs  in the following  website 
as “known” to prolong QT:  
https://crediblemeds.org/pdftemp/pdf/CombinedList.pdf  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  81 of 89  
 Appendix  5    2-D TTE  Parameters  
• LVIDs  (mm)  
• LVIDd  (mm)  
• LVIDd  diameter/BSA  (mm/m2) 
• LVIDd  diameter/height (mm/m2) 
• Septal  thickness  (cm) 
• Posterior  Wall  thickness  (cm) 
• Biplane  MOD 
• LVEDV (mls/m2) 
• LVESV  (mls/m2) 
• LVSV  (mls/m2) 
• LVEF  (%) 
• Circumferential  Shortening (CS)  + EDC -ESC/EDC  
• Cardiac Output/Cardiac  Index & Stroke  Volume  (LVOT  VTI pulsed wave  Doppler  method)  
• Diastolic  Function Grade  (E/A  ratio, E/E′   ratio)  
• Mitral Valve  Regurgitation  Grade  (Quantitative)  
• Left Atrial Area  and Volume  
• Right  Ventricular  Size and Function  
• Tricuspid  Valve  Regurgitation  Velocity  
• Peak  Mitral Valve  Regurgitant  Velocity  
• Left Ventricular  Outflow  Tract  Doppler  Time  Velocity  Integral  
Abbreviations: BSA, body surface area; CS, circumferential shortening; E/A ratio, ratio of early (E) to late (A) ventricular filling 
velocity; EDC, end diastolic circumference; ESV, end systolic circumference; LV, left ventricular; LVEDV, left ventricular en d- 
diastolic volume; LVESV, left ventricular end -systolic volume; LVEF, left ventricular ejection fraction; LVIDd, left ventricular 
internal  end-diastolic  diameter;  LVIDs,  left ventricular  internal  end-systolic  diameter;  LVOT  left ventricular  outflow  tract;  MOD, 
method of disks; SVR, systemic vascular resistance; VTI, ventricular time integral  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  82 of 89  
 Appendix  6 Contraceptive  Guidance  
Definitions:  
Woman  of Childbearing Potential (WOCBP)  
A woman  is considered fertile  following menarche  and until becoming postmenopausal  unless  permanently 
sterile (see below).  
Women  in the following categories  are not considered  WOCBP  
1. Premenarchal  
2. Premenopausal  female  with 1 of the following:  
a) Documented hysterectomy.  
b) Documented bilateral  salpingectomy.  
c) Documented bilateral  oophorectomy.  
Note:  Documentation can come  from  the study  center  personnel’s:  review  of the subject’s medical 
records, medical examination, or medical history interview.  
3. Postmenopausal  female:  
a) A postmenopausal  state is defined  as no menses for 12 months  without  an alternative  medical  cause. 
A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to 
confirm  a postmenopausal  state in women  not using hormonal  contraception  or hormonal  therapy. 
However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.  
b) Females  on hormone  therapy  and whose  menopausal status  is in doubt will be  required  to use 1 of 
the non- estrogen hormonal highly effective contraception methods if they wish to continue their 
hormone therapy during the study. Otherwise, they must discontinue hormone therapy to allow 
confirmation of postmenopausal status before study enrollment.  
Contraception  Guidance  
Male subjects  
• Male subjects with female  partners  of childbearing potential  are eligible  to participate if they agree 
to ONE of the following [during the protocol -defined time frame in Section 5.1 ]: 
− Are abstinent from penile -vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long- term and persistent basis) and agree to remain abstinent for duration 
of study and for no less than 90 days after the administration of study treatment.  
− Agree to use a male condom and have their partner use of a contraceptive method with a 
failure rate of <1  % per year as described in Table 16  when having penile - vaginal 
intercourse with a woman of childbearing potential who is not currently pregnant.  
• In addition, subjects must  refrain  from  donating sperm  for the duration of the study  and for no less 
than 90 days after the administration of study treatment.  
• Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile -vaginal intercourse  or use a male condom during each episode of penile penetration during 
the protocol -defined time frame.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  83 of 89  
 Female  subjects  
Female subjects of childbearing potential are eligible to participate if they agree to use a highly effective 
method of contraception consistently and correctly as described in the table below. 
Table  16 Highly  Effective  Contraceptive  Methods  
 
Highly  Effective  Contraceptive  Methods  That  Are User  Dependent  a 
Failure  rate of <1 % per year when used  consistently  and correctly.  
Combined  (estrogen  and progestogen containing)  hormonal  contraception  associated  with inhibition  of ovulationb 
Oral.  
Intravaginal.  
Transdermal.  
Progestogen  only hormonal  contraception associated  with inhibition  of ovulation 
Oral.  
Injectable.  
Highly  Effective  Methods  That  Are User  Independent  a 
Implantable progestogen  only hormonal  contraception  associated  with inhibition  of ovulationb 
Intrauterine device (IUD).  
Intrauterine  hormone -releasing  system  (IUS).  
Bilateral  tubal  occlusion.  
Vasectomized  partner 
A vasectomized  partner  is a highly  effective birth  control  method provided  that the partner  is the sole male  sexual  partner  of the 
WOCBP and the  absence of sperm has  been confirmed. If not, an additional highly effective method of contraception should be 
used.  
Sexual  abstinence  
Sexual  abstinence  is considered  a highly  effective method only  if defined  as refraining from  heterosexual  intercourse  during  the 
entire  period  of risk associated  with the study  treatment.  The reliability  of sexual  abstinence  needs  to be evaluated  in relation  to 
the duration of the study and the preferred and usual lifestyle of the subject.  
NOTES:  
a Typical  use failure  rates  may differ  from  those  when  used consistently  and correctly.  Use should  be consistent  with local 
regulations regarding the use of contraceptive methods for subjects participating in clinical studies.  
b Hormonal contraception may be susceptible to interaction with the study treatment, which may reduce the efficacy of the 
contraceptive  method.  In this case,  2 highly effective methods  of contraception  should  be utilized  during  the treatment  period 
and for at least 90 days, corresponding to time needed to eliminate study treatment plus 30 days for study treatments with 
genotoxic potential after the last dose of study treatment.  
 
Pregnancy Testing:  
• WOCBP  should only be included  after a confirmed  menstrual  period  and a negative  highly sensitive 
urine pregnancy test.  
• Additional  pregnancy  testing  should  be performed  at times  specified  in the schedule of assessments 
during the treatment period and at timepoints corresponding to protocol -defined time frame in 
Section 5.1  after the dose of study treatment and as required locally.  
Pregnancy testing  will be performed  whenever  a menstrual  cycle  is missed  or when  pregnancy is otherwise 
suspected.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  84 of 89  
 • Pregnancy testing, with a sensitivity  of 10 mIU/mL  will be  performed  in a certified  laboratory 
and in accordance with instructions provided in its package insert.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination  of a pregnancy will be reported  as an AE or SAE.  A spontaneous  abortion is 
always considered to be an SAE and will be reported as such.  
• Any post-study pregnancy related  SAE  considered  reasonably  related  to the study treatment  by the 
Investigator will be reported to the Sponsor as described in Section  8.3.10. While the Investigator 
is not obligated to actively  seek this information  in former subjects,  he or she may learn  of an SAE 
through spontaneous reporting.  
• Any female subject who becomes pregnant while participating in the study will discontinue study 
treatment or be withdrawn from the study.  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  85 of 89  
 Appendix  7 Summary of Changes 
Amendment  1: 19February2020 
Rationale for the amendment:  
The main  purpose of this amendment  is to: 
• Update the Schedule of Activities  
• Revision and  update of the Background and  Benefit/Risk sections  
• Clarification  of blood sampling  and volumes for biomarkers, PK,  and immunogenicity  
• Update of PK assessment  methods and  variables  
• Correction  of justification  for dose 
• Clarification  of eligibility  criteria  and study procedures including discontinuation criteria  and 
adverse event relatedness to study drug 
• Update the medical  monitor  
• Updates  to the document for consistency  
• Minor editorial and grammatical  changes  
Where applicable added  text is bolded and italicized . Deleted  text has strikethrough. 
Section  Change  Reason  
Title  Page  JK07  (recombinant  fusion  protein  consisting  of a fully  human 
anti-human epidermal growth factor receptor 3 [HER3] 
immunoglobin  G1 [IgG1] monoclonal  antibody  and an active 
polypeptide fragment from human neuregulin -1 [NRG -1]) Administrative  update  
Synopsis  and Pharmacokinetic  parameters  of intact  JK07  including,  but not Clarification  of PK 
Section  3.0: limited  to, maximum  concentration  (Cmax), time to Cmax (tmax), assessment  
Objectives  and area under  the concentration -time curve  to the last quantifiable   
Endpoints  concentration  and extrapolated  to infinity  [AUC (0-last) and  
 AUC (0-inf)], half-life (t1/2), elimination  rate constant  (λz),  
 systemic  clearance  (CL),  and volume  of distribution  (Vz).  
 Surrogate  assessment  measurement  of intact  JK07  stability  to  
 be evaluated  carried  out through  parallel  assays  to detect  both  
 the JK07  antibody  domain  and the JK07  NRG -1 peptide   
 fragment  in the evaluation  of pharmacokinetic  parameters .  
Table  1: SoA,  
new footnote  “e” All AEs, including SAEs will be collected from the time of study 
enrollment  and until 30 days after  the IP administration.  Following 
the first 30 days, only SAEs deemed at least possibly related to the  
study  drug  or study  procedures  should  be collected.  Refer  to Table  9 
for additional details.  Clarification  of AE 
assessment timing  
Section  2.2: 
Background   Revision  of text and 
reference format  
Section  2.3: 
Benefit/Risk 
Assessment   Revision  of text and 
reference format  
Table  1: SoA 
and Section  4.1: 
Study  Design  Day 1: Addition of blood sample collection prior to IP 
administration  of baseline  myocardial  biomarkers,  PK and 
immunogenicity assessment.  Clarification  of blood 
sampling  
Section  4.2: Deletion  of monitoring  of MCP -1 (monocyte  chemoattractant  Clarification  of biomarkers  
Scientific  protein),  IL-6 (interleukin -6), aldosterone,  pro-collagen  5,  
Rationale  and aldolase,  and myoglobin.   
Section  8.8: Clarification  of the immunoassays  to be used for assessment  of  
Biomarkers  JK07  exposure.   
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  86 of 89  
  
Section  Change  Reason  
Section 4.3: 
Justification  of 
Dose  Cohort  dose levels  of JK07  are as follows:  the clinical  starting 
dose of a single 0.03 mg/kg IV infusion has been selected at  
1/3032  of the human  equivalent  dose at the NOAEL  in the 
cynomolgus monkey (3 mg/kg/week).  Correction  
Section  5.2: 
Exclusion 
Criterion 8  Sustained systolic  blood pressure  <100 mm Hg and/or diastolic 
blood pressure <50 mm Hg (confirmed by a duplicate seated reading) on at least 3 consecutive readings (self -monitored or 
office) following informed consent and prior to randomization, or overt symptomatic hypotension defined as a decrease in 
systolic  blood pressure  of 20 mm Hg or a decrease in diastolic 
blood pressure  of 10 mm Hg within  three  minutes  of standing  
when  compared with blood pressure  from  the sitting  or supine  
position or accompanied by dizziness, syncope, blurry vision.  Clarification  
Section  5.2: 
Exclusion 
Criterion 9  Sustained Resting heart rate >100 beats per minute (bpm) at 
Screening  (Visit 1)  or prior  to randomization which is sustained  
for >15 minutes in two episodes separated by one hour of 
observation.  Clarification  
Section  5.3: 
Lifestyle 
Considerations  Subjects  should  be in a fasted  state (at least 10 hours)  at assigned 
or designated times as per the study team for all other visits.  Addition  of fasting  prior  to 
all visits  
Section  5.3.2: 
Caffeine, Alcohol, and 
Tobacco  CBD products will not be permitted from two weeks prior to IP 
administration until after the final follow -up visit.  Addition  of restriction  on 
use of CBD products.  
Section 7.1: 
Discontinuation of Study Treatment  If a subject, who does not meet enrollment criteria, is 
inadvertently enrolled, that subject must and the failure to meet 
enrollment  criteria  is discovered  prior  to IP administration , the 
subject should be discontinued from the study treatment  and the 
Sponsor or Sponsor designee must be contacted. An exception  
mayIf a subject, who does not meet enrollment criteria, is 
inadvertently enrolled in  the study and has already  received IP 
administration, the subject should be granted in rare  
circumstances for which there is a compelling safety reason to  
allow the subject allowed to continue . In these rare cases, the  
Investigator  must  obtain  documented approval  from  the Sponsor  
or Sponsor  designee to allow  the subject  to continue  in the study 
with the study  given  that following  the single  IP administration  
there  are no additional  treatments  and no invasive  tests.  Clarification of 
discontinuation  criteria  
Section 8.3.6: 
Relationship  to 
Study Drug; Table 9 
Relatedness  Revision  of table  and definitions  Clarification  of definition  of 
degrees of relatedness  
Section 8.5.3: 
Calculation of Derivation of 
Pharmacokinetic 
Variables;  
Table  10 Deletion  of RC max, RAUC (0-inf), and RAUC (0-last) Update  to PK assessment  
Section  8.8: 
Biomarkers  Venous  blood  samples  of approximately  1410 mL will be 
collected at several time points  Clarification  of blood 
volume  
Section  11: 
Appendix  1 Insertion of complete American Cancer Society Guidelines for 
Screening  Addition  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  87 of 89  
  
Section  Change  Reason  
Section  11: 
Appendix  2 Deletion  of Mark  Tulchinskiy,  MD as medical  monitor 
Addition of Neal Salomon, MD as medical monitor  Administrative  update  
 
Amendment 2: 03March2020 
Rationale for the amendment:  
The main  purpose of this amendment  is to: 
• Update the Schedule of Activities  to reflect  Day 3 activities  and Holter/telemetry  monitoring  
• Compliance with regulatory requests  regarding inclusion/exclusion criteria  and 
Investigational Product expiration 
• Updates  to the document for consistency  
• Minor editorial and grammatical  changes  
Where applicable added  text is bolded and italicized . Deleted  text has strikethrough. 
Section  Change  Reason  
Section1.3:  SoA, 
footnote “a”  Day 3 marked  for in-patient  hospital  stay and telemetry  in 
the Schedule  of Activities.  Subjects  will be scheduled  for 
discharge on the morning of Day 3.  Telemetry monitoring will 
continue  until 48 hours  after 
completion of IP which 
extends into Day 3.  
Section  1.3: SoA, 
footnote “m”  Continuous  telemetry  monitoring  will be started  as soon  as 
practicable after hospital  admission  on Day1  and prior  to IP 
infusion,  and will be continued  until 48 hours  after the end 
of the IP infusion on Day 3 . Administrative  update  
Section 4.2: 
Scientific  Rationale 
for Study Design  Holter/telemetry  combination  prior  to dose administration  
and for 48 hours  following  dose administration.  Consistency  
Section  5.1: 
Inclusion Criterion  1 Male or female adult subjects between 18 and 80 years of 
age, with stable NYHA Class II or III HF diagnosis 
(ischemic  or nonischemic  confirmed  by medical  history)  at 
least 6 months prior to enrollment.  Compliance with FDA 
request to make  inclusion/ 
exclusion criteria  mutually 
exclusive with respect to  
non-ischemic 
cardiomyopathy.  
Section  5.2: 
Exclusion Criterion  3 Heart failure due to hypertrophic cardiomyopathy,  
restrictive cardiomyopathy, arrhythmogenic right ventricular dysplasia (ARVD), stress -induced 
("Takotsubo") cardiomyopathy, chemotherapy -induced 
cardiomyopathy, peripartum cardiomyopathy, infiltrative or inflammatory cardiomyopathies, and primary valvular disease , in the opinion of their treating cardiologist, to 
etiologies  other  than ischemic  or nonischemic. Examples  of 
exclusionary HF etiologies include primary valvular  
disease,  infiltrative  or inflammatory  cardiomyopathies  Compliance with FDA 
request to make  inclusion/ 
exclusion criteria  mutually 
exclusive with respect to 
non-ischemic 
cardiomyopathy 
Section  6.1: Table  5 JK07  infusions  will be prepared  at the study  center  for 
administration within 4 6 hours following the dose 
preparation.  
Placebo  i nfusions  will be prepared  at the study  center  for 
administration within 4 6 hours following the dose 
preparation.  
Intravenous  (IV) infusion  over 60 minutes  using a syringe 
pump or infusion pump.  Compliance with FDA 
request to reduce IP hold 
time from  six hours  to four 
hours.  
 
 
Administrative change: To 
provide  greater  flexibility  to 
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  88 of 89  
  
Section  Change  Reason  
  sites in delivering the 
specified  infusion volume  in 
the allotted time.  
Section 6.2: 
Preparation/ 
Handling/  Storage  All investigational  drug supplies  in the study  will be stored 
at 2-8 °C - 4ºC in a secure place under the responsibility of 
the Investigator or other authorized individual.  Administrative  change:  The 
storage temperature was incorrectly listed as - 4°C, 
which does not allow for standard temperature  
variance  under  refrigeration.  
Table  13: Safety  
Laboratory 
Assessments  Myoglobin  added  to the list of analytes  for urinalysis  Administrative  update  
Table 14: Schedule of Protocol -required 
Safety Laboratory 
Assessments 
Performed by the Local Laboratory  LDH added to the list of additional biomarkers at 
Screening, Day 1 prior to IP administration, Day 1 at 4, 8,  
& 12 hours  post dose,  Day 2 at 24 hours  post dose,  Day 3 at 
48 hours post dose, and on Days 7, 15, 30, 60, 90, 135, and  
180. Administrative  update  
CONFIDENTIAL 
FINAL  Protocol  JK07.1.01 - Amendment  3 
09 APR  2021  
Page  89 of 89  
 Instructions  to the Investigator:  Please  SIGN  and DATE  this signature page.  PRINT your  name,  title, and the name of the study  center  in 
which the study will be conducted. Return the signed copy to Salubris Biotherapeutics, Inc.  Appendix  8    Signature of  Investigator  
PROTOCOL  TITLE:  A Randomized, Double -Blind,  Placebo -controlled, Single -ascending  Dose  Study to 
Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With 
Reduced Ejection Fraction (HFrEF)  
PROTOCOL  NO:    JK07.1.01 
VERSION:  Amendment  3 
This protocol is a confidential communication of Salubris Biotherapeutics, Inc. I confirm that I have read 
this protocol, I understand it, and I will work according to this protocol. I will also work consistently with 
the ethical  principles  that have  their origin  in the Declaration  of Helsinki  and that are consistent  with Good 
Clinical Practices and the applicable laws and regulations. Acceptance of this document constitutes my 
agreement that no unpublished information contained herein will be published or disclosed without prior 
written approval from the Sponsor.  
 
 
 
I have  read  this protocol  in its entirety  and agree to conduct  the study  accordingly:  
 
 
 
Signature  of Investigator:     Date:    
Printed  Name:      
Investigator  Title:      
 
 
Name/Address of Center:    
 
 
 
 